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Abstract
Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that catalyses the 
synthesis of ADP-ribose polymers from NAD+ in response to DNA strand breaks. It 
plays a major role in controlling the repair of damaged DNA and has been implicated 
in the pathogenesis of a great variety of human diseases, such as cancer, 
ischaemia-reperfusion injury and inflammatory disorders where massive, oxidative 
stress-induced damage to DNA resulted in PARP-1 overactivation, leading to cellular 
NAD+ depletion and cell death. However, this series of events may be prevented 
through pharmacological inhibition of NAD+ cleavage by PARP-1. Accordingly, 
PARP-1 inhibitor provides an exciting, novel therapeutic approach to a wide range of 
diseases. We have recently identified 5-aminoisoquinolin-1 (2//)-one hydrochloride 
(5AIQ.HC1) as a potent, water-soluble PARP-1 inhibitor that exhibited outstanding 
therapeutic benefits in a wide range of diseases in vivo. It appeared that 5AIQ.HC1 
gained much of its advantage through its excellent biopharmaceutical properties, 
such as water-solubility and biodistribution, which were severely lacking in most 
currently known PARP-1 inhibitors. Thus, we decided to exploit this discovery by 
designing and synthesising a series of related compounds which bear substituents at 
the 3- and 4-position of 5AIQ, with major emphasis on the former.
In this thesis, various chemical approaches to these targets have been investigated 
and a reliable, efficient and versatile synthetic route for the synthesis of the 
3-substituted targets has been developed, based on the Hurtley reaction. Attempts to 
effect synthesis via organometallic approaches, such as Sonogashira coupling, 
Castro-Stephens coupling, Negishi coupling and Heck coupling, revealed some of 
the limitations associated with the use of these protocols in sterically challenged and 
electron-deficient systems. The presence of a nitro function also gave rise to many 
interesting observations with regards to regioselectivity, in particular the propensity 
for 6-endo-dig ring closure to give the desired isocoumarin, rather than phthalide (via 
5-exo-dig cyclisation), which was formed in the non-nitrated analogue. A novel 
synthesis of the lead compound, 5AIQ, via the reductive cyclisation of methyl
2-cyanomethyl-3-nitrobenzoate has also been realised and this strategy could 
potentially be extended to the synthesis of the 4-substituted targets.
The successful synthesis of a series of 3-substituted targets allows, for the first time, 
a systematic investigation of their structure-activity relationship. All the members in 
this series demonstrated good water-solubility and excellent PARP-1 inhibitory 
activity in vitro, with IC50 values in low micromolar range. The 3-substituents were 
generally well tolerated by the active site and they resulted in a significant 
enhancement of PARP-1 inhibitory potency with respect to 5AIQ, the most potent 
inhibitors being 5-amino-3-methylisoquinolin-1 (2//)-one (94) (IC50O.2 3  jiM), which 
is ca. 7-fold more active than 5AIQ. Additional interactions between the
3-substituents and a deep hydrophobic pocket within the active site, as well as a 
putative, water-mediated hydrogen bond between the 5-amino group and Glu988 
probably accounts for their outstanding potencies. Thus, we have invented a novel, 
water-soluble and potent class of PARP-1 inhibitors. Their highly encouraging 
in vivo profiles and favourable physical properties made them attractive candidates 
for preclinical development.
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PolyCADP-ribose) polymerase-1 (PARP-1) [EC 2.4.2.30], also known as 
poly(ADP-ribose) synthetase (PARS) or poly(ADP-ribose) transferase (pADPRT), is 
a multifunctional enzyme that is selectively activated by DNA strand breaks. It 
catalyses poly(ADP-ribosyl)ation, which is the synthesis of long homopolymers of 
ADP-ribose through sequential attachment of ADP-ribosyl moieties from its 
substrates nicotinamide adenine dinucleotide (NAD+) (1) to a variety of acceptor 
proteins1. This enzyme is present in great abundance in most eukaryotic cells (with 
the notable exception of yeasts) and is located predominantly within the nucleus 






Nicotinamide Adenine Dinucleotide (NAD+) (1)
Though its exact biological function remains highly debatable, there is now a great 
body of evidence indicating that PARP-1 plays a major role in controlling the repair 
of damaged DNA and the maintenance of genomic integrity3’4. Current research has 
also thrown light into the possible involvement that PARP-1 may have in cellular 
proliferation5, differentiation6, gene transcription7 and cell death8. Whatever its 
precise physiological roles may be, great therapeutic benefits in a diverse range of 
diseases such as rheumatoid arthritis9, neurodegenerative disorders10, retroviral 
infection11 and ischaemia-reperfusion injury12 secondary to stroke, cardiac infarction
1
and haemorrhagic shock has recently been demonstrated through an inhibition of this 
enzyme. In view of such enormous therapeutic potentials, this enzyme rapidly 
became the target for drug development and is currently the subject of significant 
research. PARP, which was little more than a biochemical curiosity for almost three 
decades following its discovery, has finally gained its much-deserved attention.
1.2 The molecular structure of human PARP-1
The human PARP-1 is a 116 kDa protein consisting of a single polypeptide chain of 
1014 amino acid residues . It is found in the nuclei of all organs of the human body 
and is encoded by a single copy gene which is localised on chromosome 1 at position 
q41-q42— a gene consisting of 23 exons, spanning 43 Kb14. Three distinct functional 
domains were identified following limited proteolysis of the pure enzyme with 
papain and/ or a-chymotrypsin15.
• A 42 kDa N-terminal fragment, which includes the DNA-binding domain.
• A 22 kDa central fragment containing the automodification domain.
• A 52 kDa C-terminal fragment bearing the catalytic domain.
DNA binding Automodification Catalytic
domain domain domain
f l  f l l
BRCT Active site
1 206 234 383 524 859 908 1014
N-terminal C-terminal
I o
Figure 1. Schematic representation of the three functional domains ofhPARP-1 .
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1.2.1 The DNA-binding domain (DBD)
The DNA-binding domain consists of two zinc finger motifs and a nuclear 
localisation signal (NLS). The zinc fingers are loops in the polypeptide chain formed 
as a result of a zinc ion coordinating to four amino acid residues (two cysteine and 
two histidine residues). The two zinc fingers are about 28-30 amino acid residues 
apart16. They are differentially required for the recognition of single- and double­
stranded DNA breaks and the consequent activation of the enzyme. In particular, a 
deletion or mutation of the first finger (f I) resulted in a total abolition of enzymatic 
activity, whatever the nature of DNA break. Destruction of the second finger (f II), 
on the other hand, only abolishes the activation of enzyme by DNA containing single 
strand breaks16. These classical zinc finger motifs are common in many other DNA 
regulatory proteins that showed preferential binding at DNA single-strand break, for 
example the amino-terminal region of human DNA ligase m  and the carboxy- 
terminal region of DNA polymerase e17. The DBD also contains an NLS which is 
essential for effective translocation of PARP-1 into the nucleus. Within the NLS is a 
caspase-cleavage site, DEVD17.
1.2.2 The automodification domain
The automodification domain is located in the central region of PARP-1, between the 
DBD and the catalytic domains. It contains a leucine zipper motif, which may be 
involved in protein-protein interaction and a BRCT motif (breast cancer 
susceptibility protein, BRCA1, C-terminus), which is common in many proteins that 
function in DNA repair or in cell-cycle checkpoints17. In addition, there are fifteen 
highly conserved glutamate residues which are the presumed target for 
auto-poly(ADP-ribosyl)ation. Although found largely in the automodification 
domain, further sites for automodification also exist in the DBD and catalytic 
domains.
3
1.2.3 The catalytic domain
The catalytic domain is the most conserved region of the PARP-1 molecule. It
contains a block of 50 amino acids (residues 859-908) which are strictly conserved
among the vertebrates (100%) and among different species (92%) such as mouse,
18 *cow, chicken, Xenopus and Drosophilia . As such, this part of the protein is often 
referred to as the “PARP-1 signature”. This domain alone is responsible for all the 
catalytic functionality of the full length enzyme namely; NAD+ hydrolysis, initiation, 
elongation and branching of ADP-ribose polymer synthesis17. Such basal activity is 
independent of the presence of DNA strand-breaks but lacks specificity. The 
specificity of PARP-1 for damaged DNA is absolutely dependent on the integrity of 
the zinc finger domain19. Another functionally important feature in this domain is the 
presence of Glu988, a highly conserved amino acid residue that is directly involved 
in the catalysis of the ADP-ribose transfer reaction.
1.3 The PARP super family
For over three decades, it was assumed that PARP activity resulted from the function 
of a single enzyme. This assumption was challenged recently with the discovery of 
two structurally different PARP proteins, both possessing DNA-dependent 
poly(ADP-ribosyl)ating activities, in two higher plants (Arabidopsis thaliana and 
maize)20. Subsequently, it has been reported that embryonic fibroblasts derived from 
PARP-1 knockout mice were surprisingly able to synthesise ADP-ribose polymers in 
response to DNA damage caused by Af-methyl-Af-nitro-N-nitrosoguanidine 
(MNNG)21, a genotoxic agent. There was, nevertheless, an observed 90% decline in 
overall PARP activity and both the amount and length of ADP-ribose polymers were 
decreased in these cells. These findings suggested that some previously unreported 
enzyme(s) that are capable of producing ADP-ribose polymers might be present in 
these PARP knockout mice.
4
Intensive research in the last two years has begun to identify many new forms of 
human PARP, such as PARP-222, PARP-323, vault PARP (vPARP)24 and 
tankyrases , with the founding member of the PARP family (previously known as 
“PARP”) now designated as PARP-1. The huge decline in PARP activity following 
PARP-1 knockout indicates that PARP-1 is the principal member of the family and is 
responsible for majority of the poly(ADP-ribosyl)ating activities. The existence of a 
family of PARP proteins in human and other species raises a number of important 
questions with regards to their specific functions and their specific targets. Although 
research on the biological role of these novel PARP homologues is still in the 
embryonic stage, interesting differences in domain structure (summarised in Figure 
2), subcellular localization, tissue distribution and their ability to bind to DNA have 
already been established.








HPS 24 ankyrin repeats SAM
TANK-1
NTD 24 ankyrin repeats SAM
TANK-2
m
Figure 2. Comparison o f the domain structures o f six PARP enzymes29. 
HPS: histidine-, proline- and serine-rich region 
SAM: sterile alpha motif 
NTD: N-terminal domain
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1.3.1 PARP-2 and PARP-3
Among the currently identified members of PARP family, PARP-2, (62 kDa) bears 
the strongest resemblance to PARP-1 and PARP-3 (60 kDa) is the smallest PARP 
characterised22,23. They are encoded by chromosome 14qll.2-ql2 and 3p21.1-p22.2 
respectively, which are distinct from PARP-1 gene loci. Both PARP-2 and -3 are 
characterized by a short, basic N-terminal domain of variable length and a highly 
conserved catalytic domain which shares considerable homology (40% and 31% 
sequence identity respectively) with the catalytic domain of PARP-122,23. Their major 
structural differences with PARP-1 includes a smaller size and the following 
structural features:
• Absence of the nuclear localisation signal (NLS).
• Absence of the automodification domain.
• While the DNA binding domain (DBD) of PARP-2 lacks the zinc finger 
motif, this domain is absent altogether in PARP-3.
Interestingly, despite the lack of the classic zinc finger motif which acts as a nick 
sensor in PARP-1, both PARP-2 and -3 are nevertheless capable of binding to DNA 
that has been treated with DNase I and to catalyse the formation of poly(ADP-ribose) 
polymers in a DNA-dependent manner26. Furthermore, they are also capable of 
efficient automodification processes despite the absence of an automodification 
domain. This interaction could be driven by some other mechanisms involving 
binding modules that have yet to be discovered. While the catalytic function is 
structurally and mechanistically conserved between these two enzymes, their 




Vault PARP (vPARP) is a 193 kDa cytoplasmic PARP that has been found 
associated with vaults, barrel-shaped ribonucleoprotein particles of arched 
morphology reminiscent of the vaulted ceilings of cathedrals24. Unlike PARP-1, -2 or 
-3, vPARP does not require DNA for activity and therefore, understandably, does not 
contain a DBD. Its N-terminal is occupied by a BRCT motif while its C-terminal 
contains the NLS. The functional significance of vPARP is as elusive as the full 
biological role of vaults. Since vaults are implicated in cellular transport, the 
identification of vPARP as a component of the vault ribonucleoprotein complex 
suggest a role for vPARP in regulating the transport of molecules, possibly through 
poly(ADP-ribosyl)ation of the major vault protein24.
1.33 Tanky rases
As with vPARP, tankyrases do not require DNA for activity and they are localised to 
human telomeres—proteins situated at the end of eukaryotic chromosomes that are 
essential for chromosome maintenance and stability. Tankyrase-1 (TANK-1) is a 
142 kDa protein containing 24 ankyrin repeats, a sterile alpha motif (SAM), and a 
catalytic domain25. Its N-terminal has a histidine-, proline-, and serine-rich (HPS) 
region. TANK-1 probably binds to and poly(ADP-ribosyl)ates telomere repeat- 
binding factor 1 (TRF1), thereby causing the latter to be released from telomeres, 
allowing access of telomerase, a specialised reverse transcriptase that restores 
telomeric sequences lost during cell division. In this way, TANK-1 acts as a positive 
regulator for telomere length . An inference from this finding is that tankyrase- 
specific inhibitors might prove useful in anti-cancer therapies, since telomere 
maintenance is required for the continued growth of tumour cells19.
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Tankyrase-2 (TANK-2), apart from having a unique N-terminal domain (NTD), 
shows 85% homology to TANK-1 at the amino acid level25. The function of this 
perinuclear enzyme is not yet known but is probably different from that of TANK-1, 
since overexpression of TANK-1 induces progressive telomere elongation, while 
TANK-2 overexpression results in rapid cell death by necrosis27.
This list of PARP enzymes is far from complete. Molecular cloning and sequence 
analysis are beginning to add new siblings to the PARP family. Already, de Murcia's 
laboratory has very recently cloned a total of 16 PARP cDNA sequences encoding 16 
novel PARP homologues28 and there is no doubt that this family is still expanding, 
giving rise to what he described as the “expanding universe of PARP proteins”. 
PARP research now faces a stimulating challenge in elucidating the distinct (or 
sometimes overlapping) biological roles of these new members of the PARP family. 
This requires further studies using selective PARP inhibitors and modem molecular 
biological approaches. Cells and animals models that are deficient in the expression 
of specific PARP homologues as well as multiple gene knockouts that completely 
lack poly(ADP-ribosyl)ation will form the basis for future studies. Until then, the 
potentials of these new forms of PARP as drag targets remain to be defined. The 
subsequent sections deal primarily with PARP-1, the most studied and understood 
member of the family, as a therapeutic target.
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1.4 Mechanism of action of PARP-1
The activation of PARP-1 and the ensuing poly(ADP-ribosyl)ation is one of the 
earliest eukaryotic responses to DNA strand breakage. Though PARP-1 can bind to 
undamaged DNA, it displays negligible activity in the absence of DNA strand 
breaks. The obligatory triggers of PARP-1 activation are nicks and breaks in the 
DNA30, which can be induced by a variety of environmental stimuli and oxidants/ 
free radicals31. This includes hydroxyl radical, peroxynitrite, ionizing radiation and 
genotoxic agents such as MNNG.
Electron microscopy has shown that the introduction of a break in one strand of the 
DNA duplex induced flexibility at the nicked site. This caused the two DNA 
duplexes to come into close proximity with each other at an angle, forming a 
characteristic V-shape conformation which is recognisable by PARP-118. PARP-1, 
upon detection of such conformational changes, binds rapidly and specifically mainly 
through its second zinc-finger to the centre of the V covering 7±1 base pairs
1 ftsymmetrically on each side of the break .
This in turn led to the recruitment of a second PARP-1 molecule which forms a 
homodimer with the first PARP-1 molecule, possibly through the leucine zipper 
motif in the automodification domain32. The second PARP-1 molecule is believed to 
serve as a polymer acceptor during subsequent ADP-ribose polymer synthesis by the 
first PARP-1 molecule. The idea that PARP-1 functions as a dimer is supported by 
Uchida etal32 where they showed that addition of a single molecule of PARP-1 to 
damaged DNA only resulted in binding of the PARP-1 molecule to DNA without 
any detectable polymerase activity. This PARP-1 molecule remained “inactive” until 
a second molecule of PARP-1 was added. Figure 3 summarises the series of events 
that leads to the recognition and binding of PARP-1 to DNA single strand break.
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Figure 3. Model for recognition and binding of PARP-1 to DNA single strand
breaks18.
The binding of PARP-1 to damaged DNA also brings about a marked activation of 
its catalytic domain (of up to 500 times)33 and subsequent poly(ADP-ribosyl)ation. 
As in many other cellular processes such as acetylation and phosphorylation, 
poly(ADP-ribosyl)ation brings about covalent post-translational modifications of 
nuclear proteins, a process that is crucial for the regulation of activities within the 
cell34. By mechanisms that are not altogether clear, it was believed that 
poly(ADP-ribosyl)ation of nuclear proteins at the sites of DNA damage produces 
intracellular signals that initiate DNA repair and cell survival programs. ADP-ribose 
polymer formation is subjected to very complex regulatory mechanisms and consists 
of three main reactions: initiation, elongation and branching.
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1.4.1 Initiation
During initiation, PARP-1 binds to its substrate, NAD+ (1), at the NAD+ binding 
domain and catalyses the cleavage of the nicotinamide-ribose bond in NAD+. This is 
followed by the transfer of the resulting ADP-ribosyl moiety to the nucleophilic 
centre (invariably a Glutamate residue) of an appropriate protein acceptor. The 
protein acceptors may be nuclear proteins that are involved in DNA repair, DNA 
metabolism or chromatin architecture (heteromodification), for instance histones , 
high mobility group (HMG) proteins35 and DNA enzymes such as DNA 
topoisomerases I and II , DNA polymerase a  and p and DNA ligases . However 
the main protein to be poly(ADP-ribosyl)ated is PARP-1 itself , in a process known 
as automodification where the ADP-ribose moiety is being attached to the glutamate 
acid residues in the automodification domain of PARP-1.
The cleavage of the nicotinamide-ribose bond in NAD+ has an SnI character and is 
probably facilitated by an adjacent ribose oxygen lone pair, leading to an 
intermediate oxocarbenium ion40 (mechanism outlined in figure 4). The highly 
conserved Glu988 residue within the active site of PARP-1 helps catalysis in two 
respects. It binds to and polarises both the attacking nucleophile (the anchor point for 
ADP-ribose polymer synthesis) and NAD+, thereby increasing the nucleophilicity of 
the nucleophile and stabilising the oxycarbenium intermediate respectively. 
Nicotinamide is released during the process. Polymerisation reactions (chain 
elongation and branching) then follow.
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Figure 4: Proposed mechanism for poly(ADP-ribosyl)ation by PARP-140.
1.4.2 Elongation
In elongation, an a ( l" —>2') glycosidic bond is formed between C-l of the 
nicotinamide ribose and the 2-OH of the adenine ribose of the preceding ADP-ribose 
unit (Figure 5). This leads to the formation of linear polymers which may be up to 
200 residues long.
1.4.3 Branching
Branching occurs when the C-l of the nicotinamide ribose is joined with the 2-OH of 
the nicotinamide ribose of another ADP-ribose polymer via a 1'"—>2" glycosidic 




Automodification of PARP-1 eventually causes the enzyme to be detached from the 
damaged DNA due to electrical repulsion between the highly negatively charged 
ADP-ribose chains (two negative charges per monomer) and the negative charges in 
DNA molecule. Separation of PARP-1 from DNA presumably allows access of DNA 
repair enzymes such as DNA polymerase and DNA ligase to the site of damage42, 
setting off a series of DNA repair processes. The detachment of PARP-1 from the 
DNA also terminates its own catalytic activity. Hence, automodification represents a 
major regulatory mechanism for PARP-1 resulting in the down-regulation of the 
enzyme and the cessation of further ADP-ribose polymer synthesis.
1.5 Catabolism of ADP-ribose polymers
Poly(ADP-ribosyl)ation is a dynamic process, as indicated by the very short half-life 
(less than 1 minute)43 of the polymer in vivo. The transient nature of the polymer is 
attributable to its fast degradation by at least two types of enzymes: 
poly(ADP-ribose) glycohydrolase (PARG) and ADP-ribosyl protein lyase44. Once 
the ADP-ribose polymer is formed, it is almost immediately hydrolysed by the 
constitutively active PARG, which cleaves the ribose-ribose linkage in the linear 
(1"—>2' glycosidic bond) and branched (1'"—>2" glycosidic bond) portion of the 
polymer to produce ADP-ribose monomers44. Because the Km value of PARG is 
about 100 times lower for larger ADP-ribose polymers than for smaller ones45, the 
enzyme probably hydrolyses bigger fragments first, then switches to removal of 
ADP-ribose units one by one. Despite the many new PARP genes that were 
described, so far there is still only one PARG enzyme. As with PARP-1, PARG is 
localised to the nucleus46. It is about 13-50 fold less abundant than PARP-1 but its 
specific catalytic activity is about 50-70 fold higher. Hence there is no kinetic 
constraint in its ability to cope with large amount of ADP-ribose polymer being 
formed by PARP-1 during DNA damage47.
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ADP-ribosyl protein lyase then removes the remaining proximal ADP-ribose moiety 
from the acceptor proteins by breaking the ADP-ribose glutamate ester bond44. This 
yields a dehydrated form of ADP-ribose, 5-ADP-3-deoxypent-2-enofuranose (2), and 
releases the acceptor proteins, allowing them to resume their activities. The rapid 
biosynthesis and degradation of ADP-ribose polymer constitute a cycle (figure 5), 




















Figure 5. Biosynthesis and degradation of ADP-ribose polymers. Catalytic activities 
of ADP-ribosyl protein lyase (indicated by black arrow) and PARG (white arrows) 
lead to formation of (2) and ADP-ribose respectively48.
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1.6 PARP-1: The “guardian angel” of the genome
It has been estimated that there are about one million PARP-1 molecules per cell, in 
another word one PARP-1 molecule for each 1000 base pairs of DNA49. Considering 
such great abundance, this enzyme must serve some important physiological 
function(s). One such physiological role has clearly been identified to be the 
cytoprotective effect of PARP-1 with regard to cell survival and maintenance of 
genomic stability under genotoxic stress3,4. It is also generally believed that PARP-1 
is involved in the regulation of other DNA plasticity-related phenomena5'8, such as 
DNA replication, cellular proliferation and differentiation, gene transcription, 
chromatin remodelling, gene expression and cell death.
1.6.1 PARP-1 in DNA repair and maintenance of genomic integrity
PARP-1 has long been implicated in DNA repair, since it is activated by DNA strand 
breaks3. Such activation is immediate and can be elicited by a very small amount of 
DNA damage. Indeed many studies have now clearly indicated that PARP-1 plays a 
pivotal role in controlling DNA base-excision repair and is part of an intricate DNA 
surveillance network that protect the cell genome from the deleterious consequences 
of accumulated unrepaired or misrepaired lesions. These studies collectively 
demonstrated that PARP-1 knockout mice show normal foetal and postnatal 
development but have inherent genomic instability as evidenced by an increased 
number of micronuclei26,50 (chromatin fragments indicating chromosomal damage). 
They are also severely hypersensitive to DNA damage induced by ionising radiation 
and monofunctional alkylating agents51,52. A substantial delay in DNA base excision 
repair and a high frequency of sister chromatid exchange was also observed. The 
involvement of PARP-1 in genomic housekeeping is further indicated by the 
interaction of PARP-1 with other nick sensors such as DNA ligase i n  and DNA 
repair effectors, such as DNA polymerase53. Hence, although PARP-1 appears to be 
dispensable for normal cellular activities such as growth, development or 
differentiation, it should be considered an essential survival factor for recovery 
following DNA damage. The exact mechanism by which the poly(ADP-ribosyl)ating
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activities of PARP-1 facilitates DNA repair has not been clearly defined. It is 
postulated that these polymers play structural and functional roles in the DNA repair 
process.
1.6.1.1 Structural roles
In regards to a possible structural role, rapid synthesis of a large number of 
negatively charged polymers provides a mechanism to prevent the damaged DNA 
from associating with the recombination systems and helps to repel other DNA 
molecules54. It also causes a relaxation of the chromatin superstructure as will be 
explained in section 1.6.3. Detachment of PARP-1, on the other hand, allows access 
of DNA repair enzymes such as DNA polymerase and DNA ligase to the site of 
damage42. It is believed that the timing of PARP-1 attachment to and release from the 
DNA strand break may help to synchronise the whole repair process. Once the repair 
is completed, there will be no more strand break to stimulate PARP-1 and hence 
synthesis of ADP-ribose chains stops. Remaining polymer molecules will then be 
rapidly degraded by PARG and ADP-ribosyl protein lyase, allowing the DNA 
molecule to restore its pre-damaged primary structure44.
1.6.1.2 Functional roles
It is also possible that the ADP-ribose polymer has a more direct functional role in 
DNA repair. Poly(ADP-ribosyl)ation has different regulatory effects on the various 
acceptor proteins55. For instance, it inhibits DNA polymerase a  and p, topoisomerase 
I and n ,  Ca2+/Mg2+ endonucleases and DNA ligase EL It is possible that, through 
poly(ADP-ribosyl)ation of these proteins, PARP-1 controls and coordinates the 
various enzymatic processes that are involved in DNA repair, thereby responding as 
a general director of the crisis situation that exists in DNA damage.
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1.6.2 PARP-1 in DNA replication and cellular differentiation
A wealth of information has now been gathered that seems to indicate the possible 
involvement of PARP-1 in the regulation of DNA replication. Several research 
groups have reported on separate occasions the observation that ADP-ribose polymer 
metabolism is accelerated in the nuclei of proliferating cells56"58. PARP-1 was also 
found to co-purify with key components of multiprotein replication complex (MRC), 
many replication factors and centromere proteins59,60. In addition, various 
experimental models using PARP-1 knockout cells and pharmacological inhibition 
have demonstrated an inhibition of DNA replication and cell proliferation61, hence 
suggesting a possible role of PARP-1 in regulating these two processes.
Given that replication and differentiation are closely coupled processes, it is not 
surprising that PARP-1 may also be involved in the regulation of cellular 
differentiation. This is an important process where cells undergo a series of 
proliferative steps during which they gain new functions and lose others in order to 
fulfil certain tasks. Examples of such highly specialized cells include hepatocytes, 
neurons and renal tubular cells. Differentiation is a strictly controlled process, 
requiring concerted gene activation and repression. The idea that PARP-1 may 
regulate this process is supported by the findings that PARP-1 inhibitors were found 
to inhibit differentiation of human granulocyte-macrophage progenitor cells to the 
macrophage lineage62. Overexpression of PARP-1 also arrests NB4 cells and blocks 
all trans-retinoic acid-induced terminal neutrophilic differentiation .
1.6.3 PARP-1 in gene transcription and chromatin remodelling
The frequent association of PARP-1 with transcriptionally active regions of 
chromatin34,42 suggests yet another possible role for this enzyme, i.e. the regulation 
of transcription. One component of the transcription-regulating activity of PARP-1 
may be the regulation of chromatin structure and function through 
poly(ADP-ribosyl)ation of histones (the next major protein acceptors of 
poly(ADP-ribose) after PARP-1). These are the principal structural proteins of
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eukaryotic chromosomes that help to hold the nucleotide together and condense the 
chromatin. Their positive charges, due to high proportion of lysine and arginine 
residues, enable them to bind tightly to DNA. Poly(ADP-ribosyl)ation of histones 
confers negative charge to the latter, leading to electrostatic repulsion with DNA 
molecules and consequently, decondensation and relaxation of chromatin64. Such 
loosening of the chromatin structure makes genes more accessible for the 
transcriptional machinery. This mechanism has also been implicated in DNA repair, 
DNA replication and chromatin remodelling42.
1.6.4 PARP-1 in gene expression
There was recently a remarkable observation that PARP-1 may help regulate the 
expression of various proteins at the transcriptional level65. Of special importance is 
the regulation by PARP-1 of the production of inflammatory mediators. Although 
details for this mechanism are still far from clear, it appears to involve interaction of 
PARP-1 with nuclear factor B (NF-kB), a key transcription factor regulating the 
expression of several elements of inflammation66, such as cytokines, chemokines, 
intercellular adhesion molecule-1 (ICAM-1) and inflammatory mediators, such as 
inducible form of nitric oxide synthase (/NOS) and cyclooxygenase. Studies have 
showed that PARP-1 deficient cells were defective in NF-kB dependent transcription 
activation in response to tumour necrosis factor (TNF)67. Treating mice with 
bacterial lipopolysaccharide (LPS), an endotoxin, resulted in the rapid activation of 
NF-kB in macrophages from PARP-1 but not from PARP-1 knockout mice. In fact, 
PARP-1-deficient mice were extremely resistant to LPS-induced endotoxic shock67.
Continuous efforts by research groups worldwide have led to a better understanding 
of the biochemistry of PARP-1 and, as more of its secrets get unlocked, more 
physiological functions emerge. In addition to those already discussed above, this 
protein is currently also implied in an array of other functions such as the regulation 
of cytoskeletal organisation68, the control of the ageing process69 and viral 
replication70.
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1.7 PARP-1: The “Janus-faced” enzyme
1.7.1 Cellular energy dynamics
Paradoxically, despite PARP-1 having the cytoprotective, “guardian angel” functions 
discussed above, its over-activation can actually induce cell death. It seems that the 
PARP-1 directed DNA repair process is a highly inefficient and energy-consuming 
process. With the formation of each ADP-ribose polymer, PARP-1 consumes up to 
200 molecules of NAD+. In addition, the rate of turnover of nuclear NAD+ in a 
normal intact cell is estimated to be at least 100-fold less than the 
poly(ADP-ribosyl)ating activity of PARP-171, the actual rate of which depends on 
the degree of DNA damage in a dose-dependent manner. As a result, over-activation 
of PARP-1, consequent to massive DNA damage, may actually lead to a crisis 
situation where there is rapid (within only a few minutes) and severe depletion of 
intracellular NAD+ level.
NAD+ is an important respiratory coenzyme that regulates an array of vital cellular 
processes, such as glycolysis and mitochondria respiration, thereby providing ATP
79for most cellular processes . It also serves as the precursor for nicotinamide adenine 
dinucleotide phosphate (NADP), which acts as a cofactor for the pentose shunt, and 
is involved in the maintenance of reduced glutathione pools73. The result of massive 
NAD+ usage is a decline in the rate of all these vital processes, leading to cellular 
dysfunction and ultimately cell death. Moreover, under these precarious conditions, 
phosphoribosyl pyrophosphate synthetase and nicotinamide mononucleotide 
adenylyl transferase consume ATP in an effort to replenish the cellular NAD+ store55, 
further worsening the energy shortage and leading to a pronounced reduction of 
several crucial energy-dependent processes, such as DNA, RNA and protein 
synthesis74.
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1.7.2 The “suicide hypothesis”
PARP-1 then appears to be a “Janus-faced” enzyme that performs two seemingly 
contradictory functions—DNA repair that enables the cell to survive or NAD+ 
depletion that leads to cell death. Based on this observation, Berger55 proposed a 
hypothesis postulating that the activation of PARP-1 by massive levels of DNA 
damage is actually a suicide response since it results in a rapid depletion of NAD+ 
and ATP and the cells die before there is any opportunity to repair the damage. This 
cell death is presumably nature’s way of preventing gravely damaged cells from 
attempting to repair themselves, as such cells tends to have high mutation frequency 
and can undergo potentially malignant transformation. PARP-1 activation then 
served as a safety mechanism whereby massively damaged cells are removed from 
the population. The profound depletion of NAD+ and ATP associated with PARP-1 
activation also raised the possibility that even with milder activation of the enzyme 
associated with physiological DNA repair, the partial energy depletion provided by 
PARP-1 activation may prevent the cells from “over-exerting” themselves until DNA 
repair is completed71.
1.7.3 The “molecular switch hypothesis”
The “suicide hypothesis” is controversial because it was never established whether 
an extensively damaged cell dies because of a depleted NAD+/ ATP pool or from the 
DNA damage itself. Nevertheless, it is currently accepted that PARP-1 is involved in 
the two main pathways of cell death: apoptosis and necrosis, the actual mode of cell 
death being determined chiefly by the level of NAD+ and ATP75. It was therefore 
plausible to hypothesise that PARP-1, being a NAD+-catabolizing enzyme, may 
serve as a molecular switch between apoptosis and necrosis76. According to this 
hypothesis, cells exposed to DNA-damaging agents (especially oxidative insults) can 
enter three different routes as determined by the severity of DNA damage (Figure 6):
20
1) PARP-1 activated by mild genotoxic stimuli facilitates DNA repair by signalling 
cell-cycle arrest and by interacting with DNA repair enzymes and DNA- 
dependent protein kinase. As a result, DNA damage is repaired, and cells survive 
without the risk of passing on mutated genes.
2) More severe DNA damage induces apoptotic cell death during which caspases, 
the main executor enzymes of the apoptotic process, inactivate PARP-1 by 
cleaving it into two fragments (p89 and p24) at the DEVD motif in the nuclear 
localization signal of PARP-177. Cleavage at this site separates the DNA binding 
domain from the catalytic domain, resulting in inactivation of the enzyme. The 
cleavage fragments further contribute to the suppression of PARP-1 activity 
through inhibition of dimerisation and DNA binding of intact PARP-1 by p89 
and p24 respectively78. This pathway allows cells with irreparable DNA damage 
to be eliminated in a safe way i.e. via ingestion by macrophages. Cleavage of 
PARP-1 is believed to aim at preventing the activation of PARP-1 (by the 
ensuing DNA fragmentation) and thereby preventing cells from the pathological 
sequel of the third route in which cells die by necrosis, a less controlled 
mechanism posing danger for bystander cells.
3) The third route, necrotic cell death, is induced by extensive DNA breakage that 
is usually triggered by a massive degree of oxidative stress (hydroxyl radical, 
peroxynitrite). The overactivation of PARP-1 depletes the intracellular stores of 
NAD+ and consequently ATP level. This severely compromised cellular 
energetic state prevents cell death via the apoptotic pathway because many steps
79of apoptosis are known to depend on ATP . Necrosis represents a more severe 
form of cell demise compared with apoptosis. In addition to numerous 
biochemical and morphological differences between apoptosis and necrosis, 
probably the most distinctive feature of necrosis is the disintegration of the
on
plasma membrane . Consequent leakage of cellular content from necrotic cells 
into the surrounding tissue may contribute to inflammatory responses and further 
injuries.
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Figure 6. Responses o f PARP-1 to different severity o f  DNA damage81
Research into the “suicidal” role of PARP-1 gained new momentum over the last 
decade with the important discoveries that DNA damage and DNA repair are not 
confined to a few relatively uncommon genetic disorders and that a great variety of 
human diseases, such as cancer, ischaemia-reperfusion injury, inflammatory 
disorders and neurodegenerative diseases involve damage to DNA as a crucial 
element to their pathogenesis. Most of these damages are caused by oxidative stress 
where PARP-1 is very much involved as the final mediator of cellular injury and 
death. PARP-1 inhibition, therefore, provides an exciting, novel therapeutic approach 
to a wide range of diseases. Many pharmaceutical companies have seized upon this 
possibility and are already actively making pharmacologically useful PARP-1 
inhibitors. There has never been a more exciting time than now in this field. The 
next two sections are devoted to the discussion of the therapeutic effects of PARP-1 
inhibitors in various disease models and the development of PARP-1 inhibitors.
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1.8 Therapeutic potential of PARP-1 inhibition
1.8.1 The concept of ischaemia-reperfusion injury
Clinically, when there is a substantial reduction of blood flow to the tissues, the cells 
are said to be ischaemic. Ischaemia is a common condition during surgery and in 
many diseases, such as myocardial infarction, stroke and haemorrhage. Without 
question, early reperfusion is an absolute prerequisite for the survival of ischaemic 
tissues. However, that is not without hazard. Reperfusion has often been observed to 
exacerbate the injury sustained by the ischaemic tissues and lethally damage the 
organs (ischaemia-reperfusion injury)82. The damage, which occurred during the 
early minutes of reperfiision, appeared to be far greater than would have occurred if 
the ischaemia has been maintained.
Recent studies confirmed this “oxygen paradox” and suggested that reperfiision 
could trigger sudden metabolic and physiological changes, most notably, an outburst 
of oxidants and free radical production, in particular, hydrogen peroxide, hydroxyl 
radical, superoxide anion, nitric oxide and peroxynitrite31 (Table 1). These are 
believed to be the major contributing factors in the origin and progression of 
reperfusion injuries. Not only are they capable of exerting cytotoxic effects, 
independently or synergistically, via a number of mechanisms, both hydroxyl radical 
and peroxynitrite (a highly reactive oxidant produced from the reaction between 
nitric oxide and superoxide) can also trigger massive DNA single strand break, 
leading to PARP-1 over-activation . As described earlier in section 1.7.1, 
over-activation of PARP-1 depletes intracellular NAD+ reservoir and consequently 
ATP store, culminating in cell dysfunction or necrosis45-47. Over-activation of 
PARP-1 also induces the expression of a number of genes that are essential for
f%f% f ninflammatory responses (overviewed in section 1.6.4) ’ . For instance, it potentiates 
NF-kB activation, resulting in a greater expression of NF-KB-dependent 
inflammatory elements, such as cytokines, chemokines, /NOS, ICAM-1 and TNF. 
Both cytokines and chemokines can trigger free-radical formation through many 
different pathways, for example by stimulating xanthine oxidase activity and by
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recruiting activated neutrophils. In addition, the level of production of nitric oxide is 
increased due to de novo /NOS expression. These events further worsen the oxidant 
stress, producing even greater PARP-1 activation and cell dysfunction (Figure 7).
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Figure 7. The involvement o f PARP-1 in the chain of events leading to 
pathophysiological changes in response to various insults.
1.8.2 PARP-1 inhibition in ischaemia-reperfusion injury
It follows that pharmacological inhibition of PARP-1 will have two beneficial effects 
in ischaemia-reperfusion injury:
1. Preserving intracellular NAD+ and ATP pools in oxidatively stressed cells, 
thereby increasing the survival of ischaemic tissues
2. Abating the inflammatory response.
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Zingarelli et alM evaluated the role of PARP-1 in an acute model of myocardial 
reperfusion injury in the rat. Surgical occlusion of myocardial blood flow followed 
by reperfusion resulted in a marked cellular injury and development of a large infarct 
area. Pharmacological inhibition of PARP with 3-aminobenzamide (3AB) 
significantly improved the outcome of myocardial dysfunction, as evidenced by a 
reduction in creatine phosphokinase levels, diminished infarct size, and preserved 
ATP pools. Other investigators85'89 confirmed their results using different animal 
models of myocardial infarction (rabbit and pig) and different PARP-1 inhibitors 
(nicotinamide, 5AIQ, PJ34). The results are summarised in Table 2.
Neural damage following stroke is thought to be elicited in large part by a massive 
release of the excitatory neurotransmitter glutamate acting upon 
TV-methyl-D-aspartate (NMDA) and other excitatory receptors90. Stimulation of 
NMDA activates the production of nitric oxide by neuronal nitric oxide synthase 
(nNOS), which ultimately accounts for reperfiision injury in the central nervous 
system. In PARP-1 knockout mice, a markedly reduced infarct volume is observed 
after transient middle cerebral artery occlusion91. Several PARP-1 inhibitors have 
also been shown to reduce infarct size and improve neurological status in cerebral 
ischaemia-reperfusion92'94.
The role of PARP-1 activation in ischaemia-reperfusion is not confined to the heart 
and brain. Recent reports have demonstrated that the inhibition of PARP-1 provides 
protective effects in many other reperfused organs such as gut95'97, skeletal muscle87, 
liver98, kidney99 and retina100. It also improves the outcome of heart transplantation101 
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Table 2. Effects o f PARP-1 inhibitors in animal models o f ischaemia-reperfusion injury.
I/R: ischaemia-reperfusion; 3AB: 3-aminobenzamide; 5AIQ: 5-aminoisoquinolin-l-one 
PJ34: A-(6-oxo-5,6-dihydro-phenanthridin-2-yl)-,/V,A-dimethylacetamide 
DPQ: 3,4-dihydro-5-[4-( 1 -piperidinyl)butoxy]-1 (2//)-isoquinolinone 
GPI-6150: 2,3-dihydrobenzopyrano[4,3,2-de]isoquinolin-\ _one
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1.8.3 PARP-1 inhibition in inflammatory diseases
In view of the role that PARP-1 has in inflammatory signal transduction and the 
observation that a high level of inflammatory responses also elicit PARP-1 mediated 
cell death, one may anticipate PARP-1 inhibitors to protect against inflammation 
related cellular injuries. Indeed, the earliest implication of PARP-1 in the 
pathophysiology of inflammatory diseases was related to pancreatic islet cell injury 
and diabetes. Yamamoto et alm  demonstrated that in streptozotocin-treated islet 
cells, inhibition of PARP-1 with 3-aminobenzamide prevented NAD+ depletion and 
the suppression of pro-insulin synthesis without modifying the extent of DNA 
damage. Subsequent experiments in vivo demonstrated that such inhibition delays the 
onset of streptozotocin- and alloxan-induced diabetes105,106.
More recent studies have implicated PARP-1 in a wide range of other local or 
systemic inflammatory conditions (summarised in Table 3). Inhibition of PARP-1 
suppresses the development of rheumatoid arthritis107, colitis108 and respiratory 
inflammation109'111 in rodent or mice models. Systemic inflammatory conditions, 
such as various forms of circulatory shock are associated with a reduced 
responsiveness of blood vessels to vasoconstrictor agents (a result of nitric oxide and 
peroxynitrite production), myocardial dysfunction and impaired intracellular 
energetic processes, culminating in multiple organ failure. Inhibition of PARP-1 
significantly improves the survival rate of mice which have been injected with a high 
dose of endotoxin97,112 and in septic shock induced by E. co/i113.
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Pretreatment protects against alloxan- or 
streptozotocin-induced decrease in 
proinsulin synthesis
Arthritis






3AB108 Normalises colonic permeability, reduces 
tumour necrosis factor-a and interferon-y 
secretion, reduces inducible nitric-oxide 
synthase expression, reduces 







Suppress NMDA receptor-mediated lung 
edema formation and endotoxin-induced 





Significantly reduce the 
lipopolysaccharide-induced 





PJ34113 Improve survival and maintain cardiac 
function





1.8.4 PARP-1 inhibition in cancer treatment
Most anti-tumour agents and radiotherapy eliminate fast-growing tumour cells by 
disrupting DNA replication and halting the cell cycle. However the effectiveness of 
these treatments is often limited by the lack of selectivity for cancer cells. As a result, 
many rapidly dividing normal cells, such as bone marrow, gastrointestinal epithelial 
cells and endothelial cells, are damaged along with the tumour cells. As such, 
selective sensitisation of tumour cells to the cytotoxic effects of these agents is 
necessary. The rationale for the use of PARP-1 inhibitors as chemo- and 
radio-sensitisers comes from the observation that PARP-1 is important for DNA 
base-excision repair and its inhibition caused a significant delay in the DNA repair 
processes. Accordingly, PARP-1 inhibitors, by preventing tumour cell from repairing 
its DNA, would potentiate the cytotoxic effects of both chemo- and radio-therapeutic 
agents used in the treatment of cancer. Indeed, several lines of evidence now indicate 
that tumour cells can be sensitised by PARP inhibitors to A-methyl-A-nitrosourea, 
bleomycin, campthotecin, and ionising radiation-induced cytotoxicity114"116. The 
results are summarised in Table 4.
Many anti-tumour drugs can also induce oxidative stress in several tissues and 
trigger PARP-1-mediated cell dysfunction and organ injuries117,118. The use of 
PARP-1 inhibitors in combination with chemotherapeutic agents provides further 
advantage of attenuating their adverse effects without compromising their anti­
tumour efficacy. For instance, PARP-1 inhibitors such as PJ34 and BGP-15 have 
demonstrated efficacy in counteracting doxorubicin-induced cardiotoxicity117 and 
cisplatin-induced nephrotoxicity118, respectively.
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1.8.5 PARP-1 inhibition in HTV-1 infection
There is an increasing body of evidence suggesting the involvement of PARP-1 in 
HIV-1 infection. During the life cycle of the HIV-1 virus within the infected cell, the 
RNA genome of the virus is reverse-transcribed into double-stranded DNA by 
reverse transcriptase119. The proviral DNA, in turn, enters the nucleus, where the 
virion-associated viral enzyme, integrase, catalyses the integration of the viral 
double-stranded DNA into the host genome. This process requires nicking of both 
DNA strands and may therefore lead to PARP-1 activation. Indeed, increased 
PARP-1 activity of HIV-1-infected cells has been reported by Furlini et a /120, 
indicating that the HIV-1 life cycle may require poly(ADP-ribosyl)ation. 
Furthermore, two studies121,122 independently showed that benzopyrone derivatives, 
benzamides and nicotinamide possessed potent antiviral effects in HIV-infected 
cells. At present, it seems that PARP-1 regulates HIV infection at two levels: 
integration and transcription119 and PARP-1 inhibition may be a viable strategy in 
controlling HIV-1 infection.
1.8.6 Other diseases
Preliminary data also indicate the beneficial effects of PARP-1 inhibitors in a variety 
of other diseases including Parkinson's disease123, Alzheimer's disease124, endothelial 
dysfunction associated with ageing and hypertension125, acetaminophen-induced 
hepatotoxicity126 and UV radiation-induced dermal necrosis127 (summarised in Table










Enhance cytotoxicity of lymphoma 
cells
N-methyl-N-nitrosourea 3AB114 Potentiate cytotoxicity
Temozolamide 3AB, Benzamide, 
PD128763 &
NU1025116
Potentiate cytotoxicity of murine 
leukaemia L1210 cells






Prevent depression of left ventricular 
function
Prevent kidney dysfunction
HIV-1 infection 6ABP & INH2BP121 
Benzamides & 
Nicotinamide122





Protect against MPTP-induced 








Suppress acetaminophen-induced liver 
damage
Photodamage in skin BPG-15127 Topical application reduce UV 
radiation-induced skin damage
Table 4. Effects o f PARP-1 inhibitors in cancer therapy, HIV-1 infection and other diseases. 
MPTP: 1-methy 1-4-phenyl-1,2,3,6-tetrahydropyridine; 3AB: 3-aminobenzamide;
PND: 6(5//)-phenanthridinone; PD128763: 3,4-dihydro-5-methylisoquinolin-l(27/)-one; 
NU1025: 8-hydroxy-2-methylquinozolin-4(3//)-one;
PJ34: N-(6-oxo-5,6-dihydro-phenanthridin-2-yl)-N,V-dimethylacetamide;




1.9 Possible side effects of PARP-1 inhibitors
The remarkable cytoprotective effects of PARP-1 inhibitors observed over a wide 
range of human diseases is very encouraging. However, before potent PARP-1 
inhibitors can be used in humans, crucial safety issues must be addressed. It is 
noteworthy that human clinical trials with nicotinamide in Type I diabetic patients128 
represent the only example to date where a PARP-1 inhibitor has been administered 
to a human being. This is possible as nicotinamide is a vitamin (Vitamin B3), with an 
established safety profile in humans. Although several small Phase II trials gave 
promising results, one is unable to fully ascertain its effect in Phase m  trial due to its 
low potency.
On the negative side is the pioneering work of Okamoto et alm  who was the first 
group to point out that, since PARP-1 has been implicated in DNA repair and 
maintenance of genomic integrity, one possible risk associated with long-term 
PARP-1 inhibition might be an increase in mutation rate and cancer formation. In an 
elegant experiment, they showed that PARP inhibitors could prevent the onset of 
diabetes but the result of this intervention was the appearance of pancreatic tumours. 
However, Menissier-de Murcia et al129 did not find an excess of tumours in the 
PARP-1 deficient mice that they have constructed, indicating that whilst general 
inhibition of PARP lead to untoward effects, selective PARP-1 inhibition is 
relatively well tolerated.
PARP-1 inhibitors, in theory, may also interfere with the binding of NAD+ to other 
enzymes that require NAD+ for their functions, leading to various adverse effects. In 
addition, many of the PARP-1 inhibitors are planar cyclic systems (Figure 8). Such 
molecules are prone to DNA intercalation and may be associated with an increased 
risk of genotoxic effects. These possibilities further highlight the importance for the 
development of PARP-1 selective inhibitors.
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1.10 Development of PARP-1 inhibitors
Intensive research, especially over the last decade, by both academic and 
pharmaceutical laboratories, has yielded multiple classes of PARP-1 inhibitors with 
hundreds of compounds, the vast majority of which bind to the nicotinamide binding 
domain of the enzyme and act as competitive, reversible inhibitors with respect to 
NAD+, the natural substrate for PARP-1.
1.10.1 Nicotinamide and NAD+-related compounds
The earliest compounds that were shown to inhibit PARP-1 bear structural 
similarities to NAD+; these include nicotinamide (3), purine analogues [e.g. 
theophylline (4)] and pyrimidine analogues [e.g. 5-bromouridine (5), thymidine 
(6)]130. However, it was quickly realised that these compounds were not very 
selective in their actions and many of them interfere with other cellular processes. 
Nicotinamide, for instance, served as substrates for NAD+ metabolising enzymes 
such as nicotinamide-N-methyltransferase deaminase and phosphoribosyl 
transferase131. Thymidine, on the other hand, inhibits DNA synthesis via depletion of 
cellular dCTP level130.





1.10.2 Benzamide and 3-subsitiuted benzamides
Clearly, more selective PARP-1 inhibitors are required if they are to have any 
therapeutic application. This led to the discovery of benzamide (7), a close structural
1 ^9analogue of nicotinamide, by Shall in 1975 . Benzamide is more specific in its
action because it lacks the ring nitrogen in nicotinamide and, therefore, cannot be 
metabolised by NAD+ biosynthetic enzymes. However it suffers from poor 
water-solubility, given the hydrophobic nature of its structure. Good water solubility 
is a desirable feature in PARP-1 inhibitors because it facilitates their in vivo 
administration. Compounds that lack water solubility require other biocompatible 
vehicles. Often, dimethylsulphoxide (DMSO) is used; however, it is a potent 
scavenger of hydroxyl radicals and recent study also indicates that it inhibits PARP-1 
activity . This causes substantial problems in the experiment and makes any 
interpretation of results very difficult.
In an attempt to improve the aqueous solubility of benzamide, Purnell and Whish 
substituted the 3-position of benzamide with polar substituents134. This position 
corresponds to the location of the ring nitrogen in nicotinamide and, at this position, 
it is likely to bind with the ribose nucleoside-binding domain where they function as 
competitive inhibitors due to the lack of a cleavable C-N bond135. The 3-substituted 
benzamides, namely 3-aminobenzamide 
(8), 3-methoxybenzamide (9) and 
3-hydroxybenzamide (10), were found to 
combine reasonably good water solubility 
with moderate PARP-1 inhibitory 
activity136. Although unlikely as drug 
candidates, they serve as powerful 
experimental tools in elucidating the 
biological role of PARP-1. They have also 
become the benchmark compounds 




Code R IC50 (MM)
(7) H 22.0
(8) [3AB] n h 2 9.0
(9) OMe 17.0
(10) OH 9.10
Table 5. PARP-1 inhibitory activity 
of benzamide and various 
3-substituted benzamides136.
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1.10.3 Structure activity relationship of PARP-1 inhibitors
The emergence of 3-substituted benzamides as prototype PARP-1 inhibitors has 
stimulated considerable interest in the structure activity relationship (SAR) of this 
class of compounds and a number of very detailed investigations by research groups 
working independently have been undertaken136'139. Inevitably, different assay 
methods and conditions have been utilised by different research groups in their 
evaluation of PARP-1 inhibitory activities and this caused considerable variations in 
the inhibition constants ( I C 5 0 ,  K„ E C 5 0 ) .  As such, any direct comparison of the 
results is difficult and has left more or less inconclusiveness to the studies. In an 
attempt to account for such discrepancies, Banasik et alue conducted one of the most 
comprehensive evaluations to date where they compared more than 170 compounds 
from a variety of structural classes for their ability to inhibit PARP-1 using 
standardised assay methods. They found that all the strong PARP-1 inhibitors have a 
common structural motif: the benzamide pharmacophore (outlined in red, Figure 8) 
which mimics the nicotinamide portion of NAD+ (1). This pharmacophore is thought 
to occupy the nicotinamide-binding site of PARP-1 and it consists of two important 
structural features: a carboxamide function and an aromatic ring.
Benzamides Isoquinolinones Phenanthridinones 1,8-naphthalimides
Benzopyrano-
isoquinolinones Benzimidazoles Quinazolinones Imidazobenzodiazepines
Figure 8. The benzamide pharmacophore for PARP-1 inhibition.
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1.10.3.1 The carboxamide function
The presence of an unsubstituted carboxamide group was found to be an essential 
pre-requisite for significant activity. Removal or alteration of this amide moiety 
resulted in abrogation of activity in almost every instance. For example, replacement 
of the amide group in benzamide with a carboxylate (11), a sulphonamide (12) or a 
thioamide group (13) resulted in a dramatic loss of activity140, as did N-alkylation 
(14)134. The position of the carboxamide function, however, was less critical, with 
pyridine-2-carboxamide (15) and pyridine-4-carboxamide (16) both exhibiting 















It is believed that the carboxamide forms hydrogen-bonds with the amino acid 
residues in the active site, which are crucial in holding the molecule in place within 
the domain. For such interaction to occur, the carboxamide group must be at the right 
conformation. In a compelling and elegant experiment to identify the active 
conformation, Suto et al made a series of rigid benzamide analogues, the 
3,4-dihydroisoquinolinones, by closing the amide nitrogen upon the benzene ring 
with an ethane bridge. They found that the 5-substituted dihydroisoquinolin-l-ones 
(17a-d), where the carboxamide is in the a«ft-orientation, were 50 to 75 fold more 
potent than the 7-substituted jyw-analogues (18a-d). They were also significantly 
more potent than the unconstrained 3-aminobenzamide (8) (IC50 9.0 |iM) where 
equal population of both rotamers exist. To provide further evidence, they then 
synthesised a series of 2,3-disubstituted benzamides. These compounds had either a
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hydroxyl or a methoxy group in the 3-position and various alkyl groups in the
2-position. All were found to be completely inactive except for
3-hydroxy-2-methylbenzamide which has only very weak activity (IC50 590 pM). 
Energy calculation revealed that the presence of a 2-substituent restricts the rotation 
of the amide, causing them to exist predominantly in the less hindered, nevertheless 
inactive syrc-conformation. Hence Suto clearly demonstrated that the biologically 
active conformation is one where the carboxamide group is orientated in such a way 
that the carbonyl group is anti to the 1,2-bond of the ring i.e. anti-conformation.
Dihydroisoquinolinone derivatives
Active anh-conformation Inactive svn-conformation
Code R IC50 (pM)
17a N 02 3.2
18a N 02 13
17b OMe 0.42
18b OMe 120
17c n h 2 0.41












R = Me, Et, Propyl 
R' = H or Me
Figure 9. Conformational study on dihydroisoquinolinone and benzamide PARP-1 
inhibitors138.
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1.10.3.2 The aromatic ring
The aromatic ring is also crucial for PARP-1 inhibitory activity. Whilst the saturated 
analogue of benzamide, cyclohexanecarboxamide, was found to be devoid of 
activity, addition of a ring nitrogen was well tolerated, with pyrazinamide displaying 
similar inhibitory potency to that of nicotinamide (3) (IC50 210 |nM)137. In contrast to 
earlier reports which showed that replacement of the benzene ring with a thiophene 
ring in thiophene-3-carboxamide reduced the inhibitory potency, a recent study by 
Shinkwin et a l157 demonstrated that the isomeric thiophene-2-carboxamide displayed 
good PARP-1 inhibition, with potency of the same order of magnitude as benzamide. 
Similar inhibitory activity was also observed for thieno[3,4-c]pyridin-4(5//)-ones 
(19) and thieno[3,4-d]pyrimidin-4(3//)-ones (20), which are heterocyclic analogues 
of isoquinolin-l(2//)-ones (23) and quinazolin-4-ones (31) respectively, thus 
demonstrating that the heterocyclic ring can indeed substitute for the benzene ring 
without significant loss in PARP inhibitory potency.
It was postulated that the presence of an electron-rich aromatic ring enhanced the 
ability of the carbonyl group to participate in hydrogen-bonding within the active 
site40. In addition, there is also non-polar interaction between the aromatic ring and 
the active site. Such interaction might contribute to the increased activity of the 




R = Me or Ph
(19) (20)











The positioning of the substituents on the 
benzene ring was also found to be critical 
for optimal activity. When the substituent 7
in 5-substituted dihydroisoquinolinones J1
was moved to the 6, 7 or 8 position (which 
corresponds to position 4, 5 and 6 of 
benzamides respectively), activity was 
decreased138 (Table 6). It was believed 
that substituents at the 5-position (or 3- 
position of benzamides) was 
accommodated within the ribose-
nucleoside binding domain. In contrast to Table 6. Effects of substituents on
various positions of the aromatic 
the substrates NAD+, these compounds are ring138.
incapable of undergoing analogous C-N
bond cleavage, thus serving as competitive inhibitors.
In summary, the following structural features are essential for PARP-1 inhibition 
(Figure 10):
1. An unsubstituted aromatic or polyaromatic heterocyclic system.
2. A carboxamide group which is restricted into the arch-conformation.
3. Presence of at least one amide proton.





Electron rich aromatic ring At least one amide proton
No substituent permitted
XT . , ,  „  v , , 3 /  Bulky substituent permitted hereNon-cleavable C-X bond  ► I r y  J v
Figure 10. Structure activity relationship for inhibitors of PARP-140.
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The availability of X-ray crystallographic structures of the catalytic fragment of 
PARP-1, and those crystallised with competitive inhibitors, such as PD128763 (22f), 
NU1025 (31d) and 3-methoxybenzamide (9) have helped confirmed the above SAR 
scheme and enabled us to rationalise it on a structural basis141' 143. It was found that in 
all the above PARP-1-inhibitor crystal structures, the position of binding is similar
i.e. in the nicotinamide sub-site of the NAD+-binding domain of PARP-1. This is 
represented by the motif found for PD 128763 (Figure 11). The carboxamide group 
invariably forms three important hydrogen-bonds: The inhibitor carbonyl oxygen 
accepts two hydrogen bonds, one from the side chain of Ser904, the other from 
Gly863 polypeptide amide NH. The third hydrogen-bond is formed between the 
carboxamide NH and Gly863 carbonyl oxygen. In addition, a parallel tyrosine 
residue (Tyr907) within the active site interacts with the planar aromatic portions of 
the inhibitors, presumably through n-n  interactions, forming a “7t-electron 
sandwich”. This accounts for the propensity for planar aromatic compounds to bind 
to the active site.
Additional interactions between the inhibitors and the active sites were also observed 
and these were specific for specific classes of inhibitors, accounting for greater 
potencies. For instance, interaction between Glu988 and the methyl carbon atom of 
PD 128763 (22f) was observed142. This glutamate catalyses PARP-1 activity by 
serving as a general base which activates the acceptor protein for nucleophilic attack 
at the C-l of the nicotinamide ribose. It also stabilises the intermediate oxocarbenium 





Figure 11. Enzyme-inhibitor interaction between PARP-1 catalytic fragm ent and  
PD128763 (22/)'".
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1.10.4 Dihydroisoquinolinones and isoquinolinones
As a result of Suto’s studies, numerous structural modifications have been made to 
the parent dihydroisoquinolinone and isoquinolinone, giving rise to a great number 
of highly potent and selective PARP-1 inhibitors. The most potent inhibitor 
identified in these two classes of compounds are DPQ (22g) 91’93’144, which was
recently patented by Guilford Pharmaceuticals, and 5-hydroxyisoquinolin-1-one
1(23e) respectively. It was believed that the structurally flexible butoxy-piperidine 
side chain at the 5-position of DPQ favours its insertion into the hydrophobic pocket 
within the active site, thereby increasing its potency tremendously. Other compounds 
of great therapeutic interest are PD 128763 (22f)* 16’145’146 and 5AIQ
(23d)86,98,101’103,111
Dihydroisoquinolinones (22) Isoquinolinones (23)
Code R ICso (pM)1
17a n o 2 3.2
(a) [DHIQ] H 1.5
17b OMe 0.42
17c n h 2 0.41
(f) [PD128763] Me 0.14
17d OH 0.10
(g) [DPQ] •v ^  0.04V s!
Code R IC50 (pM)
- (a) H 6.2
(b) n o 2 3.2
(c) OMe 0.58
(d) [5AIQ] n h 2 0.24
(e) OH 0.14
Table 7. PARP-1 inhibitory activity o f various 5-substituted
138dihydroisoquinolinones and isoquinolinones .
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1.10.5 Isoquinolinones-related compounds
The isoquinolinone core is also present in various tricyclic and tetracyclic 
compounds such as phenanthridinones (24a-c), thieno[2,3-c]isoquinoline (25a-d) 
(SKB), 1,8-naphthalamide (26a & b)136 and benzopyrano[4,3,2-de]isoquinolinones 
(27, 28a-c). Among these compounds, PJ34 (24c)89’94’97’101’110’113’117’125 (INOTEK 
Pharmaceuticals) and GPI-6150 (27)96'147 (Guilford Pharmaceuticals) have been
extensively studied and published. 
Phenanthridinones (24)
R
Code R IC50 (pM)
(b) N 02 0.35
O o 04
[PJ34] JL .NMe, (EC50)
Thieno[2,3-c]isoquinolines (25)
\  / H  
N
R «==y












IC5q = 0.060 pM____________________






Table 8. PARP-1 inhibitory activity o f  isoquinolinone-related compounds.
1.10.6 Benzoxazoles and benzimidazoles
On the basis of currently accepted structural requirements for PARP-1 inhibition, in 
particular the need for an anti disposition of the amido moiety, researchers at the 
University of Newcastle-upon-Tyne designed a series of 
benzoxazole-4-carboxamides135 and benzimidazole-4-carboxamides148 compounds 
that elegantly favoured the active anft'-conformation by means of an intramolecular 
H-bonding between the amide proton and the cyclic nitrogen. These compounds 
possess good donor properties by virtue of the electron-rich heterocycle and they 
exhibit potencies superior to those usually shown by monocyclic carboxamides, with 
IC50 values ranging from 1 to 10 pM. In general, benzimidazole analogues are a few 
times more potent than the corresponding benzoxazoles. Compounds with substituted 
phenyl group at 2-position, such as (29b), (30e) and (30f) are the most potent 
examples in these classes of inhibitors.
BenzoxazoIe-4-carboxamides (29) Benzimidazoles-4-carboxamides (30)
Code R IC50 (pM) Code R Kt (nM)
(a) Me 9.5 (a) H 95
(b) Ph 0.44 (b) Me 99





Table 9. PARP-1 inhibitory activity o f  benzoxazole-4-carboxamides and 
benzimidazole-4-carboxamides.
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1.10.7 Quinazolinones and phthalazinones
During initial attempts at the synthesis of benzoxazole-4-carboxamides, an 
unexpected rearrangement, which resulted in the formation of quinazolinone 
derivatives, occurred149. These compound were then assayed for inhibitory activities 
against PARP-1 and were found to be very potent, particularly 
8-hydroxyquinazolinones, such as (NU1025) (31d) and (NU1057) (32d)116’135. In 
general, those with substituted phenyl at the 2-position are also more active. 
Juxtaposition of the second ring nitrogen of quinazolinones gives rise to another 
class of PARP-1 inhibitor, the phthalazinones. KuDOS Pharmaceuticals tested 
various 4-benzyl analogues of phthalazinone (33a). Most of the 52 compounds tested 













0.78 Code X R IC50 (pM)
(c) Me Me 0.39 (a) OH H 1.06
(d) OH Me 0.40 (b) OH n h 2 0.52
[NU1025] (c) OH OH 0.29









(g) OMe OMe 2.0
T N (h) OMe CN 1.34
4 (i) OMe N 02 0.85
R <j) Me H 0.87






















(c) 0^  x 0.04 (0 ) Me N 02 0.13
J U  H (P) Me c f 3 > 10
Table 10. PARP-1 inhibitory activity of quinazolinones and phthalazinones.
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1.10.8 Benzimidazole-related compounds
A natural extension of the benzimidazole class of compounds is to replace the 
hydrogen-bond that encourages the a«fr-conformation with a covalent bond. This 
gave rise to hundreds of tricyclic PARP-1 inhibitors based on indole
•  151(dihydrodiazepinoindolinones and tetrahydroazapinoindolinones) and
benzimidazole (imidazobenzodiazepines)152,153 structures (Table 11).
Surprisingly, these 7-membered derivatives are no more potent than the 
benzimidazoles. This may be ascribed to a shift in the orientation of the amido group, 
which reduces its ability to form productive H-bonding with the active site154. As 
with benzimidazole-4-carboxamides, substituted phenyl groups at C-2 enhances 
potency over the parent structures, with Kj in the low nM range (1-100 nM)153. 
Potency could be further increased if the 2-phenyl substituents were attached via a 
preferably unsubstituted, ethylene bridge (compare Kj of (36c) with that of (36h)). 
However, substituents bulkier than these tends towards higher Kj values (36h-j).
1.10.9 Isoindolinones
Another class of PARP-1 inhibitors, isoindolinones, 
incorporate the requisite lactam in a 5-membered ring.
The simple 5-substituted derivatives (39) have only 
poor potency (IC50 > 1 0  pM) but more elaborate side 
chains improve activity. Since Guilford’s claim on the 
tetracyclic isoindolinones (40), polycycles incorporating 
the isoindolinone group have been published, a vast 
majority of which have IC50 values below 100 nM.
(39)













































Code R K, (nM) (1) 66
(a)
(b) XX (IC50 18 nM) 1 (m) x s .  Me ^  NX 88
Table 11. PARP-1 inhibitory activity o f selected benzimidazole-related compounds.
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1.10.10 Miscellaneous classes of compounds
While much development centred around the lactam or carboxamide pharmacophore, 
there are several groups of compounds that do not possess this functionality. Most of 
these are inhibitors of moderate potency compared to those discussed above and they 
have very different modes of action. For instance, 5-iodo-6-amino-1,2-benzopyrone 
(INH2BP) (41) inhibits PARP-1 by uniquely oxidising one of its two zinc fingers, 
resulting in zinc ion ejection and a concomitant inactivation of its activity155. Other 
examples include aryl carboxylic acids containing a 4-r-butylbenzene-l,2-diol 





(41) IC50 10 \sM (42) IC5o 2.2 pM (43) IC50 <10 pM
1.10.11 Approaches to irreversible PARP-1 inhibitors
1 SSWatson et al has recently proposed a design for a mechanism-based irreversible 
inhibitor of PARP-1. According to the accepted mechanism for PARP-1-catalysed 
formation of poly(ADP-ribose) from NAD+ (Figure 4), a benzamide or 
isoquinolin-l(2//)-one with an electrophilic substituents at the 3- or 5-position 
respectively may trap the attacking glutamate residue (during initiation) or the ribose 
hydroxyl in ADP-ribosyl moiety (during polymerisation), thus capping the polymer 
or it may react with other appropriately placed nucleophile within the active site of 
PARP-1, leading to a blockage of the binding site (Figure 12).
However, subsequent bioassays of a series of 3-substituted benzamide and 
5-substituted isoquinolin-l(2H)-one showed that these compounds were not acting as 
time-dependent irreversible inhibitors of PARP-1 as they did not observe any
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increase in PARP-1 inhibitory activity when the enzyme was pre-incubated with the 
inhibitor for different time intervals up to 30 min before the assay was started. 
Nevertheless, they identified 5-iodoisoquinolin-l(2//)-ones and 
5-bromoisoquinolin-l(2//)-ones as particularly potent PARP-1 inhibitors, with 
virtually total abolition of enzymatic activity at a concentration of ca. 10 |iM.




Figure 12. Proposed mechanism-based irreversible inhibitor o f PARP-1 158
1.11 Challenges
A better knowledge of the SAR of PARP-1 inhibitors and computer-aided drug 
design has greatly accelerated drug discovery. The extensive work of the last few 
years has seen the emergence of several classes of highly potent PARP-1 inhibitors 
with 10 to 1000-fold increase in potency compared to those compounds described by 
Banasik ten years ago. Though an increased in potency can be considered a good 
starting point for the pharmaceutical development of PARP-1 inhibitors, other 
equally important factors, such as biodistribution and water-solubility should also be 
considered. However in the passionate quest for greater potency, relatively much less 
effort has been expended on these areas. To address these challenges, recent works in 
our laboratory have led to the development of PARP-1 inhibitors with improved 
biodistribution159'161 as well as highly water-soluble PARP-1 inhibitors103.
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1.11.1 Bioreductive prodrugs of PARP-1 inhibitors
The inspiration for improvement of the biodistribution of PARP-1 inhibitors came 
from the observation that many disease states where PARP-1 inhibition is 
therapeutically beneficial, such as cancers, inflammatory disorders and 
ischaemia-reperfusion injuries are marked by acute or chronic tissue hypoxia. Such a 
physiological difference in the concentration of oxygen between normal and hypoxic 
tissues was being exploited through design of biologically inactive prodrug systems 
which, upon selective bioreduction in hypoxic tissue, would release PARP-1 
inhibitors only in that tissue. This would improve greatly the selectivity of 
biodistribution and consequently reduce the dosage required for therapy. Four 
different types of redox-sensitive triggers were designed and the proposed 
mechanism for bioreductive release of PARP-1 inhibitors (DRUG) from 
nitroheterocyclylmethyl Trigger159,160 and 4,7-dioxoindole-3-methyl Trigger161 were 




a: X = O, Y = CH R = H or OH
b: X = MeN, Y = N 
c: X = S, Y = CH
Figure 13. Proposed mechanism o f reductively triggered release o f  drugs from  
5-nitrofuran-2-ylmethyl (a), 1-methyl-2-nitroimidazole - 5-ylmethy I (b) and















Figure 14. Proposed mechanism o f  reductively triggered release o f drugs from  
4 ,7-dioxoindole-3-methyl prodrugs161.
In view of the high inhibitory potency of 5-iodo- and
5-bromoisoquinolin-l(2//)-ones , these inhibitors were chosen as the DRUG for 
linkage to the Triggers. Since the PARP-1 inhibitory activity of
isoquinolin-l(2/f)-ones depends critically on the benzamide group, masking of the 
pharmacophore was achieved either by attachment of the Trigger at oxygen (giving




1 -alkoxyisoquinolinones 2-alkylisoquinolin-1 -ones
R = H, I or Br
Their release studies, performed with reductant systems that were designed to mimic 
the bioreduction of heterocyclic nitro groups in hypoxic tissues, indicated a 
successful expulsion of 5-substituted isoquinolin-l-ones from 
1 -(5-nitrothien-2-ylmethoxy)isoquinolines and
2-(5-nitrofuran-2-ylmethyl)isoquinolines upon reductive triggering with 
sodium borohydride/ palladium/ aqueous propan-2-ol system. Isoquinolin-l-ones
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were also found to be rapidly and quantitatively released from their
2-(l-methyl-2-nitroimidazole-5-ylmethyl)- and l-(4,7-dioxoindole-3-methoxy) 
derivatives by treatment with with zinc/ ammonium chloride and tin(II) chloride 
respectively. Thus, our laboratory has successfully developed highly effective 
prodrugs for the selective delivery of PARP-1 inhibitors to hypoxic tissues.
1.11.2 Water-soluble PARP-1 inhibitors
It is noteworthy that the planar cyclic systems that appear to be so critical for 
PARP-1 inhibition, unfortunately, also make the molecule highly water-insoluble. 
Many of the potent PARP-1 inhibitors, such as 5-hydroxydihydroisoquinolin-l-one 
(17d), DPQ (22g), PND (24a), GPI-6150 (27) and INH2BP (41) have very poor 
water-solubility and this gives rise to various inherent practical problems.
As mentioned earlier in section 1.10.2, DMSO is often used in place of water as a 
biocompatible vehicle for in vivo administration. However, it is a potent scavenger of 
hydroxyl radicals. Thus it is able to reduce the organ injury and dysfunction in 
situations where the production of hydroxyl radicals is observed, such as 
haemorrhagic and endotoxic shock. Moreover, DMSO itself also inhibits PARP-1 
activity133. This causes a great amount of ambiguity in the determination of the actual 
PARP-1 inhibitory activity of the compound in question. In addition, low 
water-solubility may also present formulation problems later in the drug 
development process.
Our laboratory has recently described a new, reliable and 
efficient synthesis of the known PARP-1 inhibitor 5AIQ (23d)
(IC50 0.24 jLiM)103. This inhibitor, which was only sparingly 
soluble in water, was then converted to its highly water-soluble 
hydrochloride salt, 5AIQ.HC1, and subsequently we, in 
collaboration with Professor Christoph Thiemermann and other 5AIQ.HC1 
research groups, proceeded to investigate its pharmocological 




infarction , ischaemia-reperfusion of the liver and kidney , heart 
transplantation101 and acute lung inflammation111. In all these studies, 5AIQ.HC1 was 
found to exhibit tremendous therapeutic benefits. Particularly noteworthy are its 
protective effects on ischaemia-reperfusion injury caused by severe haemorrhage and 
resuscitation in anaesthetized rats where it demonstrated exceptional potency in
1 fttabolishing multiple organ injury and dysfunction : Compared to other PARP-1 
inhibitors such as 3-aminobenzamides (8) (10 mg Kg'1 i.v.) and
5-hydroxyisoquinolin-1 (2//)-one (17d) (1-3 mg Kg'1 i.v.), only a remarkably low i.v. 
dose of 0.03 mg Kg'1 is required to confer similar protection. The concentration at 
which 5AIQ.HC1 provides protection against oxidative injury (0.1-0.3 jiM) in vitro 
does not appear to be consistent with its unusually high in vivo efficacy. It appears 
that 5AIQ.HC1 gains much of its advantage over other PARP-1 inhibitors through its 
excellent water-solubility, which conferred it with favourable pharmacokinetics, such 
as good bioavailability and biodistribution.




2.1 Aims of the research
The aim of this research is to design and to synthesise potent, selective and 
water-soluble PARP-1 inhibitors using currently established SAR.
2.2 Research proposal
Armed with highly encouraging potency in vivo, enzyme selectivity and the very 
good water-solubility of 5AIQ.HC1, we decided to build upon this lead by designing 
and synthesising a series of related inhibitors which are novel. The important design 
criteria are high selectivity and potency, while retaining the excellent 
biopharmaceutical properties. As such, the 5-amino group, which enables 5AIQ to be 
easily converted into the water-soluble hydrochloride salt and consequently giving it 
excellent in vivo potency, will be retained in the design.
Previous studies on the dihydroisoquinolin-l(2//)-one and isoquinolin-1 (2//)-one 
classes of PARP-1 inhibitors centred around modifications at the 5, 6, 7 or 
8-position138'158 and, to date, very little is known about the 
effects of substituents on the 3- and 4-positions on their 
PARP-1 inhibitory activity. However, X-ray crystallographic 
data from other classes of PARP-1 inhibitors, such as 
quinazolinones (31) and phthalazinones (33), seemed to suggest 
that substituents may be permitted at these regions and that they 
probably bind to the hydrophobic pockets142'149. Thus an 
introduction of substituents (alkyl and aryl) at the 3- or 
4-position of 5AIQ may further improve its potency through an 
increased interaction with the active site. This has, therefore, 
led us to the investigation of a series of 3-substituted (44) and
4-substituted isoquinolin-l(2//)-one hydrochlorides (45), with
NHiCl R
(45)
R = alkyl or aryl
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particular emphasis on the former.
The proposed target compounds have many desirable structural properties. It 
contains the benzamide pharmacophore which is considered an essential pre-requisite 
for significant PARP-1 inhibitory activity (Figure 10). In addition, the amide 
function is incorporated into an aromatic, heterocyclic fused ring.
1. This restricts the amide group at an anti-conformation which is the 
orientation required for hydrogen-bonding with the active site.
2. The presence of the electron-rich aromatic ring system will further enhance 
the ability of the carbonyl group to participate in hydrogen-bonding.
3. A large, planar fused ring will also increase the non-polar interaction between 
the aromatic ring and the active site and possibly contributing to an increased 
potency.
Recent X-ray crystallographic data have also demonstrated 
possible hydrogen-bonding between Glu988 and the amino 
group of 4-amino-1,8-naphthalimide (26b)142. Since this 
corresponds, approximately, to the 5-position of 5AIQ, it is 
likely that the 5-amino group in 5AIQ may also display 
similar interactions with the active site, thereby contributing 
to its exceptional PARP-1 inhibitory potency in vivo. It is therefore of interest briefly 
to examine this interaction through the synthesis of an A-substituted 5AIQ (46).
It was intended that these novel target compounds be initially tested for their water 
solubility and their in vitro PARP-1 inhibitory potency. This would allow a 
systematic analysis of the SAR on the effects of substituents at the 3-position of this 
class of compounds, through which further structural refinement for greater potency 
may be achieved. Selected inhibitors will subsequently be evaluated for their in vivo 
protective ability in various disease models in animals, especially their effects 
against ischaemia-reperfusion injury and inflammatory disorders.
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Results and Discussions
3.1 3-Substituted 5-aminoisoquinolin-l(2H)-ones 
• 3.1.1 Retrosynthetic analysis
The first series of target compounds that were investigated were the 3-substituted
5-aminoisoquinolin-1 (2//)-ones. In designing our synthetic strategies, conscious 
effort was being made to ensure sufficient versatility to allow for a great variety of 
substituents (alkyl and aryl substituents of various electronic and steric nature) to be 
attached at the 3-position via a common synthetic route. Ideally, diversification 
should occur at a late stage of synthesis to avoid inefficient repetition of synthetic 
steps. Thus, preparative methods that call for a late disconnection of 3-substituents 
and those that are not generally amenable for the convenient introduction of 
substituents at the 3-position, such as reduction of phthalides , ozonisation of 
indenes163 and oxidation of isochromans164 were not considered.
Retrosynthetic analysis of our 3-substituted target gave the pathway as illustrated in 
Scheme 1. We approached our retrosynthesis by first performing two functional 
group interconversions (FGI) on the target molecule and this led us to the 
corresponding 5-nitroisocoumarin (47). These conversions are reasonable, as both 
the reduction of the nitro group to amine (e.g. via hydrogenolysis or acid/metal 
reduction) and the conversation of isocoumarin to isoquinolin-1 (2H)-one (e.g. by 
treatment with boiling ammonia-saturated 2-methoxyethanol) are well-established 
reactions that are highly reliable and efficient. Though the nitro group, being highly 
electron-withdrawing, is likely to reduce the reactivity of the aromatic ring towards 
electrophilic attack and should, in most cases, be disconnected first, we reasoned that 
an incorporation of nitro group during the beginning of synthesis will avoid the need 
for subsequent regioselective nitration of the 3-substituted isocoumarin or 
isoquinolin- l(2//)-one ring.
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The challenge, then, was to devise a synthetic strategy for the construction of the 
isocoumarin (47). Disconnection at the C-O bond of the isocoumarin as shown, i.e., 
ring opening is rational because the reverse lactonisation process is a very fast 
reaction, easily accomplished, for instance, through the use of an acid catalyst. This 
took us to back to synthon (48) which may be disguised in the form of an aryl alkyne 

























Scheme 1. Retrosynthetic analysis o f the 3-substituted target.
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3.1.2 Route I: aryl alkyne formation
Route I requires the formation of functionalised aryl alkynes (49) (Scheme 2) which 
is most reliably and conveniently achieved using organometallic approaches. A 
number of aryl-alkyne coupling methodologies have been developed over the past 
few decades and the most widely exploited methods involved the reaction of aryl 
halides or triflates with terminal alkynes under palladium or palladium/copper 
catalysis, such as Sonogashira coupling reaction and alkyne version of Heck 
coupling reaction165. Alternatively, coupling reactions with metallated (tin, zinc) 
alkynes under palladium catalysis, such as Negishi alkynylation166 have also been 
satisfactorily applied in a number of cases.
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Among this wide array of coupling reactions, it was decided that Sonogashira 
coupling reaction167 be used for the synthesis of this aromatic alkyne because it has 
enjoyed tremendous success in the synthesis of a wide range of heterocyclic 
compounds and is generally considered to be superior over other currently known 
protocols. It is also highly versatile, has great tolerance for nearly all types of 
functional groups and may be carried out under extremely mild conditions. This is 
especially important since two sensitive functional groups (nitro and carbonyl 
groups) are both present in our initial target (49). Sonogashira reaction cross-couples 
an aryl or vinyl halide (electrophile) with a terminal alkyne (nucleophile) in the 
presence of an aliphatic amine (base) and a catalytic amount of palladium-phosphine 





Scheme 3. Representative reaction conditions for Sonogashira coupling reaction.
1 bRAccording to Sonogashira , the general order of reactivity of the organic halide is 
in line with the reactivity of the leaving group. Hence an iodo-aryl generally affords 
shorter reaction times and higher yield compared to its bromo or chloro counterparts. 
In addition, Sakamoto et al recently reported that the cyclisation of 
ethyl 2-phenylethynylbenzoate, via heating with sulphuric acid in the presence of 
mercury(II) sulphate, gave 3-phenylisocoumarin in much higher yield (97%) 
compared to its corresponding carboxylic acid, 2-phenylethynylbenzoic acid, which 
afforded the same product in 18% yield. Thus, to ensure high yield in subsequent 
annulation process, we decided to use an iodo-ester instead of an iodo-carboxylic 
acid as the electrophile for the coupling reaction.







Based on these observations, a C-C disconnection of (49) (Route A, Scheme 2) led 
us back to two starting materials: methyl 2-iodo-3-nitrobenzoate (68) and the 
substituted ethyne (51). Accordingly, a direct Sonogashira coupling between the 
halide (68) and the alkyne (51) would afford the desired functionalised aryl alkynes 
(49). However such an approach presents two major potential problems:
1. The use of sterically hindered aryl halides, such as compound (68), is
generally known to interfere with the success of the coupling reaction. It has
previously been observed that reactions in which one or both ortho positions
of the halide were substituted were considerably more difficult and they
1usually suffered from poor yield .
2. Most substituted ethynes of the type (51) are either very expensive or not 
commercially available and their synthesis is tedious.
To overcome these difficulties, a conversion of halide (68) to a sterically less 
hindered alkyne (71), i.e. a switch of the coupling partners was considered (Route B, 
Scheme 2). The alkyne (71) will then serve as a precursor through which the various 
desired substituents may be introduced through Sonogashira coupling with 
appropriate organo-iodides. Unlike substituted ethynes (51), organo-iodides are 
relatively cheap and widely commercially available. Hence the type of substituents 
that could be introduced by this route would not be limited.
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The most direct route to the synthesis of alkyne (71) is to cross-couple the iodo-ester 
(68) with ethyne gas (Route C, Scheme 2). However the alkyne that was initially 
formed, (71), would be more acidic than ethyne itself, thus competing more 
favourably for coupling reaction with halide (68) and ultimately leading to the 










Scheme 4. Formation o f 1,2-disubstituted alkyne from Sonogashira coupling 
reaction between alkyne (71) and iodo-ester (68).
An indirect route involving protection and deprotection of the ethynyl group is, 
therefore, necessary and the protecting group that is commonly used for this purpose 
is the trimethylsilyl (TMS) group. Thus, an alternative method for the synthesis of 
alkyne (71) would be to couple halide (68) with trimethylsilylacetylene (TMSA), 
which is commercially available, followed by TMS-deprotection of the resultant 
alkyne (69) as illustrated in Route D (Scheme 2).
Regardless of the actual synthetic route chosen, all the Sonogashira coupling 
processes outlined above inevitably required the use of 
methyl 2-iodo-3-nitrobenzoate (68) as the halide electrophilic partner. Since this 
compound was not commercially available, our preliminary aim, was to synthesise 
this iodo-ester.
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3.1.3 Synthesis of methyl 2-iodo-3-nitrobenzoate
Retrosynthetic analysis suggested methyl 2-aminobenzoate as a suitable starting 




















Scheme 5. Retrosynthetic analysis, o f  methyl 2-iodo-3-nitrobenzoate (68).
A nitro group was first introduced at the 3-position by means of standard nitration 
procedure utilising a mixture of nitric acid and acetic anhydride in acetic acid at 
10±5°C (Scheme 6). Relatively mild nitrating conditions were necessary since the 
employment of more forceful conditions, such as mixed nitric and sulphuric acids, 
would risk oxidising the amino group. It is likely that the acetic anhydride acetylates 
the amino group of the starting material, methyl 2-aminobenzoate, thereby protecting 
it from oxidation. Alternatively, acetylation could also occur after the ring has been 
nitrated, i.e. in compound (64), since the highly electron-donating amino group 
greatly enhances the rate of electrophilic substitution of NC>2+ species onto the 
aromatic ring. This ring-activating property of the amine was taken into 
consideration in deciding the sequence of synthesis. Reversing the order, i.e. to 
replace the amino group with the iodo function first, would have resulted in a marked
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deactivation of the benzene ring, making it much less reactive towards subsequent 
electrophilic substitution of NC>2+.
The above reaction yielded a mixture of 5- (61) and 3- (62) nitro compounds which 
was in line with the strong o,p-directing effect of the amino function. There was no 
formation of 3,5-dinitro products. This, again, is conceivable since the nitro group is 
deactivating and the reaction usually stops after one nitro group has entered into the 
ring. The desired 3-nitro compound (62) was then separated from its isomer (61) by 
column chromatography and it was found to be the minor product (20% yield). 
Given that the electronic environment of the 3- and 5-position are about the same, a 
preference for the formation of the 5-nitro isomer was probably due to the presence 
of a bulky acetamido group which made electrophilic attack by the bulky NC>2+ more 
difficult at the 3-position compared to the 5-position.
The acetamido function of (62) was then hydrolysed back to the amino group with 
boiling aqueous hydrochloric acid. This gave the carboxylic acid (63) which was 
subsequently converted to the methyl ester (64) via acid-catalysed esterification 
process. Finally diazotization (NaNC>2, HC1) and iodination (KI, I2) of this ester gave 
the desired methyl 2-iodo-3-nitrobenzoate (68) but at an unexpectedly low yield of 
4%. Since this iodo-ester was required to serve as the starting material for the 
preparation of the target compounds and a large quantity of it was required, this 
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Scheme 6. Chemical synthesis o f methyl 2-iodo-3-nitrobenzoate (68).
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Two possible complications with this reaction were proposed:
1. The amino group of (64) is ortho to two strongly electron-withdrawing 
groups, namely the nitro and ester functions and this probably decreases the 
reactivity of the amine towards diazotization.
amino and the ester groups leads to the formation of a stable six-membered 
ring which may further decrease its reactivity.
To circumvent these problems, another method of synthesis employing commercially 
available 2-amino-3-nitrotoluene as starting material was considered (Route B, 
Scheme 6). In this starting compound, the nitro group was already correctly placed at 
the 3-position. This enabled us to avert the highly inefficient nitration process which 
was previously found to nitrate preferentially at the 5-position. In addition, it was 
believed that the replacement of the electron-withdrawing ester function with a 
methyl group would render the amino group more reactive towards diazotization and 
iodination now that the ring-deactivating effect of the ester function and the highly 
stabilising intramolecular hydrogen-bonding were removed. Indeed, this was borne 
out by the relatively much higher yield of iodinated product (65) (78%) obtained 
when 2-amino-3-nitrotoluene was treated with analogous diazotization and 
iodination conditions. Unfortunately, subsequent oxidation of the methyl group with 
potassium permanganate was unsuccessful and the reaction gave a black solid that 
could not be identified, instead of the desired carboxylic acid (67). The presence of 
the iodo and nitro functions presumably interfered with the oxidation process.
2. In addition, highly favourable intramolecular hydrogen-bonding between the
o
Hydrogen-bonding




This led us to consider yet another synthetic approach, Route C, which was first 
described by Culhahe et al169. Unlike the preceding methods, Route A and B, this 
route utilises a different mechanism for the introduction of the iodo function, i.e. via 
decarboxylative-iodination of 3-nitrophthalic acid (Scheme 6). The latter was an 
attractive compound to start with as both the required carboxylic acid (1-position) 
and nitro functions (3-position) were already in correct relationship (meta) to each 
other. The nitro function also played a crucial role in controlling the regiospecificity 
of mercuration and decarboxylation as will be discussed later. Finally,
3-nitrophthalic acid was commercially available and was relatively cheap, making 
large-scale synthesis of the preliminary target (68) feasible.
The first stage in the synthesis was to decarboxylate 3-nitrophthalic acid with 
mercury(II) acetate, followed by electrophilic iodination with a mixture of iodine and 
potassium iodide (Scheme 6). Interestingly, this afforded only the desired
2-iodo-acid (67) (65% yield) without formation of any of the possible side products 
arising from iodination at the 1-position. Theoretically either one of the two 
carboxylic acid groups in 3-nitrophthalic acid could undergo mercuration/iodination 
to give a mixture of 1- and 2-iodinated products. The lack of formation of the former 
implied that mercuration has occurred regiospecifically at the 2-position. It appeared 
that the nitro function played an important role in directing electrophilic attack to the 
carboxylic acid which is ortho to itself since such regioselectivity was also observed 
in the mercuration of nitrobenzene where only the ortho position was being 
substituted170. Presumably the reaction proceeded through a free radical mechanism 
via an aryl-mercury intermediate, 2-hydroxymercuri-3-nitrobenzoic acid (66) as 
illustrated in Scheme 7. Incidentally, the nitro function itself is resistant to direct 
substitution by iodine.
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1. Free radical generation















Scheme 7. Proposed mechanism for the decarboxylative-iodination of
3-nitrophthalic acid.
The second stage involved an F^SCVcatalysed esterification of the iodo-acid (67) 
and this reaction proceeded smoothly affording its corresponding methyl ester (68) in 
excellent yield (95%). Thus, in three simple and reliable steps, we successfully 
synthesised compound (68) which was to serve as an important precursor for the next 
reaction— the Sonogashira coupling reaction.
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3.1.4 Sonogashira coupling reaction
As discussed earlier in section 3.1.2, it was intended that the synthesis of (71) be 
accomplished via a Sonogashira coupling between iodo-ester (68) and 
trimethylsilylacetylene (TMSA), followed by deprotection of the resulting alkyne 
(69) (Route D, Scheme 2). The coupling reaction was performed in the presence of a 
catalytic amount of bis(triphenylphosphine)palladium(II) chloride [(PPhs^PdC^] 
and copper(I) iodide in diisopropylamine (DIPA) and dry THF. The mixture was 
stirred at 45°C for 72 h under argon.
The catalyst, or pre-catalyst to be exact, used in this reaction, (PPh3)2PdCl2, was 
prepared separately by heating a mixture of palladium(II) chloride and two 
equivalent of triphenylphosphine in DMF at 80°C for 24 h. Although the 
coordinatively unsaturated Pd(0) is the catalytically active species, it is often more 
convenient to use Pd(II) derivatives, such as palladium(II) acetate [Pd(OAc)2] and 
bis(acetonitrile)palladium(II) chloride [(MeCN^PdCb] because they are usually 
more stable and less sensitive to air than their Pd(0) counterparts. They are also 
generally more soluble in organic solvents. The copper(I) salt functions as an 
important co-catalyst that facilitate the substitution reaction, without which, the 
reactions invariably fail. Diisopropylamine (DIPA), on the other hand, serves as a 
base and is sometimes used as a solvent. Other alkyl amine bases that are also 
commonly used for Sonogashira coupling include triethylamine and diethylamine.
Although the detailed mechanism of the reaction is yet to be established, it seemed 
likely that the substitution reaction occurs via a catalytic cycle which consists of


















Scheme 8. Proposed mechanism for Sonogashira coupling between 
methyl 2-iodo-3-nitrobenzoate (68) and trimethylsilylacetylene.
Under the reaction conditions, (PPhs^PdCU was rapidly reduced in situ to give the 
catalytic species bis(triphenylphosphine)palladium(0). Oxidative addition of this 
Pd(0) complex with the aryl iodide (68) gave a Pd(II) intermediate (52), which, in 
turn, underwent transmetallation with an alkynyl copper species (53) to yield a 
diorgano-Pd(II) complex (54). The copper species (53) was generated in situ from a 
reaction between TMSA and the co-catalyst copper(I) iodide, with the aid of 
diisopropylamine (DIPA) as shown in Scheme 9. The conversion of TMSA to (53), 
which underwent transmetallation more readily, greatly accelerated the coupling 
process since transmetallation is the rate-determining step in the whole cycle. Finally 
coupling of the two organic ligands and elimination gave the desired
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methyl 3-nitro-2-(2-trimethylsilylethynyl)benzoate (69) in 30% yield with 
concomitant regeneration of the Pd(0) catalyst, thus closing the catalytic cycle. The 
reaction also gave methyl 3-nitrobenzoate (70) as a side product (39% yield). It was 
believed that the latter was formed as a result of a replacement of iodine with 
hydrogen during the coupling process. Presumably steric retardation of the rate of 





Scheme 9. Formation o f alkynyl copper species (53) from a reaction between TMSA 
and copper(I) iodide under the presence o f diisopropylamine (DIPA).
In general, the reported yield for most Sonogashira coupling reactions vary from 
good to excellent (70-95%). The long reaction time (72 h), modest yield of the 
desired alkyne (69) (30%) and relatively high yield of the unwanted side product (70) 
(39%) could be indications of sub-optimal experimental conditions for this particular 
coupling reaction. Alternatively, it could also signify an inherent problem associated 
with the use of sterically hindered halides such as compound (68) where both its 
ortho positions were substituted with bulky groups. It is noteworthy that virtually all 
the successful Sonogashira reactions reported, to date, involved relatively unhindered 
aryl halides. 2-iodonitrobenzene and methyl 2-iodobenzoate were about the closest 
examples we could find in the literature that were comparable to our experiment. 
Thus, it was not unexpected that the reaction with halide (68) suffered low yield.
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If steric factors were indeed the problem, we reasoned that a replacement of the 
bulky ester function with a “slender” nitrile group might help relieved some of the 
steric strain on the halide, resulting in better yield. To explore this idea,
2-iodo-3-nitrobenzonitrile (74) was synthesised. This was easily achieved in 
excellent yield from its carboxylic acid (67) via dehydration of its corresponding 
amide (73) as shown in Scheme 10. Surprisingly, subsequent analogous Sonogashira 
coupling with TMSA did not afford the desired coupling product or the reduced 
product (70). Instead it gave the starting material (74) in virtually quantitative yield. 

























Scheme 10. Chemical synthesis o f 2-iodo-3-nitrobenzonitrile (74) and its 
Sonogashira coupling with TMSA.
Simultaneous effort was also directed at re-examining the experimental conditions. 
Attempts to improve the efficiency of the Sonogashira coupling reaction by varying 
the following parameters were unsuccessful.
• Reaction temperature
• Palladium catalyst used: tetrakis(triphenylphosphine)palladium(0), 
palladium(II) acetate
• Alkyl amine base used: diethylamine, triethylamine
• Protecting group for ethyne: triisopropylsilane acetylene (TIPSA)
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Despite not being able to improve the yield of the coupling reaction, we moved on to 
desilylate alkyne (69) to methyl 2-ethynyl-3-nitrobenzoate (71) (Scheme 11). This 
was accomplished by stirring compound (69) with tetrabutylammonium fluoride 
(TBAF) in THF at 0°C. However the yield this reaction was disappointingly low 
(9%). Attempts to improve the yield using other deprotection methods, such as 
potassium fluoride and methanolic potassium carbonate were unsuccessful. The 
difficulties encountered and the low yield obtained discouraged further synthetic 
steps. Nevertheless, it must be said that a successful synthesis of arylalkyne (69), 
albeit in modest yield, greatly encouraged us to investigate the viability of using 
direct coupling of the iodo-ester (68) with substituted ethyne (51) to effect synthesis 
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Scheme 11. Sonogashira coupling o f methyl 2-iodo-3-nitrobenzoate (68) with 
phenylethyne and TMSA and subsequent desilylation o f  
methyl 3-nitro-2-(2-trimethylsilylethynyl)benzoate (69).
We begin our studies by first performing a Sonogashira coupling reaction between 
(68) and phenylethyne (the least expensive one among the few commercially 
available aryl ethynes) under the same reaction conditions as with TMSA. Quite 
unexpectedly, this reaction gave the coupling product,
(71) 9%
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methyl 3-nitro-2-(2-phenylethynyl)benzoate (84), in very good yield (80%) and the 
reaction was completed in a much shorter period of time (48 h compared to 72 h with 
TMSA). Again, as in the previous reaction, the reduced side product (70) was 
isolated, but in relatively lower yield (18%) (Scheme 11).
Having successfully coupled phenylethyne to the iodo-ester (68), we carried on to 
explore the reaction with other aryl ethynes. This required, first and foremost, the 
synthesis of a series of ethynes with the desired functionalities since most of them 
were not commercially available. To achieve this, we cross-coupled the various 
suitably substituted aryl iodides with TMSA under Sonogashira reaction conditions, 
followed by desilylation of the coupling products with TBAF. The results of the 
experiments were summarised in Table 12.
(PPh3)2PdCl2
Cul TBAF
R 1 +  ^ -----TMS ----------------------- ► R-----^ -----TMS ------------------► R-----
TMSA DIPA
Yield of products (%)
R K ------ — 1 M o K " ri
jy 91 (75) 83 (76)cr 93 (77) 64 (78)
jy 90 (79) -
jy 95 (80) -
yy 92 (81) -
yy 95 (82) -
89 (83) -
Table 12. Synthesis o f  a series o f  substituted ethynes via Sonogashira 
coupling reaction. (-) denotes unsuccessful attempts.
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It is interesting to note that all coupling reactions studied proceeded with excellent 
yield (ca 90%) regardless of the nature of the substituents, demonstrating once again 
the wide applicability of Sonogashira coupling reaction. Desilylation was again the 
problematic step in the synthesis. Among the various alkynylated products, only
4-nitro-l-[(trimethylsilyl)ethynyl]benzene (75) and
4-[(trimethylsilyl)ethynyl]pyridine (77) underwent deprotection smoothly to give
l-ethynyl-4-nitrobenzene (76) and 4-ethynylpyridine (78), respectively, while the 
rest remained largely unchanged under the reaction condition. Unable to account for 
the repeated lack of success in this seemingly standard deprotection reaction, we 
decided to switch to another method of synthesis that eliminated the need for 
desilylation altogether.
Negishi171 has recently described a novel method for the direct synthesis of terminal 
alkynes without the need for protection and deprotection of the ethynyl group. It was 
observed that ethynylmagnesium bromide readily cross-coupled with a variety of 
aryl iodides in the presence of palladium-phosphine catalyst, such as 
tetrakis(triphenylphosphine)palladium(0) ((PPh3)4Pd) to produce directly the 
corresponding terminal alkynes in high yield. However there is one severe limitation 
associated with this method of preparation. The high ionicity of C-Mg bond in 
organo-magnesium reagents renders them extremely reactive towards electrophilic 
functionalities, such as the carbonyl and the nitro groups. Consequently, this method 
was not previously considered for the direct synthesis of 
methyl 2-ethynyl-3-nitrobenzoate (71) from methyl 2-iodo-3-nitrobenzoate (68).
Using this Negishi protocol, we successfully synthesised
l-ethynyl-4-methoxybenzene (117) and l-ethynyl-4-methylbenzene (118) in 
excellent yields of 90% and 92% respectively. Presumably, functional groups, such 
as trifluoromethyl, chloro and thiophene were incompatible with the 
organo-magnesium reagent under the reaction conditions, hence accounting for the 
failure of these halides to cross-couple with ethynylmagnesium bromide. The results 
were summarised in Table 13.
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(PPh3)4Pd
R 1 i = =  M gBr  ► R‘
T H F
R Yield of






Table 13. Synthesis o f a series o f  substituted ethynes via 
Negishi coupling reaction. (-) denotes unsuccessful attempts.
Sonogashira coupling reactions between iodo-ester (68) and the following ethynes:
1-ethynyl-4-nitrobenzene (76), 4-ethynylpyridine (78), l-ethynyl-4-m ethoxybenzene 
(117) and l-ethynyl-4-m ethylbenzene (118) were then undertaken (Table 14). To our 
great disappointm ent, none o f the reactions were successful and m ost o f them  
afforded only the de-iodinated side product (70). This observation is puzzling in view 
of the success that we had w ith phenylethyne. W e do not consider these substituted 
aryl ethynes to be sterically very different from  phenylethyne, especially
4-ethynylpyridine (78), hence the differences in the fate of these ethynes cannot be 
explained sterically. The outcom e also appeared to be independent o f the electronic 
nature o f the ethyne used since both electron-deficient ethynes,
1-ethynyl-4-nitrobenzene (76), and electron-rich ethynes,












Yield of products (%)
R Aryl alkyne (70)
TMS 30 (69) 39
TIPS - -
a 80 (84) 18jcr " 26
jcr ■ 6
„ „ J C r
"
12a " -
Table 14. Sonogashira coupling reaction between halide (68) and various 
substituted ethynes. (-) denotes unsuccessful attempts.
Thus, we have essentially exhausted all possibilities of synthesising our 3-substituted 
targets via Sonogashira coupling reaction and, regrettably, we were only able to 
prepare methyl 3-nitro-2-(2-phenylethynyl)benzoate (84) in good yield through this 
protocol.
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3.1.5 Cyclisation of methyl 3-nitro-2-(2-phenylethynyl)benzoate
The next step was to cyclise the aryl alkyne (84) using mercury(II) sulphate and 
concentrated sulphuric acid in acetone. It was believed that heteroannulation 
proceeded via the mechanism outlined in Scheme 12. The first step presumably 
involves the formation of the bridged mercurium complex (55) via electrophilic 
addition of Hg2+ to the alkyne. This was opened by an intramolecular attack by the 
carbonyl oxygen of the methyl ester. Theoretically, there are two possible ways in 
which cyclisation can occur. The carbonyl oxygen may either attack in a 5-exo-dig 
manner (Path A) to give a 5-membered side product, 3-benzylidene-4-nitro-phthalide 
(58), via cation (56) or it may undergo 6-endo-dig ring closure (Path B) to give the 
desired 5-nitro-3-phenylisocoumarin (86) via cation (57). According to Baldwin’s 
rules for ring closure172, both reactions are favourable because both carbon of the 
acetylene has two n* orbitals, one of which must always lie in the plane of the new 
ring, making it very easy for the lone pair on carbonyl oxygen to overlap with. Hence 
a mixture of phthalide and isocoumarin was expected from the reaction.
This was found to be generally true in the case of transition metal-catalysed 
cyclisation reactions. In particular, Ogawa et alm  recently reported that
2-(l-alkynyl)benzoic acid gave (Z)-3-(l-alkylidene)-phthalides and
3-alkylisocoumarin as major and minor products, respectively, in the presence of 
catalytic amounts of silver or silver(I) iodide. Likewise, treatment of the acid with 
catalytic amount of (MeCN^PdCL185 or zinc(I) chloride186 also yielded a mixture of 
phthalide and isocoumarin, though the latter was now found to be the major product. 
Sakamoto et alm  also reported similar findings for the mercury-mediated cyclisation 
of 2-phenylethynylbenzamide. However, they observed that the analogous 
cyclisation of the corresponding carboxylic acid, 2-phenylethynylbenzoic acid, and 
ester, ethyl 2-phenylethynylbenzoate, gave 3-phenylisocoumarin exclusively under
I 07
the same reaction conditions, in contrast to the results obtained by Villemin et al 
where they demonstrated that the sulphuric acid-catalysed heteroannulation 


























(86)n o 2 h
S c h e m e  1 2 .  Proposed mechanism for the formation o f phthalide (58) and 
isocoumarin (86).
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It appeared that the outcome of the cyclisation reaction was not only affected by the 
catalyst used, but also on the functional groups present in the aryl alkyne.
It is interesting to note that the heteroannulation process in our experiment was found 
to be completely regiospecific in that only one cyclisation product (a yellow solid) 
was obtained from this reaction and at an excellent yield of 95%. The task, then, was 
to establish the molecular structure of this yellow solid, or rather, to determine which 
of the two probable products, phthalide (58) or isocoumarin (8 6 ) was actually 
formed. It has to be said that both compounds are structural isomers and their 
differentiation is not straightforward.
1. To begin with, both isomers are novel compounds, hence their identity cannot 
be easily determined through a comparison of their melting points with 
authentic samples.
2. Their lH and 13C NMR spectra are also expected to be very similar. The 
vinylic protons for both the phthalide and isocoumarin are expected to give a 
signal at about the same region in the NMR spectrum, i.e., a chemical shift 
of about 6  to 7 p.p.m.
NOESY NMR spectra would be invaluable had there not been a nitro group 
at the 4- and 5-position of the phthalide and isocoumarin respectively.
3. Being isomers, they also share the same molecular mass and their 
fragmentation pattern from mass spectroscopy (Electron Impact or Chemical 
Ionisation) would not be very different.
4. Finally, though the yellow solid could be recrystallised easily with 
hexane-ethyl acetate mixture to form yellow needles, these crystals were 
considered too small and therefore unsuitable for X-ray crystallography 
determination.
Fortunately, we were provided with two valuable pieces of information from its IR 
(KBrdisc) and !H NMR (CDCI3) spectra. The yellow solid has a carbonyl C=0 
stretch of 1739 cm'1. It is known that the C=0 stretch of 5-membered lactone ring 
normally absorbs in the range between 1780 to 1760 cm'1, whereas that of the
79
6-membered lactone ring is observed at a lower range of 1750 to 1730 cm'1. Thus, 
this was our first hint towards a 6-membered isocoumarin structure.
We also observed that the vinylic proton gave a signal at 8h 7.89 p.p.m. and that this 
proton is coupled with one of the aromatic protons on the heterocyclic ring (doublet, 
J  = 0.8 Hz). The vinylic proton in phthalide is at least six bond distance apart from 
the nearest protons on the heterocyclic ring (5-H or 7-H). This is too far away for any 
significant proton-proton coupling to occur. The vinylic proton in isocoumarin, on 
the other hand, could interact with the proton at 8-position via extended W-type 
long-range coupling. Indeed, this was found to be the case as 8-H gave a 
double-double-doublet and one of its coupling constant (5J) is also 0.8 Hz.
These spectroscopic evidences allowed us to assign tentatively the isocoumarin 
structure, 5-nitro-3-phenylisocoumarin (86), to the yellow solid. Our result could be 
rationalised by the proposed mechanism depicted in Scheme 12. The presence of a 
neighbouring powerfully electron-withdrawing nitro group possibly made carbon B 
more electron-deficient compared to carbon A, thus greatly favouring 6-endo-dig 
over 5-exo-dig ring closure, accounting for the lack of formation of any 5-membered 
phthalide product.
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3.1.6 Formation of 5-amino-3-phenyisoquinolin-l(2Z7)-one hydrochloride
Having successfully synthesised isocoumarin (8 6 ), attempts were then made to 
reduce selectively the nitro function via catalytic hydrogenation with 10% Pd/C and 
hydrogen. Surprisingly, the compound remained unchanged even after stirring at 
room temperature for 24 h. It was thought that trace amount of mercury (mercury(II) 
sulphate was used in cyclisation reaction prior to this), which was not completely 
removed from the compounds during work-up procedures, could interfere with the 
reduction process by poisoning the palladium catalyst. This led us to the use of other 
nitro-selective reducing agents which are not normally affected by the presence of 
mercury, such as Raney Nickel and tin(EI) chloride. However, in both cases, the nitro 
group remained highly resistant towards reduction. In fact, treatment of the 
isocoumarin with tin(II) chloride in methanol at 70°C appeared to have resulted in 
ring opening of the lactone ring. This was evidenced from the JH NMR (CDCI3) 
spectrum of the product which gave a singlet for three protons at 8  3.93 p.p.m., 
indicating the presence of a methyl ester function. Such ring opening could be caused 
by a nucleophilic attack of the carbonyl carbon of the lactone ring by the methoxy 
anion. To overcome this problem, a more bulky protic solvent may be used. 
Alternatively, the isocoumarin could be converted to its corresponding 
isoquinolin- 1 (2//)-one (89) first, in the hope that the lactam ring, which was more 
resistant to ring-opening than the lactone ring, would be able to survive the 
conditions used during subsequent tin(II) chloride reduction (Scheme 13).
Many different chemical approaches have been reported in the literature for the 
conversion of isocoumarins to isoquinolin- 1 (2//)-ones. These include treatment with 
ethanolic ammonia in a sealed tube183, reaction with ammonium carbonate in acetic 
acid188 and heating with ammonia at high temperature158,159. The latter was one of the 
simplest procedures that have been published without recourse to difficult reagents 
and elevated pressure. Thus, isocoumarin (8 6 ) was treated with boiling 
ammonia-saturated 2 -methoxyethanol and this afforded
5-nitro-3-phenylisoquinolin-1 (2//)-one (89) in good yield (73%).
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The isoquinolin-l(2//)-one was then catalytically reduced with tin(II) chloride by 
heating at 70°C in ethanol. This time, the reaction went smoothly, albeit in a 
moderate yield of 57%, affording the target compound 
5-amino-3-phenylisoquinolin-l(2//)-one (90) which was only sparingly soluble in 
water. The latter was then converted to its hydrochloride salt by stirring with aqueous 
hydrochloric acid (2 M) for 30 min and the product, 
5-amino-3-phenylisoquinolin-l(2//)-one hydrochloride (91), was found to be readily 
soluble in water, with an aqueous solubility of more than 10 m gm l1. Thus, we have 
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3.1.7 Castro-Stephens coupling reaction
Castro and Stephens173 have previously demonstrated that a variety of aryl alkynes 
may be obtained by a copper-promoted cross-coupling reaction of aryl halides and 
copper(I) acetylides. It represents an earlier, “non-palladium” version of Sonogashira 
coupling reactions now commonly known as the Castro-Stephens coupling reaction. 
In one of their studies174 on the scope and utility of the reaction, they reported that 
the interaction of copper(I) acetylides with aryl halides bearing an ortho nucleophilic 
substituent did not furnish aryl alkynes, but rather underwent rapid cyclisation to the 
corresponding heterocycles exclusively and they claimed that 2-iodobenzoic acid 
reacted with copper(I) phenylacetylide to yield 3-phenylisocoumarin. However, 
regrettably, a few years later, they reported that the product has been erroneously 
identified and it was, in fact, the isomeric 3-benzylidenephthalide as proven by 
comparison with an authentic sample. Their work is summarised in Scheme 14 
below. Incidentally, Larock et a lm  repeated the coupling reaction with copper(I) 
propylacetylide using the ester equivalent, methyl 2-iodobenzoate and they obtained 







Scheme 14. 2-iodobenzoic acid reacted with copper(I) phenylacetylide to yield
3-benzylidenephthalide instead o f the isomeric 3-phenylisocoumarin174.
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We consider it possibly significant that the presence of a highly 
electron-withdrawing nitro group in the 2-iodo-3-nitrobenzoic acid (67) might favour 
the formation of isocoumarin rather than phthalide. This assumption was based on 
our earlier observation on the acid-catalysed, mercury-mediated ring closure of 
methyl 3-nitro-2-(2-phenylethynyl)benzoate (84) (section 3.L5) where a yellow 
solid, which was believed to be 5-nitro-3-phenylisocoumarin (86), was the only 
isomer isolated. Consequently this simple procedure, with appropriate experimental 
modifications, may provide an acceptable synthetic route to other 3-substituted 
5-nitroisocoumarins.
To test this hypothesis, we exposed 2-iodo-3-nitrobenzoic acid (67) (synthesised via 
the method described in Route C, Scheme 6) to copper(I) phenylacetylide in boiling 
pyridine under nitrogen. Copper(I) phenylacetylide is a bright canary yellow solid 
which was separately prepared by mixing an ethanolic solution of phenylethyne with 
an equivalent amount of copper(I) iodide in aqueous ammonia. Upon working-up, 
the coupling reaction gave a product (74% yield) which, to our excitement, has the 
same melting point and spectroscopic data (IR and NMR) as that of the yellow 
solid (86). Again, this was the only cyclisation product formed, thus supporting the 
idea that the ortho-nitro group does indeed have a crucial influence on the direction 
of ring closure. A small amount of the symmetrical diyne (87) was also isolated in 
5% yield. This was undoubtly the result of oxidative homodimerisation of copper(I) 
phenylacetylide, i.e. Glaser coupling, which is a frequent complication in 
Stephens-Castro coupling reaction if oxygen was not strictly excluded from the
175reaction mixture .
This methodology was then applied to a series of copper(I) acetylides as shown in 
Table 15. It is interesting to note that, among the five acetylides investigated, only 
copper(I) 4-methoxyphenylacetylide and copper(I) 4-methylphenylacetylide 
underwent successful coupling and in both cases they consistently gave just one 
cyclisation product, (97) and (103) respectively, along with the Glaser coupling 
products (96) and (102) respectively. The novel compounds, (103) could be 
recrystallised with a mixture of hexane and ethyl acetate to form large yellow
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needles. Subsequent X-ray crystallography (Appendix) supported the
5-nitro-3-(4-methylphenyl)isocoumarin structure, thus indirectly confirming our 
previous structural assignment on the yellow solid (86).
Cu-
pyridine +  R-
n o 2
Isocoumarin Glaser product
Yield of products (%)
R Isocoumarin Glaser producta 74 (86) 5 (87)
„jy 29 (97) 1 (96)




Table 15: Castro-Stephens coupling reactions between 2-iodo-3-nitrobenz.oic acid 
(67) and various copper(I) acetylides. (-) denotes unsuccessful attempts.
It is also noteworthy that though 4-methoxyphenylethyne (117) and
4-methylphenylethyne (118) failed to cross-couple under the Sonogashira protocol, 
their copper(I) derivatives underwent Castro-Stephens coupling smoothly. This 
seemed to suggest that one possible reason for the lack of success previously 
observed with Sonogashira coupling (Table 14) was that the substituted ethynes were 
not nucleophilic enough. Presumably they did not react with copper(I) iodide as 
proposed to give the copper(I) species. Instead they probably served as electrophiles 
for Michael-type additions with DIP A as shown in Scheme 15.
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Scheme 15. Michael-type addition reaction between substituted ethyne and DIPA.
Such complications have recently been reported by Yoneda et a /189 in their attempts 
to effect Sonogashira coupling of iodobenzene with trifluoromethylethyne under 
(PPh3)4Pd and diethylamine. They found that none of the coupling product was 
formed, instead the ethyne reacted with the amine to give the disubstituted alkene, 
N, N-diethyl-3,3,3-trifluoro-1 -propenylamine.
The poor nucleophilicity of copper(I) 4-nitrophenylacetylide, 
copper(I) 4-fluorophenylacetylide and copper(I) 4-pyridinylacetylide could also 
possibly account for their inability to undergo coupling with
2-iodo-3-nitrobenzoic acid (67).
On the basis of these experimental observations, the mechanism for the coupling
173process, originally proposed by Castro and Stephens , may now be adapted as 
follows (Scheme 16): 2-iodo-3-nitrobenzoic acid (67) initially cross-coupled with 
copper(I) acetylide to give a 4-membered transition state (58). This, upon extrusion 
of copper(I) iodide, led to the formation of the alkynylated compound which 
underwent rapid cyclisation to the corresponding isocoumarin. The cyclisation 
reaction could be catalysed by pyridine (acting as a base) or by copper (acting as a 












Scheme 16. Castro-Stephens coupling o f  2-iodo-3-nitrobenzoic acid (67) with 
copper(I) acetylide and subsequent cyclisation to form  the 3-substituted isocoumarin.
Incidentally, it has been reported that the reaction of copper(I) phenylacetylide with
2-iodobenzamide gave a deep red product 3-amino-2-phenylinden-1 -one (59) instead 
of 2-(2-phenylethynyl)benzamide (60) (Scheme 17)176. This discouraged attempt to 







Scheme 17. Castro-Stephens coupling o f 2-iodobenzamide with copper(I) 
phenylacetylide gave 3 -amino-2-phenylinden-1 -one (59) instead o f
2-(2-phenylethynyl)benzamide (60)176.
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We have also examined the possibility of using palladium-catalysed intramolecular 
Heck coupling reaction177, which couple an alkene with the halide to form a new 
alkene, for the construction of 5-nitro-3-phenylisocoumarin (86) as illustrated in 
Scheme 18. However, attempts to synthesise compound (166) via nucleophilic 












Scheme 18. Strategy fo r  the synthesis o f  5-nitro-3-phenylisocoumarin (86) via 
intramolecular Heck coupling reaction.
Thus we have investigated the various organometallic approaches to the synthesis of 
the 3-substituted isocoumarins and with the exception of
5-nitro-3-phenylisocoumarin (86), 5-nitro-3-(4-methoxyphenyl)isocoumarin (97) and
5-nitro-3-(4-methylphenyl)isocoumarin (103), most of them were synthetically 
inaccessible through these methods.
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3.1.8 Route II: enamine formation
While an exploration of Route I was underway, parallel effort was also directed at 
investigating the alternative synthetic strategy outlined in Scheme 1 which required 
the use of aryl ethene (50) as the equivalent of the synthon (48). We were quick to 
consider the use of the corresponding enamine, where the leaving group is a 
dimethylamino group (Route II), as our precursor since we have previously described 
a simple and reliable method of synthesising such enamines103,178.
We reported that a condensation of methyl 2-methyl-3-nitrobenzoate with 
dimethylformamide dimethyl acetal (dimethoxymethyl dimethylamine, DMFDMA) 
at high temperature (150°C) gave the enamine 
methyl 2-(2-£-dimethylaminoethenyl)-3-nitrobenzoate (166) (Scheme 19). 
Immediate passage of this crude enamine through undried silica gel (column 
chromatography) not only provides sufficient acid catalysis to hydrolyse the enamine 
and to cyclise the intermediate enol to 5-nitroisocoumarin, but also purifies the 
product, all in one elegant step. Greatly encouraged by the success and ease of this 
synthetic route, we decided to adopt this method for the preparation of our
3-sbustituted targets. We rationalized that similar treatment of 
methyl 2-methyl-3-nitrobenzoate with dimethylacetamide dimethyl acetal 
(1,1-dimethoxyethyl dimethylamine, DMADMA) and dimethylbenzamide dimethyl 
acetal (1,1-dimethoxyphenyl dimethylamine, DMBDMA) may give the desired
3-methyl-5-nitroisocoumarin (88) and 5-nitro-3-phenylisocoumarin (86), 
respectively. This would represent a convenient and flexible method for the 
















N 0 2  ( 8 8 )
(DMBDMA)
Scheme 19. Chemical synthesis o f 5-nitroisocoumarin (155) via condensation o f  
methyl 2-methyl-3-nitrobenzoate (154) with DMFDMA and proposed synthesis o f
3 -methyl-5-nitroisocoumarin (88) and 5-nitro-3-phenylisocoumarin (86) via similar 
treatments.
However, to our surprise, we found that the condensation of compound (154) with 
DMADMA give a deep red solid, the strong colour of which suggested that it was 
probably not the expected 3-methyl-5-nitroisocoumarin (88) as most
5-nitroisocoumarins are yellow. This was supported by the lack of a carbonyl 
absorption in the IR spectrum. The *H NMR spectrum showed five aromatic protons 
together with signals for NMe2 (a singlet integrating for 6 protons at 8 3.13 p.p.m) 
and OMe (a singlet integrating for 3 protons at 8 4.00 p.p.m). These data, together 
with the mass spectrum, allowed the assignment of the naphthalene structure (167) to
17Rthe red solid . This novel compound was possibly formed via the following 
mechanism outlined in Scheme 20. Tautomerism of the enamine (168) to the 
alternative enamine (169), presumably via an iminium species, provides a 
nucleophilic carbon correctly located to attack the ester carbonyl to give (167). It is 
noteworthy that water is the only leaving group during this condensation reaction as
3-dimethylamino-5-nitronaphth-l-ol (170), which could be formed through the loss 
of methanol, was not obtained.
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Though the above reaction with DMADMA did not give the expected product, we 
reasoned that the condensation of (154) with DMBDMA remains a viable method for 
the synthesis of 5-nitro-3-phenylisocoumarin (86) since the intermediate enamine 
methyl 2-(2-Z-dimethylamino-2-phenylethenyl)-3-nitrobenzoate has no opportunity 
for tautomerism or further reaction under the conditions used. Unfortunately, we 
were unable to this examine this hypothesis as DMBDMA was not commercially 
available and we had difficulties synthesising it. The method described by Hanessian 
et alm , i.e. heating A^/V-dimethylbenzamide with dimethyl sulphate at 90°C for 4 
hours, followed by dropwise addition of the cooled mixture to a dry solution of 
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Scheme 20. Proposed mechanism fo r  the formation o f
3-dimethylamino-l-methoxy-5-nitronaphthalene (167).
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3.1.9 Route III: enol formation
After several unsuccessful attempts, we decided to consider a different precursor— 
the enol equivalent (Route HI, Scheme 1). This was, by no means, an arbitrary 
choice. Two major synthetic considerations lie in favour of its use:
1. The enol may be retrosynthetically disconnected to give
2-halo-3-nitrobenzoic acid, a familiar starting material where a reliable 
method of synthesis for the iodo analogue (67) has already been established 
in the beginning of our study (section 3.1.3).
2. The critical step required for assembling the carbon framework corresponds 
to a well-known reaction, the Hurtley reaction.
Hurtley180 first observed that 2-bromobenzoic acid condensed smoothly with various 
P-dicarbonyl compounds in the presence of ethanolic sodium ethoxide and either 
copper powder or copper(II) acetate as catalyst (Scheme 21). Subsequent systematic 
investigation of the nature of this reaction by Cirigottis et alm  led to the following 
conclusions:
1. The reaction succeeds best with 2-bromobenzoic acid although 2-iodobenzoic 
acid can be expected to give low yields.
2. Replacement of the carboxylic acid by any other functional group such as 
ester and hydroxyl group prevents the reaction.
3. A copper species is an essential catalyst.
Shinkwin190 later demonstrated that Hurtley reactions could also be extended to 
thiophene equivalents. Thus, 4-bromothiophene-3-carboxylic acid condensed with 
pentane-2,4-dione in the presence of copper, sodium ethoxide and ethanol to afford
4-(l-acetyl-2-oxopropyl)thiophene-3-carboxylic acid. However the reaction failed 





















Scheme 21. Hurtley condensation reaction involving 2-bromobenzoic acid and its 
thiophene analogues190.
Accordingly, a possible method of preparing 3-substituted 5-nitroisocoumarin is to 
condense 2-bromo-3-nitrobenzoic acid (85) with the enolate of fi-diketones, followed 
by deacetylation and ring closure as shown in Scheme 22. Deacetylation could be 
achieved via acid hydrolysis while cyclisation may be brought about by treatment 














Scheme 22. Proposed synthesis o f  3-substituted 5-nitroisocoumarin.
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Thus, a synthesis of these starting materials was undertaken. The bromo-acid (85) 
was satisfactorily synthesised through mercuration (mercury(II) acetate) and 
bromination (sodium bromide/bromine) of 3-nitrophthalic acid and this gave a white 
solid in good yield (74%) (Scheme 6). The p-dike tones, on the other hand, were 
easily prepared in good to excellent yield by Claisen-type condensation reactions 
between the appropriate ketones and ethyl acetate. The results were summarised in 
Table 16. We found that most acetophenones could be satisfactorily acylated with 
acetic anhydride by means of boron trifluoride-acetic acid complex. Heterocyclic 
counterparts, such as 2-acetylthiophene and 4-acetylpyridine, however, were found 
to condense poorly under such acidic conditions. Nevertheless their yields were 
tremendously improved through the use of basic condensing agents, such as sodium 
amide.
It was found that two equivalents of base (sodium amide), one equivalent of ketone 
and two equivalents of ester (ethyl acetate) were necessary to ensure optimum yield 
of the P-diketones. This could be explained by the mechanism proposed in 
Scheme 23. In the first step of the reaction, the ketone is converted completely to its 
sodium derivative by one equivalent of sodium amide. In the second step, part of the 
ketone anion condenses with ethyl acetate to form the p-diketones which reacts 
rapidly in the third step with unchanged ketone anion to form its anion and the 
original ketone. However, in the presence of an extra equivalent of sodium amide, 
the third step will be effected by the strongest base present, which is sodium amide. 
Hence the use of excess base prevented partial lost of ketone anion, consequently 
increasing the yield appreciably. An excess of ester was also used as some of them 
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Scheme 23. Proposed mechanism for the formation of /3-diketones under basic 
conditions (NaNH2).
In all cases, !H NMR spectra gave signals that could be ascribed to both the enol and 
the keto forms, implying the existence of these compounds as a slow equilibrating 
mixture of both tautomers in deuterated chloroform. The enol tautomers shows 
characteristic *H NMR signals at ca 5h16 (OH) and ca 5h 6 (C=CH) whereas their 
corresponding keto tautomers have CH2 signals at ca 5h 4. As with most p-diketones, 
the equilibrium lies well over towards the enol forms (over 90% enol in most cases) 






Scheme 24. Conjugation and intramolecular hydrogen-bonding caused the 
equilibrium to lie well over towards the enol forms.
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As a preliminary study to establish suitable reaction conditions for the condensation 
reaction, 2-bromo-3-nitrobenzoic acid (85) was boiled under reflux with
4-hydroxy-4-[4-(trifluoromethyl)phenyl]but-3-en-2-one (108) using the same
180reaction conditions prescribed by Hurtley , i.e., sodium ethoxide/ethanol/copper 
powder system (Scheme 25). The result of this reaction is particularly interesting in 
that none of the expected substitution product (171) or de-acetylated compound (172) 
was obtained. Instead the following products were isolated from column 
chromatography: the desired isocoumarin
5-nitro-3-[4-(trifluoromethyl)phenyl]isocoumarin (109) and two side products:










(110) 11% (111) 6%(109) 5%
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Scheme 25. Hurtley reaction between 2-bromo-3-nitrobenzoic acid (85) and
4-hydroxy-4-[4-(trifluoromethyl)phenyl]but-3-en-2-one (108).
It appeared that the initially formed substitution product (171) underwent rapid 
retro-Claisen reaction to give the de-acetylated compound (172) which, in turn, 
cyclised into isocoumarin (109) as shown in Scheme 26. Such an effortless
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conversion to isocoumarin presumably depends on the unique role of the strongly 
electron-withdrawing nitroaryl system in stabilising the intermediate carbanion (173) 
which renders compound (171) remarkably sensitive to a base, thus promoting the 
spontaneous loss of acetyl group and cyclisation.
EtOAc .CO->H-CO^H
EtOH
c o 2h .c o 2h
‘O Cyclisation
(109) (172)
Scheme 26. Proposed mechanism fo r  the retro-Claisen reaction o f substitution 
product (171) to form  the de-acetylated compound (172).
Under Hurtley’s experimental conditions, cleavage of the p-diketones also occurred, 
affording the side products (110) and (111). These were presumably formed via 
nucleophilic attack by ethoxide anion at either of the carbonyl carbon (C-2 or C-4) as 
illustrated in Scheme 27. It was believed that these side reactions contributed, at least 









Scheme 27. Proposed mechanism fo r  the formation o f side products (110) and (111).
In view of these observations, the Hurtley reaction conditions were modified to a
potassium r-butoxide/r-butanol/copper powder system. It was anticipated that the
deliberate use of a bulky base/solvent system would discourage nucleophilic attack
on the P-diketones, yet without compromising basicity. Although results from
Bruggink’s studies182 indicated that copper(I) was the effective catalyst, our decision
•
to keep to the use of copper powder was purely on the ground of operational 
simplicity. While reaction using copper powder could be conveniently carried out 
under normal atmospheric condition, the employment of copper(I) salts, such as 
copper(I) bromide or copper(I) iodide as catalyst would necessitate the total 
exclusion of oxygen from the reaction to prevent oxidation of copper(I) to copper (II) 
ions.
Thus, condensations of 2-bromo-3-nitrobenzoic acid (85) with the potassium enolate 
of various p-diketones were undertaken using the above modified reaction 
conditions. The results were summarised in Method A, Table 17. In general, the 
reactions went smoothly for most experiments and they were completed within 16 h. 
A switch to the use of potassium f-butoxide as base has successfully prevented the 
cleavage of p-diketones as demonstrated by the absence, of cleavage side products. 
Consequently, the overall yield of the reaction was improved. For instance, the yield 
of 5-nitro-3-[4-(trifluoromethyl)phenyl]isocoumarin (109) has increased from 5% to 
16%. As with the previous system, both the substitution product and the 
retro-Claisen reaction product were not formed. Instead, the reactions invariably 
produced a mixture of 3-methyl-5-nitroisocoumarin (88) (minor product) and the
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Table 17. Condensation of compound (85) with various P-diketones. (-) denotes 
unsuccessful attempts. (*) denotes reaction not attempted.
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It was believed that the 3-aryl substituted 5-nitroisocoumarins and
3-methyl-5-nitroisocoumarin (88) were formed via de-acetylation and


















nqz y ^ o °
^r-BuO
Me
Scheme 28. Proposed mechanism fo r  the formation o f 3-aryl-5-nitroisocoumarins 
and 3-methyl-5-nitroisocoumarin (88) via de-acetylation and de-benzoylation 
respectively.
It seems that a preference for de-acetylation or de-benzoylation depends on a balance 
of electronic and steric effects. On electronic ground, de-benzoylation is favoured as 
the benzoyl carbonyl carbon is more electrophilic than the acetyl carbonyl carbon. 
Sterically, however, de-acetylation is preferred since the methyl group is less bulky 
compared to the phenyl group. Presumably in the case of isocoumarins (97), (103), 
(109), (116) and (123), steric hindrance of the phenyl ring outweighed its 
electron-withdrawing effects, thus 3-aryl substituted 5-nitroisocoumarins were 
obtained in greater yield compared to that of 3-methyl-5-nitroisocoumarin (88).
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Accordingly, we postulated that the yield may be increased through the use of
1,3-disubstituted p-diketones, in which case only one isocoumarin product is 
possible. This was borne out by the comparatively much higher yield obtained when 
analogous condensations of 2-bromo-3-nitrobenzoic acid (85) with 1,3-disubstituted 
P-diketones were carried out as illustrated in method B, Table 17. (Synthesis of the 
latter was achieved via the use of basic condensation reagents, sodium amide and the 
results were summarised in Table 18.) Particularly noteworthy were the yields of 
isocoumarin (86) and (97) which have escalated from 4% and 15% to 78% and 60% 
respectively. Improvement in yield for the 3-alkyl substituted isocoumarins, 
however, was modest, with yields ranging from 20% to 40%.
o
A .o np OH o o oR OEt
R ^  NaNH2 R ^  R
Et20
R Yield of products (%) / (ratio of enol (a): keto (b))or (135a,b) 50 (50:1)
Pentyl (140a,b) 75 (4:1)
Isobutyl (145a,b) 26 (10:1)
Table 18. Synthesis o f a series o f 1,3-disubstituted p-diketones. Pentane-2,4-dione 
(R=Me), heptane-3,5-dione (R=Et) and 2,2,6,6-tetramethyl-3,5-heptanedione 
(R= t-Bu) are commercially available.
At first thought, the presence of an additional aromatic substituent at the 3-position 
of the P-diketone was expected to make the latter more bulky and its corresponding 
carbanion less nucleophilic, hence, less reactive towards 2-bromo-3-nitrobenzoic
1 COacid (85). However as postulated by Bruggink and McKillop , the mechanism of 
the Hurtley reaction involved the formation of a copper chelate in which the 
copper(I) ion is coordinated in a planar manner to the bromo-acid (85) and the 
carbonyl oxygen atom in the p-dicarbonyl anion as illustrated in Scheme 29. Such an 
interaction brings the nucleophile within bonding distance of the carbon bearing the
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bromine, thus enabling it to react efficiently even though it is less nucleophilic. Once 
the substitution product has formed, retro-Claisen reaction became much easier than 
before as it now involved a nucleophilic attack by butoxide anion on the more 
electrophilic benzoyl carbonyl carbon rather than on the acetyl carbonyl carbon. 
These effects were also operative in the 1,3-dialkylsubstituted p-diketones but 





7Scheme 29. Proposed mechanism for Hurtley reaction .
The inability of cyclic or crowded p-diketones, such as 
2,2,6,6-tetramethyl-3,5-heptanedione (174), 3-methyl-2,4-pentanedione (175) and
1,3-cyclohexanedione (176) to react can also be satisfactorily explained by the 
proposed mechanism. While steric factors prevented the bulky P-diketones (174) and 
(175) from coming into close proximity with the electrophilic carbon for reaction, the 
structural rigidity of the cyclohexane ring in 1,3-cyclohexanedione (176) prevented it 
from assuming the appropriate conformation required for the formation of the 
tetrahedral copper(I) complex.
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Supposedly, P-diketones containing functionalities that are able to coordinate with 
the copper(I) ion, such as hydroxy and acetoxy groups might also compete with its 
carbonyl oxygen for binding with copper(I) ion, resulting in a distortion of the 
tetrahedral intermediate and the failure to react. This may account for the lack of 
success observed with p-dicarbonyls such as: 4-hydroxy-4-(4-nitrophenyl)but-3-en- 
2-one (127), 4-hydroxy-4-(4-pyridinyl)but-3-en-2-one (128), 4-hydroxy-4-(4'- 
hydroxyphenyl)-but-3-en-2-one (129) and 4-hydroxy-4-(4-acetoxyphenyl)but-3-en-
2-one (130).
What remained to be done was to convert these isocoumarins into their 
corresponding isoquinolin-1 (2//)-one hydrochlorides. This was accomplished by 
repeating the synthetic sequence outlined in Scheme 13, i.e.,
1. Conversion of the isocoumarins to isoquinolin-1 (2H)-ones by treatment with 
boiling ammonia-saturated 2-methoxyethanol.
2. Catalytic reduction of the nitro function via heating at 70°C with tin(II) 
chloride in ethanol.
3. Formation of its hydrochloride salt by stirring with aqueous hydrochloric acid 
(2M ) .
The yields of the experiments were summarised in Table 19 below.
Hence, we have successfully exploited the high reactivity of halo-organo 
compounds, under the catalytic influence of copper, for the synthesis of a series of
3-substituted 5-aminoisoquinolin-l(2H)-ones. These target compounds will be tested 
for their water-solubility and their in vitro PARP-1 inhibitory potency. This will be 










Y i e l d  o f  p r o d u c t s  ( % )
73 ( 8 9 )  
65 ( 9 8 )  
8 6  ( 1 0 4 )  
27 ( 1 1 2 )  
64 ( 1 1 9 )  
63 ( 1 2 4 )
83 ( 1 4 8 )  
6 8  ( 9 2 )  
38 ( 1 3 2 )  
29 ( 1 3 7 )  
89 ( 1 4 2 )
B
57 ( 9 0 )  
83 ( 9 9 )  
92 ( 1 0 5 )
40  ( 1 1 3 )
41 ( 1 2 0 )
6 6  ( 1 2 5 )
64 ( 1 4 9 )
59 ( 9 3 )  
24 ( 1 3 3 )
67  ( 1 3 8 )  
83 ( 1 4 3 )
91 ( 9 1 )  
95 ( 1 0 0 )
94  ( 1 0 6 )
92  ( 1 1 4 )
95  ( 1 2 1 )
94  ( 1 2 6 )
93  ( 1 5 0 )
95  ( 9 4 )
94  ( 1 3 4 )  
93 ( 1 3 9 )  
97 ( 1 4 4 )
T a b l e  1 9 .  The conversion o f a series o f 3-substituted isocoumarins into their 
corresponding isoquinolin-l(2H)-ones hydrochlorides.
3.2 4-substituted 5-aminoisoquinolin-l(2Z/)-ones
Following the successful synthesis of a series of 3-substituted 
5-aminoisoquinolin-1 (2//)-ones, we directed our attention to the synthesis of the
4-substituted 5-aminoisoquinolin-l(2//)-ones. These were also of considerable 
interest as potential PARP-1 inhibitors, since an examination of the PARP-1 active 
site indicated that there was a relatively large binding pocket in the region 
corresponding to the 4-position of the isoquinolin-1 (2//)-one ring which could 
potentially be exploited to enhance PARP-1 inhibitory potency. In addition, the SAR 
studies150 of a series of 4-substituted phthalazinones (33) further suggested that 
benzyl groups were well tolerated in that region and that they generally improve 
inhibitory activity. We began by conducting a series of preliminary studies to explore 
the possibilities of extending some of the synthetic approaches we have previously 
studied, such as organometallic synthesis, for the preparation of the 4-substituted 
targets.
3.2.1 Suzuki or Stille coupling reactions
The first approach takes advantage of the electronic differences between the 3- and 
the 4-position of the isoquinolin-l(2H)-onc ring. The 4-position is believed to be 
more nucleophilic, compared to the 3-position, due to mesomeric electron-donating 
effect of the ring nitrogen. This was borne out by the ^  NMR of
5-nitroisoquinolin-1 (2//)-one (160) in (CDs^SO, where the additional shielding 
effect caused the signal for 4-H to be shifted upfield by 0.48 p.p.m. with respect to
3-H. Such a difference in nucleophilicity, and thus reactivity towards electrophiles, 
between the 3- and 4-position can be exploited to attach an electrophile selectively, 
such as iodine or bromine, at the 4-position. The resulting halide (162) will be of 
great value in organometallic synthesis as a scaffold through which a diverse range 
of substituents may be introduced at the 4-position via appropriate organometallic 
reagents, such as organoboranes (Suzuki coupling reaction) or organostannanes 
(Stille coupling reaction). A series of 4-substituted targets would be expected to be 
easily and conveniently generated (Scheme 30).
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Thus, iodination of 5-nitroisoquinolin-l(2//)-one (160) (synthesised according to the 
method described by McDonald et a lm ) with a solution of iodine in acetic acid was 
undertaken. However, surprisingly, the reaction mixture remained unchanged even 
after stirring for 24 h. Employment of more electrophilic conditions, such as a 
combination of lithium iodide and iodine in acetic acid and a switch to the use of 
brominating reagents (bromine being more reactive compared to iodine), such as 
bromine and A-bromosuccinimide, also failed to effect halogenation.
N 0 2  HgCl 
(177)
Mercuration
1.Hg(OAc ) 2  or 
















R = alkyl or aryl
X 2  = I2  or Br2
NBS = N-bromosuccimide







N 0 2  R
Scheme 30. Different chemical approaches fo r  the synthesis o f  4-substituted 
isoquinolin-l(2H)-ones.
An indirect method of iodination was therefore considered. This involved an initial 
substitution of the 4-position of isoquinolin-l(2//)-one (160) with mercury(II) 
chloride to form an aryl mercury salt (177) which may subsequently be converted to 
an iodide or bromide by reaction with iodine or bromine respectively. However,
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attempts to mercurate compound (160) by treatment with either mercury(II) acetate 
or mercury(II) sulphate, followed by an exchange of the acetate or the sulphate anion 
with chloride via treatment with aqueous sodium chloride led only to decomposition 
products.
3.2.2 Heck coupling reaction
The repeated failure of 5-nitroisoquinolin-l(2//)-one (160) to participate in any 
variants of iodination or bromination reactions, despite the predicted activation of the
4-position by the carboxamide group was most puzzling and this led us to modify our 
synthetic strategy. Thus, instead of converting (160) into a halide suitable for Suzuki 
or Stille coupling reactions, it will now serve as the alkene partner in an alternative 
palladium-mediated coupling reaction— the Heck coupling reaction (Scheme 30).
This is a versatile carbon-carbon bond forming reaction which allows desirable 
functionalities to be attached across alkenes. Traditionally, the Heck coupling 
reaction was based on an aryl or vinyl iodide/bromide as the electrophile and a 
terminal alkene as the nucleophile177. However, various aspects of the Heck reaction 
have been reviewed in recent years, leading to protocols that allowed for the 
coupling of aryl/vinyl halides onto heteroaryl recipients, such as thiophenes, 
imidazoles and indoles218. Such heteroaryl Heck reaction may be exemplified by the 
reaction between 2-nitrobromobenzene and benzofuran where addition occurs 












Scheme 31. Heteroaryl Heck reaction between 2-nitrobromobenzene and  
benzofuran219.
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A Heck coupling reaction between isoquinolin-l(2//)-one (160) and iodobenzene
was therefore attempted. This was carried out in the presence of a catalytic amount of
palladium(II) acetate in dry triethylamine and dry acetonitrile and the mixture was
allowed to boil for 24 h under argon. However, it gave the starting material (160) in
virtually quantitative yield, without formation of the 4-substituted product. Repeats
*
of the coupling process employing various combinations of catalysts [e.g. 
(PPh3)2PdCl2, (PPh3)4Pd] and reaction conditions (base, solvents) and analogous 
treatments of 5-nitroisocoumarin (155) all failed to improve the outcome of the 
reaction.
Incidentally, the isocoumarin (155) also failed to participate in acylation when 
treated with a mixture of benzoyl chloride and tin(IV) chloride (Lewis acid catalyst) 
(Scheme 32), even though such reactions were known to proceed with great ease 
with furans220. It appeared that there was an apparent lack of reactivity of the double 
bond across C-3 and C-4 in both the isocoumarin and the isoquinolin-l(2//)-one ring. 
Presumably, the presence of a highly electron-withdrawing 5-nitro group decreases 
the nucleophilicity of the double bond and thus causes its lack of reactivity towards 
iodine, bromine and organometallic reagents. These apparent difficulties resisted 
further attempts to effect direct synthesis of the 4-substituted targets using 
organometallic approach.
Acylation
Scheme 32. Attempted acylation o f  isocoumarin (155) with a mixture o f  benzoyl 
chloride and tin(IV) chloride.
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3.2.3 DMFDMA
In Section 3.1.8, we studied a range of reactions involving condensation between 
methyl 2-methyl-3-nitrobenzoate (154) and various acetals, such as DMFDMA and 
DMADMA. It occurred to us that this reaction could also be extended for the 
synthesis of the 4-substituted targets. Analogous condensation of DMFDMA with 
compounds of the type (178) could be employed to introduce the necessary carbon 
unit for subsequent cyclisation to the corresponding 4-substituted isocoumarins 
(Scheme 33).
M eO ^O M e
(DMFDMA)
DMF i f ^ T
^C0 2Me
Si° 2, 1f r
150°C vY ?Ŝ N M e 2 EtOAc Y t
n o 2 R n o 2  r
4-substituted
isocoumarin
Scheme 33. Chemical synthesis o f  4-substituted isocoumarin via condensation o f 
compound (178) with DMFDMA.
To investigate this idea, the novel methyl 2-benzyl-3-nitrobenzoate (161) was 
synthesised. This was accomplished in moderate yield (32%) via a Negishi coupling 
reaction between methyl 2-iodo-3-nitrobenzoate (68) and benzyl zinc bromide under 
the catalytic influence of palladium. In general, the Negishi reaction enables a 
cross-coupling between an organozinc reagent and an organohalide or triflate171;
however, various variations of the protocol, such as those employing
221organomagnesium and organotin reagents, have also been found to be successful . 
The use of alkylzinc reagents is advantageous in our experiment in that the 
carbon-zinc bond is less reactive and thus highly compatible with electrophiles that 
contain sensitive functionalities such as esters, nitro, amides and nitriles. Many 
different palladium catalysts, such as those prescribed for Sonogashira protocols, 
have also been used with much success in Negishi coupling. However, to facilitate 
the reduction of Pd(II) to Pd(0), thereby ensuring high coupling efficiency, Negishi 
et a lll] used a complex of palladium(II) catalyst, (PPhi^PdC^, and DIBAL-H (1:2)
R = alkyl or aryl
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as catalyst and this was adopted in our experimental procedure. As with the 
Sonogashira coupling reaction, the Negishi coupling probably operates by an 




Cl— Pd— PPh3  
Cl








Scheme 34. Proposed mechanism fo r  Negishi coupling reaction between 
methyl 2-iodo-3-nitrobenzoate (161) and benzyl zinc bromide.
It is interesting to note that the use of DIBAL-H in the reaction did not result in a 
reduction of the ester and nitro functions, as evidenced from the absence of amine 
and aldehyde/ alcohol absorption peaks in IR spectra.
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Unfortunately, subsequent treatment of (161) with DMFDMA / silica (column 
chromatography) did not proceed as anticipated to give the desired
1 7Q5-nitro-4-phenylisocoumarin (179) . A similar reaction with DMADMA also did
not afford the expected naphthalene product,
l-methoxy-3-dimethylamino-5-nitro-4-phenylnaphthalene (180) (Scheme 35). This 
was surprising as the arylmethyl in compound (161) was expected to be much more 
reactive due to activation by the phenyl substituent, and thus more susceptible 
towards condensation reactions with the acetals than its unsubstituted counterpart 
(154).
0M e Negishi coupling






2. S i0 2
(161) 32%
. . 1. DMADMA
2. S i0 2
OMe
NMe2
N 0 2  Ph 
(180)
N 0 2  Ph 
(179)
Scheme 35. Condensation reactions o f methyl 2-benzyl-3-nitrobenzoate (161) with 
DMFDMA and with DMADMA.
It was thought that the bulky phenyl substituent in (161) might have prevented the 
reaction from occurring. A synthesis of the sterically less hindered nitrile analogue, 
methyl 2-cyanomethyl-3-nitrobenzoate (157) was therefore undertaken and the 
proposed synthesis was outlined in Scheme 36. The first step involved a radical 
bromination of the ester (154) and this was achieved by subjecting the latter to a 
boiling mixture of bromine and dibenzoyl peroxide in carbon tetrachloride under 
irradiation with a 150 W tungsten lamp for 20 h. Additional bromination mixture was 
then added and the mixture was heated and irradiated for another 29 h. This gave the
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mono-brominated product, methyl 2-bromomethyl-3-nitrobenzoate (156), in 
excellent yield (98%). Subsequent nucleophilic substitution of (156) with 
tetraethylammonium cyanide in acetonitrile at room temperature afforded the nitrile
(157) in 68% yield.
Radical 
‘OMe Bromination . DMFDMAOMe





(156) 98% (158) 38%(154)
Reduction OMe
•CNDIBAL-H
(160) 23% (157) 68%
1. DMFDMA
2. S i0 2
Acid-catalysed 
OMe cyclisation
.CN — X —  
AcOH or HC1
N 0 2  Br 
(181) (Not formed)
(159) 23% (182)
Scheme 36. Condensation reactions o f methyl 2-bromomethyl-3-nitrobenzoate (156) 
and methyl 2-cyanomethyl-3-nitrobenzoate (157) with DMFDMA.
Both compounds (156) and (157) represents reactive equivalents of the methyl ester 
(154) where the methylene groups are activated by the electron-withdrawing bromo 
and nitrile groups respectively. Thus, condensation reactions of these two 
compounds with DMFDMA under similar reaction conditions were expected to give
4-bromo-5-nitroisocoumarin (181) and 4-cyano-5-nitroisocoumarin (182) 
respectively. However, it was observed that the bromo-compound (156) gave an
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orange oil which, upon spectroscopic determination, was found to be compound
(158) (Scheme 36). This was probably the result of a direct nucleophilic attack of the
dimethylamine group on the methylene carbon (mechanism outlined in Scheme 37),
which, in this instance, was presumably more favourable than the predicted reaction
because bromine is a good leaving group. Accordingly, this side reaction could be 
»
avoided by using trimethylorthoformate instead of DMFDMA. The cyano-compound 
(157), on the other hand, proceeded well to give the intermediate enamine (159) 
(Scheme 36). Unfortunately, attempts to effect cyclisation of this enamine with acetic 








Scheme 37. Proposed mechanism fo r  the condensation reactions between 
methyl 2-bromomethyl-3-nitrobenzoate (156) and DMFDMA.
Nevertheless, reduction of the nitrile function in compound (157) with DEBAL-H at 
-78°C successfully afforded 5-nitroisoquinolin-l(2//)-one (160) in 23% yield 
(Scheme 36). Presumably, during aqueous acid work-up, the transitional imine 
underwent rapid intramolecular nucleophilic substitution with the neighbouring 
methyl ester, resulting in the formation of a lactam ring. The proposed mechanism 








Scheme 38. Proposed mechanism fo r  the reductive cyclisation o f 
methyl 2-cyanomethyl-3-nitrobenzoate (157).
The successful synthesis of compound (160) is very encouraging. It not only 
provides a novel, reliable and simple route for the preparation of 5AIQ, but also 
represents a promising synthetic strategy for the synthesis of the 4-substituted targets 
(results to be published).
Accordingly, the desired substituents could first be introduced via alkylation of the 
methylene carbon of compound (157). This could be achieved quite simply, for 
instance via initial deprotonation with a hindered base such as lithium 
hexamethyldisilazide (LHMDS), followed by reaction with an appropriate alkylating 
agent such as methyl iodide. Subsequent ring closure of the alkylated species (184) 
with DIBAL-H could lead to the formation of 4-substituted
5-nitroisoquinolin-l(2//)-ones (Route I, Scheme 39).
Alternatively, substituents could also be introduced, via similar alkylation 
procedures, onto the methyl group in compound (154). Subsequent bromination, 
conversion to nitrile and reduction with DIBAL-H could also lead to the formation of 
the desired isoquinolin-l(2//)-ones (Route II, Scheme 39).
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Regrettably, we were not able to carry out the actual synthesis of the 4-substituted 
targets due to a shortage of time. However, since the alkylation process is a reliable 
and standard process and that we have already overcome the potentially most 
difficult step in the proposed routes, i.e. reductive cyclisation of nitrile, we believe 
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The exceptional in vivo PARP-1 inhibitory potency demonstrated by 5AIQ.HC1 was 
previously accredited to its good water-solubility and its excellent biopharmaceutical 
properties. However, recent X-ray crystallographic data has demonstrated possible 
hydrogen-bonding between Glu988 and the amino group of
4-amino-1,8-naphthalimide (26b)142. Since this corresponds, approximately, to the
5-position of 5AIQ, it is likely that the 5-amino group in 5AIQ may also form 
(water-mediated) hydrogen-bonds with the active site, thus contributing, at least in 
part, to the enhanced potency. It is therefore of interest to examine the nature of this 
interaction through the synthesis of amidine analogues of 5AIQ as exemplified by
5-[(A,A-dimethylamino)methyleneamino]isoquinolin-l(2//)-one (163). Whilst the
5-amino substituent in 5AIQ can function both as hydrogen-bond donor and 
acceptor, compound (163), in the absence of any hydrogen atom attached to the 
amino group, can only serve as hydrogen-bond acceptor. This would allow an 
investigation of the manner in which the 5-amino group participated in 
hydrogen-bonding and the effects of A-substitution on PARP-1 inhibitory activity.
Compound (163) was readily synthesised in high yield (83%) by stirring with 





(163) 83% (164) 94%
Scheme 40. Chemical synthesis o f 5-[(N,N-dimethylamino)methyleneamino] 
isoquinolin-l(2H)-one hydrochloride (164).
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Its *H NMR spectrum is particularly interesting:
1. The spectrum of the starting material, 5AIQ (23d), in (CD3)2SO showed 
separate doublet signals for isoquinolin-l(2//)-one 3-H and 4-H, the former 
being 0.35 p.p.m. downfield with respect with the latter. Whereas in the 
spectrum of the product (163) in CDCI3, the signal for 3-H was moved 
upfield due to electron-donating effect of the amidine group and this 
coincided with the chemical shift for 4-H, resulting in a singlet signal for 2 
protons at 8 7.14. The location of these two protons was confirmed by a 
‘H-^C COSY (HMQC) spectrum (Figure 15) which showed that they were 
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Figure 15. lH-13C COSY (HMQC) spectrum of 
5-[(N,N-dimethylamino)methyleneamino] isoquinolin-l(2H)-one (163).
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2. Usually vinylic protons resonate at between 5 to 6 p.p.m.; however, the signal 
observed for the N=CH proton was shifted markedly downfield at 8 7.52. 
This was presumably due to the anisotropic effect produced by the 7t-system. 
Incidentally the chemical shift of 6-H (usually observed at ca 8 6.5) was also 
moved downfield to 8 7.05, implying that the
(A,A-dimethylamino)methyleneamino- substituent is in plane with the 
isoquinolin-l(2//)-one ring. The assignment of these protons was again 
supported by the 'H-’^C COSY spectrum (Figure 15).
3. The appearance of two broad singlets for NMe2 at 8 3.05 and 3.08 indicates 
the presence of partial 7t-bonding between this nitrogen atom and the amidine 
carbon atom which slows down rotation of the two methyl groups about this 
bond.
4. The establishment of the conformation (163a) from its alternative rotamers 
(163b), (163c) and (163d) was made through the NOESY spectrum 
(Figure 16), which showed NOE connectivity between N=CH proton (8 7.52) 
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Figure 16. 1 H-'H NOESY spectrum of 5-[(N,N-dimethylamino)methyleneamino] 
isoquinolin-l(2H)-one (163).
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Such a preference for conformation may possibly explain why ( 1 6 3 )  did not undergo 
further intramolecular cyclisation to give a 3-ring product ( 1 8 3 )  as shown in 
Scheme 41 below. Alternatively, the lack of formation of this side-product may also 
be further indication of the unusual low reactivity of the double bond across C-3 and 







S c h e m e  4 1 .  Proposed mechanism fo r  the intramolecular cyclisation of
5-[(N,N-dimethylamino)methyleneamino] isoquinolin-1(2H)-one (163).
Subsequent conversion of the compound ( 1 6 3 )  to its hydrochloride salt ( 1 6 4 )  was 
achieved in 94% yield by stirring with aqueous hydrochloric acid (2 M) at room 
temperature for 5 min (Scheme 40). Thus, we have successfully synthesised a novel 
amidine analogue of 5AIQ which is highly water-soluble. Subsequent molecular 
modelling experiments on this potential PARP-1 inhibitor would allow an 
examination of any possible interaction between the 5-amino group and the active 
site and its effect on PARP-1 inhibitory activity.
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Biological Evaluation and Molecular Modelling
4.1 Enzyme-inhibition assays
As a preliminary screen, the various 3-substituted 5-aminoisoquinolin-1 (2//)-one 
hydrochlorides prepared in this study were evaluated for in vitro activity against 
purified PARP-1 enzyme isolated from HeLa nuclear extract. The above 
enzyme-inhibition assays were kindly conducted by KuDOS Pharmaceuticals Ltd. 
using the novel FlashPlate scintillation proximity assay method222, which is an 
isotopic assay that measure the activity of the inhibitor based on its ability to prevent 
PARP-1 from synthesising [3H]ADP-ribose polymers from [3H]NAD+. Any tritiated 
signal that was bound to the FlashPlate was then counted using a scintillation plate 
reader, from which the percentage inhibition was determined.
In the evaluation, five different concentrations of the inhibitor, in a range 
surrounding the IC50 value, were used. The IC50 value of the inhibitor was then 
estimated graphically from a plot of the percentage inhibition against the 
concentration of the inhibitor. For each inhibitor, three independent determinations 
were performed and their mean IC50 values were reported in Table 20. These assays 
were highly sensitive and reproducible, with standard error of mean (SEM) of less 
than 20% for most compounds tested. 5AIQ and the benchmark PARP-1 inhibitor,
3-aminobenzamide (3AB), were also tested for comparison purposes.
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NH2 NMe2 •
3AB (IC50 33pM) ( 1 6 4 )  (IC50 4.04 ± 0.89|liM)
C o m p o u n d R I C 5 0 ( m M ) ± S E M
5 A I Q H 1.60
( 9 1 ) X) 1.07 ±0.24
( 1 0 0 ) XX 0.90 ± 0.48
( 1 0 6 ) X I. 0.88 ±0.14
( 1 1 4 ) XX 0.33 ± 0.07
VXi 0.57 ± 0.03
( 1 2 1 ) XXCI
5.61 ±2.20
( 1 2 6 ) u
( 9 4 ) Methyl 0.23 ± 0.02
( 1 3 4 ) Ethyl 0.49 ± 0.04
( 1 3 9 ) Pentyl 0.32 ±0.17
( 1 4 4 ) Isobutyl 1.17 ±0.56
( 1 5 0 ) x o 5.14 ± 1.60
T a b l e  2 0 .  The IC50  values o f the various 3-substituted 5-aminoisoquinolin-l(2H)- 
hydrochlorides.
It must be noted in advance that a direct comparison of IC50 values from different 
laboratories must be exercised with caution since different assay conditions have 
been employed by different investigators and this may cause considerable variations 
in the inhibition constants. Suto et alm , for instance, measured the incorporation of
[3H]ADP-ribose polymers onto histones by PARP purified from calf thymus and they
*  1 ^6found that 3AB has an IC50 of 9.0 pM. On the other hand, Banasik et al , using a
similar assay but a different radioactive label for the substrate, [14C]NAD+, reported a
much higher IC50 value of 33 pM while Griffin et alm , in quantifying the
incorporation of [32P]ADP-ribose into acid-insoluble materials by permeabilised
L1210 murine cells, obtained an IC50 value of 19.1 pM.
In addition to the assay methods, the varying concentrations of NAD+ and PARP 
used in the evaluation further hinder direct comparison of results. Nevertheless, these 
published values remained valuable in providing information with regards to the 
general trends in inhibitory activity. It is noteworthy that the IC50 values obtained for 
known PARP-1 inhibitors using the FlashPlate method were largely comparable to 
those reported in the literatures222, however those obtained for 5AIQ (1.6 (iM) and 
3AB (33. pM) were a few fold higher than the values reported by Suto et a /138, i.e.
0.24 pM and 9.0 pM respectively. Such differences should be taken into 
consideration during subsequent discussion on the SARs of our target compounds.
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4.2 Structure-activity relationship
In general, besides having very good water-solubility profile, most of the
3-substituted isoquinolin-l(2//)-ones exhibited excellent PARP-1 inhibitory potency 
with IC50 values in low micromolar range (Table 20). These compounds are also 
considerably more active than the classical 3AB (ca 30-fold) and, with the exception 
of ( 1 2 6 )  (R= thiophene) and ( 1 5 0 )  (R = benzyl), all 3-substituents led to an 
improvement of potency with respect to the parent compound, 5AIQ, though no clear 















(106) (114)1(121) (126) (94) 
0.88 0.33 0.57 5.61 0.23
(134) (139)I(144)](150)| (164) 
0.49 0.32 1.17 5.14 4.04
C o m p o u n d s
F i g u r e  1 7 .  The IC50 values o f the 3-aryl substituted 5AIQ (blue bars) and 3-alkyl 
substituted 5AIQ (yellow bars). The red bar represents the 5-amidine analogue o f  
5AIQ.
Apart from this generalisation, however, more subtle effects cooperate in 
determining the potency of the individual inhibitors. It appeared that the presence of 
an alkyl substituent (Figure 17, yellow bars) confers a slightly greater enhancement 
in PARP-1 inhibitory activities than an aryl moiety (Figure 17, blue bars), possibly 
suggesting a slightly more favourable interaction between these alkyl groups and the 
active site at the 3-position. This is especially evident with compounds
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( 9 4 )  (R = methyl, IC5o0.23pM) and ( 1 3 9 )  (R = pentyl, IC5o 0.32 |llM), which are 
about 5- and 3-fold, respectively, more potent than the 3-phenyl substituted 
compound ( 9 1 )  (IC50 1.07 pM), making them among the most potent members in this 
series. These observations are in line with those reported by Griffin et a /148 where 
they found that the 2-methylquinazolin-4-ones, ( 3 1 b )  (IC50O.78 pM) and ( 3 1 c )  
(IC50O.39 pM), were 5- and 2-fold more potent than their 2-phenyl counterparts, 
( 3 2 f )  (IC5o4.2 pM) and ( 3 2 j )  (ICsoO.87 pM) respectively (Table 21). Also notable is 
the significant loss of activity with ( 1 5 0 )  (R = benzyl, IC5o5.14 pM) and, to a lesser 
extend, ( 1 4 4 )  (R = isobutyl, ICsol.HpM ), indicating a possible discrimination 
against rigid substituents at this end of the binding site.






Code X R IC50 ( p M ) Code X R IC50 ( p M )
(a) H H 9.50 (f) OMe H 4.20
( b ) OMe Me 0.78 a) Me H 0.87
( c ) Me Me 0.39 a) Me OH 0.22
( m ) Me CN 0.27
( n ) Me OMe 0.19
( 0 ) Me N 02 0.13
( P )  ............... Me c f 3 > 10
T a b l e  2 1 .  IC50  values o f a series o f 3-alkyl and 3-phenyl substituted quinazolinones 
against PARP-1.
The inhibition data further suggest that a phenyl group (compound ( 9 1 ) )  is well 
accepted at the 3-position and that the presence of a para-substituent in the phenyl 
ring seemed to increase the activity slightly, though there is no clear relationship 
between the nature of the substituent and inhibitory potency since the active site is 
able to tolerate a variety of electronically and sterically differing substituents. 
Nevertheless, inductive electron-withdrawing functionalities, such as trifluoromethyl
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and chloro, appear to confer slightly greater improvement in activity as compound 
(114) (IC50O.33  jllM) and (121) (ICsoO.57 |xM) are both slightly (ca 2 to 3-fold) more 
potent than the rest.
Such beneficial effects of a para-substituent on the phenyl group have also been 
noted with the 2-phenylquinazolin-4-ones, such as (32j), where the presence of 
electron-donating groups, such as hydroxy and methoxy (compounds (321) and 
(32n)) and electron-withdrawing groups, such as nitro and cyano (compounds (32o) 
and (32m)) markedly increased inhibitory potencies148. However, contrary to our 
findings, a trifluoromethyl group caused deleterious effect on activity as 
demonstrated by (32p) (Table 21).
It is also interesting to note that the introduction of a thiophene ring at the 3-position 
resulted in a drastic loss of potency, as demonstrated by (126) (IC50 5.61 |XM), which 
is 5-fold less potent with respect to (91) (IC50 1*07 |xM). Such a peculiar behaviour is 




To better understand the above observations, molecular modelling of 5AIQ and the 
novel PARP-1 inhibitors, (94), (114), (126) and (164), was undertaken and this was 
effected using Hyperchem® 7.5. The molecular structure of these compounds were 
constructed from previously solved co-crystal X-ray structure of 
2-methyl-8-hydroxyquinazolin-4-one (31d) bound to the catalytic domain of chicken 
PARP-1, the atomic coordinates of which were being retrieved from the Protein Data 
Bank (PDB) database (PDB code: 4PAX). The use of the active site of chicken 
PARP-1 is reasonable since it bears a close homology to human PARP-1. The 
inhibitor-enzyme complex thus formed was then minimised, requiring the crucial 
interaction between the nicotinamide moiety and the active site to be fixed.
All the inhibitors examined displayed conserved and non-conserved interactions. 
Conserved interactions are those involving the benzamide pharmacophore and are 
exhibited across all classes of competitive PARP-1 inhibitors (Figure 18-23). These 
include:
1. Three critical hydrogen bond interactions between the carboxamide moiety 
and two amino acid residues, Ser904 and Gly863, where the inhibitor 
carbonyl oxygen accepts two hydrogen bonds, one from the side chain of 
Ser904 (2.25 A) and the other from Gly863 polypeptide amide NH (1.59 A). 
The third hydrogen-bond is formed between the carboxamide NH and Gly863 
carbonyl oxygen (2.08 A). Presumably, steric repulsion between the large 
sulphur atom in the thiophene ring of (126) and the carboxamide group 
disrupts its favourable binding conformation to the active site, thereby 
leading to a decrease in potency (Figure 21).
2. A parallel tyrosine residue, Tyr907, within the active site also forms a 
“7i-electron sandwich” which is beneficial for binding planar aromatic 
compounds, especially extended planar structure, such as the 
isoquinolin- l(2//)-one ring.
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Non-conserved interactions are strictly dependent on the structural diversity of the 
inhibitors. The alkyl and aryl side chains of the 3-substituted 5AIQ were able to form 
additional interactions with the deep hydrophobic pocket extending from that region, 
as exemplified by (94) and (114) (Figure 24 and 25), thus possibly accounting for 
their increased potencies with respect to 5AIQ. Further studies also established 
another large hydrophobic pocket in the region corresponding to the 4-position and 
this could potentially be exploited for further enhancement of inhibitory activity 
through substitution at that position.
It was also observed that the 5-amino group in these inhibitors were well 
accommodated within a relatively smaller binding pocket and were in close 
proximity with the important catalytic Glu988 in the active site. X-ray crystal 
structure of the catalytic fragment of chicken PARP-1 further revealed the presence 
of an ordered water molecule between the amino group and the carboxylate side 
chain of Glu988. Both observations are consistent with our postulate that a putative 
water-mediated hydrogen bond exists between the 5-amino group and Glu988 within 
the active site.
To explore the nature of this hydrogen bond, 5AIQ was substituted, at the 
A5-position, with an amidine group and this resulted in a 2.5-fold reduction in 
activity ((164), IC50 4.04 pM). Such a loss of potency could suggest the requirement 
for a hydrogen bond donor, rather than an acceptor, at this position. Alternatively, it 
could also be the result of steric interference between the rigid and bulky amidine 
group and the active site as illustrated in Figure 26. Further work with less bulky 
substituents at the 5-position is required to elucidate the exact influence such 
hydrogen-bonding on PARP-1 activities.
Incidentally, an energy minimisation experiment on (163) (Figure 27) provided 
further evidence in support of our previous assignment of (163a) as the lower energy 
conformation and, hence, the preferred rotamer (Section 3.3). The alternative rotamer 
(163c), formed via rotation about the C5-N bond, revealed steric clash between 4-H 
and amidine-CH, making it energetically unfavourable.
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Thus, we have described, herein, a series of novel, water-soluble and potent PARP-1 
inhibitors. A combination of favourable physical properties and highly promising 
in vitro profiles renders them excellent candidates for pre-clinical development. 
Patent application is currently underway and publications will soon follow.
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Figure 18. Molecular modelling o f 5AIQ, showing three critical hydrogen bond
interactions between the carboxamide moiety and two amino acid residues, Ser904
and Gly863 (top) and “7t-electron sandwich” with the parallel Tyr907 (bottom).
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Tyr907
Putative \  
H-bonding
Glu988
Figure 19. Molecular modelling o f (94), showing three critical hydrogen bond
interactions between the carboxamide moiety and two amino acid residues, Ser904
and Gly863 (top) and “7T-electron sandwich” with the parallel Tyr907 (bottom).
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Figure 20. Molecular modelling of (114), showing three critical hydrogen bond
interactions between the carboxamide moiety and two amino acid residues, Ser904
and Gly863 (top) and “n-electron sandwich” with the parallel Tyr907 (bottom).
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Figure 21. Molecular modelling o f  one rotamer o f  (126), showing three critical 
hydrogen bond interactions between the carboxamide moiety and two amino acid 






Figure 22. Molecular modelling of another rotamer of (126).
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Figure 23. Molecular modelling of (164), showing three critical hydrogen bond
interactions between the carboxamide moiety and two amino acid residues, Ser904




Figure 24. Molecular modelling of (94) revealed the presence o f a large binding 
pocket extending from the region corresponding to the 3-position o f 5AIQ and a 
relatively smaller pocket beneath the 5-amino group.
Figure 25. Insertion o f the phenyl ring o f (114) into the large binding pocket.
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In conclusion, various approaches to the synthesis of the novel class of PARP-1 
inhibitor, 3-substituted 5-aminoisoquinolin-1 (2//)-one hydrochlorides, have been 
investigated and we have successfully developed a reliable, efficient and versatile 
synthetic route, through which a series of highly water-soluble target compounds, 
bearing varying substituents at the 3-position, was generated.
In addition, a novel synthesis of the lead compound, 5AIQ, via the reductive 
cyclisation of methyl 2-cyanomethyl-3-nitrobenzoate (157) has also been realised. 
This strategy could potentially be extended to the synthesis of another class of 
potential PARP-1 inhibitors, the 4-substituted isoquinolin-1 (2//)-ones.
Effort to synthesise the 3-substituted targets via organometallic approaches, such as 
Sonogashira coupling, Castro-Stephens coupling and Negishi coupling were largely 
frustrated by the use of sterically demanding, trisubstituted halide partners. The 
presence of a highly electron-withdrawing nitro function, which is conjugated with 
the double bond across C-3 and C-4 in both the isocoumarin and the 
isoquinolin-l(2//)-one ring, also interfered with the Heck synthesis of the 
4-substituted targets. Thus, these experiments revealed some of the limitations and 
difficulties associated with the use of these organometallic protocols as synthetic 
tools.
Many interesting chemistry has also been observed, presumably owing to the 
presence of a 3-nitro function. In particular, decarboxylation/mercuration and 
iodination of 3-nitrophthalic acid was found to occur regiospecifically at the
2-position, giving 2-iodo-3-nitrobenzoic acid (67) as the only substitution product. 
Such regioselectivity was also consistently observed in our mercury and 
copper-catalysed cyclisation of arylalkyne where only the desired isocoumarin was 
formed {via a 6-endo-dig route), as opposed to the non-nitrated analogue, which gave 
the 5-membered phthalide as the major product. Finally, the strongly
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electron-withdrawing nitroaryl system played a unique role in promoting 
spontaneous retro-Claisen reaction on the Hurtley condensation product and its 
subsequent cyclisation into the desired isocoumarin.
Preliminary biological evaluation of this series of compounds showed excellent 
in vitro inhibitory activity against PARP-1, with IC50 values in low micromolar 
range. Most of the 3-substituents were well received by the active site and they 
resulted in a significant enhancement of PARP-1 inhibitory potency with respect to 
5AIQ. This was particularly evident for 5-amino-3-methylisoquinolin-l(2//)-one 
(94) (IC50 0.23 (iM), 5-amino-3-pentylisoquinolin-1 (2//)-one (139) (IC50 0.32 pM) 
and 5-amino-3-[4-(trifluoromethyl)phenyl]isoquinolin-1 (2//)-one (114)
(IC50 0.33 pM), which were among the most potent members of this series. Besides 
the usual conserved interactions, molecular modelling experiments further identified 
additional favourable interactions between the 3-substituents and a deep hydrophobic 
pocket within the active site, as well as a putative, water-mediated hydrogen bond 
between the 5-amino group and Glu988, all of which unquestionably contributed 
towards their outstanding potencies.
Greatly encouraged by these highly promising data, our immediate interest would be 
to evaluate the in vivo protective ability of selected inhibitors in various disease 
models in animals, especially their effects against ischaemia-reperfusion injury and 
inflammatory disorders. Future work would involve effecting the synthesis of the 
4-substituted targets via the proposed synthetic routes and, possibly, a synthesis of 





All melting points were determined using a Reichert-Jung Thermo Galen Kofler 
block and are uncorrected. IR spectra were recorded on a Perkim-Elmer RXI FT-IR 
spectrometer, either as a liquid (film) or as a KBr disc (KBr). v max values are given in 
cm'1. NMR spectra were recorded on either a JOEL GX 270 (270.05 MHz ]H; 
67.8 MHz 13C) or EX 400 (399.65 MHz 'H; 100.4 MHz 13C; 376.05 MHz 19F) 
spectrometer. Tetramethylsilane was used as an internal standard for samples 
dissolved in CDCI3 and (CD3)2SO. For samples dissolved in D2O,
3-(Trimethylsilyl)propanoic-2,2,3,3-c?4 acid sodium salt was used instead. 
Multiplicities are indicated by s (singlet), d (doublet), t (triplet), q (quartet), 
m (multiplet) and br (broad). Mass spectra were obtained by either Electron Impact 
(El) or Fast Atom Bombardment (FAB) (with m-nitrobenzyl alcohol as the matrix) at 
the University of Bath Mass Spectrometry Service using a VG 7070 Mass 
Spectrometer. Microanalysis was carried out at the University of Bath Microanalysis 
Service. Thin layer chromatography (TLC) was performed on silica gel 60 
F254-coated aluminium sheets (Merck) and visualisation was accomplished by UV 
light or FeCB. Flash column chromatography was performed using silica gel 60 
(0.040-0.063 mm, Merck) as the stationary phase.
All reagents for chemical synthesis were purchased from Aldrich and Lancaster 
Chemical Company and were used without further purification. Experiments were 
conducted at ambient temperature, unless otherwise stated. Where experiments were 
repeated, only one description was provided. Solutions in organic solvents were dried 
using anhydrous MgSCU and solvents were evaporated under reduced pressure. THF 
and diisoproplyamine were freshly distilled under nitrogen from 
sodium/benzophenone and calcium hydride respectively.
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A solution of AC2 O (35.0 g, 343 mmol) and H N O 3 (70%, 50 ml, 556 mmol) in AcOH 
(30 ml) was added dropw ise to a solution o f methyl 2-am inobenzoate (24.5 g, 
162 m mol) in AC2 O (170 g, 1.7 mol) during 2 h at 10 ±  5°C and stirred (at that 
tem perature) for 2.5 h. The solution was then poured into ice-H 2 0  (100 ml) and the 
precipitate was filtered, washed (H 2O) and recrystallised (CHCI3 , M eOH) to give 
(61) (25.9 g, 67%) as yellow crystals; Rf = 0.48 (hexane / EtOAc 3:2); 
m p 122-123°C (lit . 191 mp 121-123°C); 'H  NM R (CDC13) 6  2.31 (3 H, s, CO CH 3),
4.01 (3 H, s, CO 2 CH 3 ), 8.37 (1 H, dd, 7 = 9.8, 2.7 Hz, 4-H), 8.93 ( 1  H, d, 
7  = 2.7 Hz, 6 -H), 8 .94 (1  H, d, 7 = 9 .8  Hz, 3-H), 11.39(1 H, b r s ,  NH).
The filtrate was extracted w ith CHCI3 , dried and evaporated. This gave an oily 
residue which was recrystallised from  Et2 0  to give (62) (7.6 g, 20%) as pale yellow 
crystals; R f = 0.28 (hexane / EtOAc 3:2); mp 115-116°C (lit . 192 mp 115-117°C); 
IR Umax (KBr) 1326 & 1535 (N 0 2), 1682 (amide I), 1723 (ester C = 0), 3320 (NH); 
‘H N M R  (CDCI3 ) 6  2.09 (3 H, s, CO CH 3), 3.97 (3 H, s, C 0 2CH3), 7.31 (1 H, t, 
7 = 7.8 Hz, 5-H), 8.08 (1 H, d d ,7  = 7.8, 1.6 Hz, 4-H), 8.21 (1 H, d d ,7  = 7.8, 1.6 Hz, 
6 -H), 10.35 (1 H, br s, NH); MS (FAB +ve ion) m/z 239.0658 (M + H) 







Compound (62) (2.3 g, 9.7 mmol) was boiled under reflux with aqueous HC1 (9 M, 
100 ml) for 48 h. Filtration and drying of the precipitate yielded (63) (1.7 g, 97%) as 
orange crystals; Rf = 0.63 (CHCI3 / MeOH / AcOH 10:1:0.1); mp 207-208°C (lit.193 
mp 202-204°C); IR t w  (KBr) 1351 & 1538 (N02), 1680 (C=0), 2800-3100 (OH), 
3340 & 3460 (NH2); ‘H NMR ((CD3)2SO) 5 6.73 (1 H, t, 7.8 Hz, 5-H), 8.24 (1 H, 
dd, J  = 7.8, 1.7 Hz, 4-H), 8.31 (1 H, dd, J  = 7.8, 1.7 Hz, 6-H), 8.55 (2 H, br s, NH2), 





A solution of (63) (1.5 g, 8.2 mmol) in MeOH (100 ml) and H2SO4 (1 ml) was boiled 
under reflux for 48 h. The solution was poured into ice-H20  (300 ml) and the 
precipitate was filtered, dried and recrystallised (MeOH). This 
gave (64) (1.1 g, 68%) as bright yellow crystals; Rf = 0.61 (hexane / EtOAc 2:3); 
mp 94°C (hexane, EtOAc) (lit.148 mp 96°C); IR \)max (KBr) 1343 & 1526 (N 02), 
1702 (C=0), 3317 & 3452 (NH2); 'H NMR (CDCI3) 8 3.92 (3 H, s, C 0 2CH3), 
6.66 (1 H, t, /  = 7.8 Hz, 5-H), 8.24 (1 H, dd, = 7.8, 1.7 Hz, 4-H), 8.38 (1 H, dd, 
7=7.8, 1.7 Hz, 6-H), 8.50 (2 H, br s, NH2); MS (El +) 196.0486 (M)




A solution of NaNC>2 (1.0 g, 15 mmol) in H2O (10 ml) was added dropwise to a 
solution of 2-methyl-6-nitroaniline (2.0 g, 13 mmol) in aqueous HC1 (2 M, 30 ml) at 
0°C. After stirring for 15 min, KI (6.0 g, 36 mmol) in H20  (10 ml) was added and the 
mixture was allowed to stand at room temperature for 1 h. The mixture was then 
carefully heated until evolution of N2 and I2 ceased. Evaporation and recrystallisation 
(EtOH) gave (65) (2.7 g, 78%) as orange crystals; Rf = 0.52 (hexane / EtOAc 4:1); 
mp 69°C (EtOH) (lit.195 mp 68-69°C); ‘H NMR (CDC13) 8 2.58 (3 H, s, CH3), 7.34 
(1 H, t, /  = 7.8 Hz. 5-H), 7.43 (2 H, d, J  = 7.8 Hz, 4,6-H2); MS (El +) 262.9437




3-Nitrophthalic acid (21.1 g, 100 mmol) in hot aqueous NaOH (10%, 80 ml) was 
added to Hg(OAc)2 (35.0 g, 110 mmol) in hot AcOH (5 ml) and H2O (70 ml). The 
mixture was heated at 170°C (oil bath temperature) for 70 h and was then filtered. 
The precipitate was washed (H2O, then EtOH), dried and boiled under reflux in 
aqueous NaOH (3.5%, 500 ml). Aqueous HC1 (2 M, 12 ml) was then slowly added, 
with vigorous stirring, and the solution was allowed to cool to room temperature. 
AcOH (3 ml) was then added and this gave a curdy cream precipitate, which 
dissolved upon addition of a mixture of KI (19.0 g, 114 mmol) and I2 (29.0 g, 114 - 
mmol) in H2O (30 ml). The solution was boiled under reflux for 24 h, cooled and
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neutralised with aqueous NaOH. It was then filtered and acidified with concentrated 
HC1. The precipitate formed was filtered, dried and recrystallised (EtOH) to give 
(67) (19.1 g, 65%) as yellow crystals; Rf = 0.61 (CH2C12 / MeOH / AcOH 9:1:0.1); 
mp 204-205°C (lit.196 mp 205-206°C); IR t w  (KBr) 1375 & 1542 (NOj), 1712 
(C=0), 2543-3063 (OH); 'H NMR ((CD3)2SO) 8 7.66 (1 H, t, = 7.8 Hz, 5-H), 7.79 
(1 H, dd, J  = 7.8, 1.7 Hz, 4-H), 7.92 (1 H, dd, = 7.8, 1.7 Hz, 6-H); 
I3C NMR (CDC13) 8 86.87 (C-2), 125.48 (C-5), 130.32 (C-4), 131.64 (C-6), 
142.54 (C-l), 156.40 (C-3), 168.70 (C=0); MS (FAB+ve ion)





NaN02 (1.30 g, 18.8 mmol) in H20  (5 ml) was added to a suspension of (64) (300 
mg, 1.5 mmol) in aqueous HC1 (2 M, 20 ml) at 2 ± 2°C during 30 min. The 
diazonium solution was then added dropwise to a solution of KI (2.5 g, 15 mmol) 
and I2 (1.8 g, 7.1 mmol) in DMSO (35 ml) at 5°C and the mixture was stirred at 50°C 
for 20 min. Extraction (EtOAc), washing (H20), drying (MgS04) and evaporation to 
give (68) (20 mg, 4%) as yellow crystals; Rf = 0.33 (hexane / EtOAc 4:1); 
mp 66-67°C (lit.196 mp 64-66°C); IR t w  (KBr) 1351 & 1533 (N02), 1705 (C=0); 
'H NMR (CDC13) 8 3.99 (3 H, s, CH3), 7.54 (1 H, t, 7.8 Hz, 5-H), 7.70 (1 H, dd, 
J  = 7.8, 1.7 Hz, 4-H), 7.77 (1 H, dd, /  = 7.8, 1.7 Hz, 6-H); MS (El +) m/z 306.9347 
(M) (12C8H6IN04  requires 306.9342), 276 (M -  OMe).
Method B:
Compound (67) (4.0 g, 14 mmol) in MeOH (120 ml) and H2S04 (3 ml) was boiled 
under reflux for 48 h, then poured into ice-H20 (300 ml). The precipitate formed
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was filtered, dried and recrystallised (MeOH) gave (68) (4.0 g, 95%) as yellow 






The Pd catalyst, (PPh3)2PdCl2, used in this reaction was prepared as follows:
A mixture of PPh3 (375 mg, 1.4 mmol) and PdCF (130 mg, 0.7 mmol) in DMF (20 
ml) was heated at 80°C for 24 h. Filtration and drying yielded (PPl^PdC F as a 
yellow powder (470 mg, 94%).
A solution of (68) (3.0 g, 9.8 mmol) in dry THF (120 ml) was added to a suspension 
of (PPh3)2PdCl2 (300 mg, 0.4 mmol) and Cul (400 mg, 2.1 mmol) in dry 
diisopropylamine (40 ml) and the mixture was stirred at 45°C for 30 min under Ar. 
Trimethylsilylethyne (1.1 g, 11 mmol) was then added during 30 min and the mixture 
was stirred for another 72 h at 45°C. Filtration (through Celite®), evaporation and 
chromatography (hexane / CH2CI2 3:2) gave (69) (810 mg, 30%) as a reddish-brown 
oil; Rf = 0.38 (hexane / EtOAc 4:1); IR \)max (KBr) 1351 & 1532 (N02), 1738 (C=0), 
2219 (O C ); 'H NMR (CDC13) 8 0.28 (9 H, s, Si(CH3)3), 3.96 (3 H, s, CH3), 7.49 
(1 H, t, J  = 7.8 Hz, 5-H), 7.96 (1 H, dd, J  = 7.8, 1.6 Hz, 4-H), 8.01 (1 H, dd, 7.8,
1.6 Hz, 6-H); MS (FAB +ve ion) m/z278.0843 (M + H) (12Ci3H16N 04Si requires
278.0849).
Also isolated by chromatography was (70) (690 mg, 39%) as yellow crystals; 
Rf= 0.50 (hexane / EtOAc 4:1); mp 75-76°C (lit.197 mp 78-80°C); 'H NMR (CDC13) 
8 3.99 (3 H, s, CH3), 7.66 (1 H, t, J  = 7.8 Hz, 5-H), 8.37 (1 H, ddd, = 7.8, 2.4,
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1.2 Hz, 4-H), 8.42 (1 H, ddd, J = 7.8, 2.4, 1.2, Hz, 6-H), 8.87 (1 H, t, = 2.4 Hz, 





To a solution of (69) (400 mg, 1.4 mmol) in THF (50 ml) and H20  (2.5 ml) was 
added tetrabutylammonium fluoride (1.0 M in THF, 5.0 ml, 5.0 mmol) at 0°C and 
the mixture was stirred at room temperature for 16 h. The mixture was then diluted 
with Et20  and washed successively with saturated aqueous NH4CI solution and H20. 
Evaporation and chromatography (hexane / EtOAc 7:3) gave (71) (28 mg, 9%) as a 
yellow oil; Rf = 0.53 (hexane / EtOAc 7:3); IR \)max (KBr) 1351 & 1532 (N02), 1738 
(C=0), 2219 (C=C); 'H NMR (CDC13) 8 3.67 (1 H, s O C H ), 3.90 (3 H, s, CH3), 
7.48 (1 H, t, J = 7.8 Hz, 5-H), 7.91 (1 H, dd, = 7.8, 1.2 Hz, 4-H), 8.00 (1 H, dd, 
7=  7.8, 1.2 Hz, 6-H); MS (El +) m/z 205.0381 (M) (12CioH7N 04 requires 205.0375).
2-iodo-3-nitrobenzoyl chloride (72).
o
To a solution of (67) (3.0 g, 10 mmol) in DMF (5 ml) was carefully added SOCl2 (30 
ml) and the mixture was boiled under reflux for 24 h. Evaporation and 
recrystallisation (petroleum ether) yielded (72) (3.1 g, 97%) as yellow crystals; 
Rf= 0.88 (hexane / EtOAc 1:4); mp 70-71°C (petroleum ether) (lit.198 mp 71-73°C); 
IR Umax (KBr) 1348 & 1530 (N02), 1758 (C=Q); ‘H NMR (CDC13) 8 7.64 (1 H, t,
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7 = 7.8 Hz, 5-H), 7.78(1 H ,dd ,7  = 7.8, 1.6 Hz, 4-H), 7.95(1 H, dd, 7 = 7.8, 1.6 Hz,
6-H); MS (El +) m/z312.8821 (M) (12C7H-,37C1INOi requires 312.8817), 310.8848 
(M) (12C7H335C1IN03 requires 310.8846), 276 (M -  Cl).
2-Iodo-3-nitrobenzamide (73).
A solution of ethereal NH3 was produced by slow addition of K 2CO 3 to an 
immiscible mixture of Et20  (200 ml) and concentrated aqueous NH3 (20 ml). The top 
ethereal layer was then carefully transferred to (72) (3.0 g, 9.6 mmol) in Et20  (10 ml) 
via a glass pipette. The mixture was stirred at room temperature for 1 h, then 
evaporated to yield (73) (2.6 g, 92%) as yellow crystals; Rf = 0.53 (hexane / EtOAc 
1:4); 220-221°C (lit.199 mp 223-225°C); IR r w  (KBr) 1365 & 1525 (N02), 
1627 (Amide II), 1654 (Amide I), 3177 & 3358 (NH2); 'H NM R ((CD 3 )2 SO) 
5 7.51 (1 H, dd, 7 = 7.8, 1.2 Hz, 6-H), 7.61 (1 H, t, 7 = 7.8 Hz, 5-H), 7.75 (1 H, br s, 
NH), 7.82 (1 H, dd, 7 = 7.8, 1.2 Hz, 4-H), 8.02 (1 H, br s, NH); M S (FAB +ve ion) 
m /z292.9423 (M + H) (12C7H5IN20 3 requires 292.9423).
2-Iodo-3-nitrobenzonitrile (74).
■CN
To (73) (2.6 g, 8.9 mmol) in THF (50 ml) was carefully added SOCl2 (15 ml) and the 
suspension was boiled under reflux for 24 h. Ice-H20  (100 ml) was then added and 
the mixture made alkaline with cold aqueous NaOH (10%, 100 ml). Extraction 
(CHCI3), washing (saturated NaHC0 3 , then H20) and evaporation gave (74) (2.3 g,
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94%) as yellow crystals; Rf = 0.70 (hexane / EtOAc 1:4); mp 147-148°C; IR 
(KBr) 1357 & 1532 (N02), 2233 (CN); 'H NMR ((CD3)2SO) 8  7.80 (1 H, t, 
J  = 8.2 Hz, 5-H), 8.12(1 H, dd, 7 = 8.2, 1.6 Hz, 6-H), 8.18(1 H,dd, 7= 8 .2 , 1.6 Hz, 
4-H); MS (El +) m/z273.9245 (M) ( l2C7H,IN20 2 requires 273.9239), 228 (M -N 0 2).
4-Nitro-l-[(trimethylsilyI)ethynyI]benzene (75).
Trimethylsilylethyne (1.2 g, 12 mmol) was slowly added to a suspension of
4-nitroiodobenzene (2.5 g, 10 mmol), (PPh3)2PdCl2 (200 mg, 0.3 mmol) and Cul 
(100 mg, 0.5 mmol) in dry Et3N (25 ml). The mixture was stirred at 45°C for 1 h 
under Ar, then quenched with H20  (200 ml) and filtered through Celite®. The filtrate 
was extracted with Et2 0 , dried and evaporated to give (75) (2.0 g, 91%) as yellow 
crystals; Rf = 0.69 (hexane); mp 93-94°C (lit.200 mp 97-98°C); IR \)max (KBr) 1345 & 
1520 (N02), 2160 (C=C); *H NMR (CDCI3 ) 6 0.09 (9 H, s, Si(CH3)3), 7.41 (2 H, d, 
J  = 9.0 Hz, 2,6-H2), 7.98 (2 H, d, J  = 9.0 Hz, 3,5-H2).
l-EthynyI-4-nitrobenzene (76).
H
Tetrabutylammonium fluoride (1.0 M in THF, 2.5 ml, 2.5 mmol) was added 
dropwise to a solution of (75) (500 mg, 2.3 mmol) in THF (20 ml) and H20  (3 ml) at 
-78°C. The mixture was stirred for 1 h, then quenched with H20  (200 ml) and 
extracted with Et20. Evaporation and chromatography (hexane / EtOAc 7:3) gave 
(76) (280 mg, 83%) as orange-brown crystals; Rf = 0.40 (hexane); mp 145-146°C 
(lit.201 mp 147-149°C); IR t)max (KBr) 1343 & 1512 (N02), 2012 (CsC), 3260
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(CsCH); 'H NMR (CDClj) 8 3.36 (1 H, s, C=CH), 7.64 (2 H, d, 9 .0 Hz, 2,6-H2), 
8.20 (2 H, d, J  = 9.0 Hz, 3,5-H2); MS (El +) 147.0322 (M) ( '2C8H5N 0 2 requires
147.0320), 101 (M -  N 02).
4-[(Trimethylsilyl)ethynyl]pyridine (77).
Trimethylsilylethyne (460 mg, 4.7 mmol) was slowly added to a suspension of
4-iodopyridine (1.0 g, 4.9 mmol), (PPh3)2PdCl2 (100 mg, 0.1 mmol) and Cul (300 
mg, 1.6 mmol) in dry diisopropylamine (25 ml). The mixture was stirred at 45°C for 
1 h under Ar, then quenched with H20  (200 ml) and filtered through Celite®. The 
filtrate was extracted with Et20 , dried and evaporated to give (77) (790 mg, 93%) as 
a yellow oil; Rf = 0.72 (hexane); IR Umax (KBr) 2165 (C=C); ‘H NM R (CDC13) 




TBAF (1.0 M in THF, 2.5 ml, 2.5 mmol) was added dropwise to a solution of (77) 
(400 mg, 2.3 mmol) in THF (20 ml) and H20  (3 ml) at -78°C. The mixture was 
stirred for 1 h, then quenched with H20  (200 ml), extracted with Et20  and 
evaporated to give (78) (150 mg, 64%) as a yellow, light-sensitive oil; Rf = 0.23 
(CH2C12 / MeOH 50:1); IR \j„,« (film) 2120 (O C ), 3300 (C=CH); 'H NMR (CDC13) 
8 3.29 (1 H, s, CsCH), 7.32 (2 H, d, J  = 5.6 Hz, 3,5-H2), 8.57 (2 H, d, = 5.6 Hz,




Trimethylsilylethyne (1.2 g, 12 mmol) was slowly added to a suspension of 
4-methoxyiodobenzene (2.3 g, 9.8 mmol), (PPI^PdCE (200 mg, 0.3 mmol) and Cul 
(100 mg, 0.5 mmol) in dry Et3N (25 ml). The mixture was stirred at 45°C for 1 h 
under Ax, then quenched with H2O (200 ml) and filtered through Celite®. The filtrate 
was extracted with Et2 0 , dried and evaporated to give (79) (1.8 g, 90%) as a 
colourless oil; Rf = 0.33 (hexane); lit.202 bp 96 (1.5 torr); IR \)max (KBr) 2160 (CsC); 
*H NMR (CDCI3 ) 6 0.24 (9 H, s, Si(CH3)3), 3.81 (3 H, s, OCH3), 6.81 (2 H, d, 
7 = 9.0 Hz, 3,5-H2), 7.40 (2 H, d, 7 = 9.0 Hz, 2,6-H2); MS (El +) m/z 204.0973 (M) 
(12Ci2Hi6 0 Si requires 204.0970), 189 (M -  Me).
4-Methyl-l-[(trimethylsilyl)ethynyl]benzene (80).
Me'
Trimethylsilylethyne (1.2 g, 12 mmol) was slowly added to a suspension of
4-methyliodobenzene (2.2 g, 10 mmol), (PP t^PdC ^ (200 mg, 0.3 mmol) and Cul 
(100 mg, 0.5 mmol) in dry Et3N (25 ml). The mixture was stirred at 45°C for 1 h 
under Ar, then quenched with H2O (200 ml) and filtered through Celite®. The filtrate 
was extracted with Et2 0 , dried and evaporated to give (80) (1.7 g, 95%) as a 
colourless oil; Rf = 0.72 (hexane); lit.223 bp 116 (16 torr); IR Dmax (KBr) 2120 (C=C); 
*H NMR (CDCI3) 6 0.24 (9 H, s, Si(CH3)3), 2.31 (3 H, s, CH3), 7.07 (2 H, d, 





Trimethylsilylethyne (1.2 g, 12 mmol) was slowly added to a suspension of
4-(trifiuoromethyl)iodobenzene (2.7 g, 9.9 mmol), (PPh3)2PdCl2 (200 mg, 0.3 mmol) 
and Cul (100 mg, 0.5 mmol) in dry Et3N (25 ml). The mixture was stirred at 45°C for 
1 h under Ar, then quenched with H20  (200 ml) and filtered through Celite®. The 
filtrate was extracted with Et20, dried and evaporated to give (81) (2.2 g, 92%) as a 
yellow oil; Rf = 0.69 (hexane); IR um„  (KBr) 2155 (C=C); ‘H NMR (CDCI3) 5 0.26 
(9 H, s, Si(CH3)3), 7.45 (2 H, d, J  = 8.2 Hz, 3,5-H2), 7.67 (2 H, d, 8.2 Hz,
2,6-H2); MS (El +) m/z 242.0737 (M) (12C,2H|3F3Si requires 242.0739).
4-Chloro-l-[(trimethylsilyl)ethynyl]benzene (82).
Trimethylsilylethyne (1.2 g, 12 mmol) was slowly added to a suspension of
4-chloroiodobenzene (2.4 g, 10 mmol), (PPh3)2PdCl2 (200 mg, 0.3 mmol) and Cul 
(100 mg, 0.5 mmol) in dry diisopropylamine (30 ml). The mixture was stirred at 
45 °C for 1 h under Ar, then quenched with H20  (200 ml) and filtered through 
Celite®. The filtrate was extracted with Et20, dried and evaporated to give (82) 
(2.0 g, 95%) as yellow crystals; Rf = 0.79 (hexane); mp 56-57°C (lit.204 mp 55°C); 
IR \)max (KBr) 2098 (C=C); *H NMR (CDC13) 5 0.25 (9 H, s, Si(CH3)3), 7.27 (2 H, d, 
J  = 8.6 Hz, 3,5-H2), 7.38 (2 H, d, J  = 8.6 Hz, 2,6-H2), MS (El +) m/z 210.0448 (M) 





Trimethylsilylethyne (1.2 g, 12.2 mmol) was slowly added to a suspension of
2-iodothiophene (2.1 g, 10.0 mmol), (PPh3)2PdCl2 (200 mg, 0.3 mmol) and Cul (100 
mg, 0.5 mmol) in dry diisopropylamine (30 ml). The mixture was stirred at 45°C for 
1 h under Ar, then quenched with H20  (200 ml) and filtered through Celite®. The 
filtrate was extracted with Et20 , dried and evaporated to give (83) (1.6 g, 89%) as a 
colourless oil; Rf = 0.64 (hexane); lit.205 bp 104 (15 torr); IR \)max (KBr) 2144 (C=C); 
*H NMR (CDC13) 6 0.25 (9 H, s, Si(CH3)3), 6.95 (1 H, dd, J  = 4.9, 3.9 Hz, 4-H), 7.24 
(2 H, m, 3,5-H2), MS (El +) m/z 180.0433 (M) (12C9H12SSi requires 180.0429).





The Pd catalyst, (PPh3)2PdCl2, used in this reaction was prepared as follows:
A mixture of PPh3 (375 mg, 1.4 mmol) and PdCl2 (130 mg, 0.7 mmol) in DMF (20 
ml) was heated at 80°C for 24 h. Filtration and drying yielded (PPh3)2PdCl2 as a 
yellow powder (470 mg, 94%).
A solution of (68) (3.0 g, 9.8 mmol) in dry THF (120 ml) was added to a suspension 
of (PPh3)2PdCl2 (300 mg, 0.4 mmol) and Cul (400 mg, 2.1 mmol) in dry 
diisopropylamine (40 ml) and the mixture was stirred at 45°C for 30 min under Ar. 
Phenylethyne (1.5 g, 15 mmol) was then added during 30 min and the mixture was
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stirred for another 48 h. Filtration (through Celite®), evaporation and 
chromatography (hexane / CH2CI2 1:1) gave (84) (2.2 g, 80%) as reddish-brown 
crystals; Rf = 0.78 (hexane / EtOAc 4:1); mp 59-60°C; IR t)max (KBr) 1343 & 1527 
(N02), 1737 (C=0), 2219 (CeC); ‘H NMR (CDCI3) 8 4.01 (3 H, s, CH3), 7.36-7.41 
(3 H, m, 3',4',5'-H3), 7.49 (1 H, t, J  = 7.8 Hz, 5-H), 7.57-7.62 (2 H, m, 2',6'-H2), 8.04  ̂
(1 H, dd, J  = 7.8, 1.2 Hz, 4-H), 8.10 (1 H, dd, J  = 7.8, 1.2 Hz, 6-H); MS 
(FAB+veion) m/z 282.0757 (M + H) (12C16H12N 04 requires 282.0766), 
266 (M -  Me), 250 (M -  OMe), 222 (M -  C 02Me).





3-Nitrophthalic acid (21.1 g, 100 mmol) in hot aqueous NaOH (10%, 80 ml) was 
added to Hg(OAc)2 (35.0 g, 110 mmol) in hot AcOH (5 ml) and H20  (70 ml). The 
mixture was heated at 170°C (oil bath temperature) for 70 h and was then filtered. 
The precipitate was washed (H20 , then EtOH), dried and boiled under reflux in 
aqueous NaOH (3.5%, 500 ml). Aqueous HC1 (2 M, 12 ml) was then slowly added, 
with vigorous stirring, and the solution was allowed to cool to room temperature. 
AcOH (3 ml) was then added and this gave a curdy cream precipitate, which 
dissolved upon addition of a mixture of NaBr (12.0 g, 117 mmol) and Br2 (19.0 g, 
119 mmol) in H20  (20 ml). The solution was boiled under reflux for 24 h, cooled and 
neutralised with aqueous NaOH. It was then filtered and acidified with concentrated 
HC1. The precipitate formed was filtered, dried and recrystallised (EtOH) to give
(85) (18.2 g, 74%) as a white solid; Rf = 0.24 (hexane / EtOAc 1:4); mp 187-188°C 
(EtOAc) (lit.206 mp 187-188°C (EtOAc)); IR x w  (KBr) 1372 & 1545 (N02),
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1713 (C=0), 2514-3068 (OH); 'H NMR ((CD,)2SO) 8 7.70 (1 H, t, 7.9 Hz, 5-H), 
7.93 (1 H, dd, J  = 7.9, 1.5 Hz, 4-H), 8.08 (1 H. dd, = 7.9, 1.5 Hz, 6-H); MS (El +) 
m/z 246.9308 (M) (12C7H48'BrN0 4  requires 246.9303), 244.9326 (M)






A mixture of (84) (2.5 g, 8.9 mmol) and HgS04  (3.0 g, 10 mmol) in acetone (80 ml) 
and concentrated H2SO4 (4 ml) was boiled under reflux for 48 h, then evaporated to 
yield a brown residue. Extraction (CHCI3), evaporation and chromatography (hexane 
/ Et20  9:1) gave (86) (2.3 g, 95%) as yellow crystals; Rf = 0.55 (hexane / EtOAc 
4:1); mp 142-143°C; IR \ w  (KBr) 1341 & 1525 (N02), 1626 (C=C), 1739 (C=0); 
'H NMR (CDCI3) 8 7.50-7.53 (3 H, m, 3',4 \ 5'-H3), 7.62 (1 H, t, = 7.8 Hz, 7-H). 
7.89 (1 H, d, J = 0.8 Hz, 4-H), 7.93-7.97 (2 H, m, 2',6'-H2), 8.51 (1 H, dd, 8.2,
1.2 Hz, 6-H), 8.65 (1 H, ddd, J  = 8.2, 1.2, 0.8 Hz, 8-H); 13C NMR (CDCI3) 
8 117.18 (C-4), 121.01 (C-3), 125.61 (C-l'), 127.59 (C-7),
127.90 (C-4'), 128.28 (C-3',5'), 128.77 (C-2',6'), 129.83 (C-10), 131.18 (C-6), 
135.44 (C-8), 148.42 (C-9), 157.06 (C-5), 165.07 (C=0); MS (El +) m/z 267.0532 
(M) (12Ci5H9N 04 requires 267.0532).
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Method B:
A solution of Cul (7.5 g, 39 mmol) in aqueous NH3 (35%, 100 ml) was slowly added 
to a solution of phenylethyne (4.0 g, 39 mmol) in EtOH (200 ml). The mixture was 
stirred at room temperature for 15 min, then filtered. The precipitate was washed 5 
times each with H2O, EtOH, then Et2 0  until the filtrate became colourless. It was 
then dried in a vacuum oven at 50°C (20 mmHg) for 2 h. This afforded 
copper(I) phenylacetylide (4.7 g, 73%) as a bright canary-yellow solid. A solution of 
(67) (3.0 g, 10.2 mmol) and copper(I) phenylacetylide (1.7 g, 10 mmol) in dry 
pyridine (100 ml) was boiled under reflux for 6  h under N2. The solution was then 
poured into H2O (300 ml), extracted (Et2<3 ) and washed (2 M aqueous HC1, 5% 
aqueous NaHCC>3, then H2O). Evaporation of the organic layer and chromatography 
(hexane / EtOAc 12:1) yielded (87) (105 mg, 5%) as a white solid; Rf = 0.95 (hexane 
/ EtOAc 9:1); mp 83-84°C (lit.207 mp 8 6 -8 8 °C); IR \ w  (KBr) 2158 (O C ); 
'HNMR(CDC13) 6  7.26-7.35 (6  H, m, 2 x 3 ',4 ',5 '-H3), 7.45-7.50 (4 H, m, 
2  x  2',6'-H2); MS (El +) nt/z 202.0784 (M) (12Ci6Hi0 requires 202.0783).
Further elution yielded (8 6 ) (2.0 g, 74%) as yellow crystals; data as above.
Method C:
To a stirred solution of 1-phenyl-1,3-butanedione (8.3 g, 51 mmol) and potassium t- 
butoxide (2.3 g, 20 mmol) in 2-methyl-2-propanol (50 ml) was added (85) (2.5 g, 10 
mmol) and Cu powder (65 mg, 1.0 mmol). The mixture was boiled under reflux for 
16 h, then poured into H2O (350 ml) and acidified with aqueous HC1 (2 M). 
Extraction (Et2 0 ), evaporation and chromatography (hexane / EtOAc 10:1) gave (8 6 ) 
(120 mg, 4%) as yellow crystals; data as above. Further elution yielded 
(8 8 ) (170 mg, 8 %) as yellow crystals; data as below.
Method D:
To a stirred solution of dibenzoylmethane (22.9 g, 102 mmol) and potassium 
f-butoxide (4.6 g, 41 mmol) in 2-methyl-2-propanol (100 ml) was added (85) (5.0 g, 
20 mmol) and Cu powder (150 mg, 2.4 mmol). The mixture was boiled under reflux 
for 16 h, then poured into H2O (350 ml) and acidified with aqueous HC1 (2 M).
157
Extraction (Et20), evaporation and chromatography (hexane / EtOAc 10:1) gave
(86) (4.2 g, 78%) as yellow crystals; data as above.
3-Methyl-5-nitroisocoumarin (88).
o
To a stirred solution of 2,4-pentanedione (5.3 g, 53 mmol) and potassium r-butoxide 
(2.3 g, 20 mmol) in 2-methyl-2-propanol (50 ml) was added (85) (2.5 g, 10 mmol) 
and Cu powder (67 mg, 1.1 mmol). The mixture was boiled under reflux for 16 h, 
then poured into H20  (350 ml) and acidified with aqueous HC1 (2 M). Extraction 
(Et20), evaporation and chromatography (hexane / EtOAc 3:2) gave (88 ) (470 mg, 
23%) as yellow crystals; Rf = 0.59 (hexane / EtOAc 4:1); mp 199-200°C; IR umax 
(KBr) 1331 & 1520 (N02), 1648 (C=C), 1746 (C=0); 'H NMR (CDCI3) 8 2.37 (3 H, 
s, CH3), 7.13 (1 H, d, J  = 0.8 Hz, 4-H), 7.55 (1 H, t, 8.2 Hz, 7-H), 8.41 (1 H, dd, 
7=  8.2, 1.2 Hz, 6-H), 8.56 (1 H, ddd, J  = 8.2, 1.2, 0.8 Hz, 8-H); l3C NMR (CDCI3) 
8 20.46 (CH3), 98.36 (C-4), 121.92 (C-3), 126.88 (C-7), 131.36 (C-6 ), 131.84 (C-10), 
135.74 (C-8), 143.85 (C-9), 158.63 (C-5), 160.83 (C=0); MS (El +) 205.0384
(M) (12Ci0H7NO4 requires 205.0375), 159 (M -  N0 2); Anal. Calcd. for C10H7NO4: C, 





A solution of (86) (1.0 g, 3.7 mmol) in 2-methoxyethanol (100 ml) was saturated 
with NH3, boiled under reflux for 4 h, then evaporated until 10 ml remained. The 
concentrate was stored at 4°C for 16 h and the precipitated crystals were filtered, 
washed (H20 , then EtOH) and recrystallised (MeOH) to give (89) (730 mg, 73%) as 
bright yellow crystals; Rf = 0.33 (hexane / EtOAc 4:1); mp 127-128°C (MeOH); 
IR (KBr) 1348 & 1536 (N02), 1655 (C=0), 3482 (NH); 'H NMR ((CD3)2SO) 
5 7.25 (1 H, s, 4-H), 7.53-7.55 (3 H, m, 3',4',5'-H3), 7.66 (1 H, t, = 7.8 Hz, 7-H), 
7.78-7.80 (2 H, m, 2',6'-H2), 8.49 (1 H, d, = 7.8 Hz, 6-H), 8.60 (1 H, d, 7.8 Hz, 





A mixture of (89) (100 mg, 376 pmol) and SnCl2 (220 mg, 1.2 mmol) in EtOH 
(20 ml) was heated at 70°C for 4 h, then carefully poured into ice-H20  (200 ml). The 
resulting suspension was made alkaline with aqueous NaOH and the precipitate was 
filtered. Extraction of the filtrate (EtOAc), evaporation and recrystallisation (hexane, 
EtOAc) gave (90) (51 mg, 57%) as yellow crystals; Rf = 0.91 (hexane / EtOAc 1:4); 
mp 215-217°C; IR \)max (KBr) 1655 (C=0), 3230 & 3329 (NH2), 3569 (NH);
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‘H NMR (CDCI3) § 4.00 (2 H, br s, NH2), 6.64 (1 H, s, 4-H), 6.93 (1 H, dd, = 7.8,
1.2 Hz, 6-H), 7.22 (1 H, t, J  = 7.8 Hz, 7-H), 7.36-7.45 (3 H, m, 3 '.4 ',5'-H3), 
7.64-7.66 (2 H, m, 2',6'-H2), 7.80 (1 H, dd, = 7.8, Hz, 8-H), 10.08 (1 H, br s, 
NH); MS (FAB +ve ion) m/z 237.1019 (M + H) (12C |5HBN20  requires 237.1028).
5-Airiino-3-phenylisoquinolin-l(2//>one hydrochloride (91).
NH
A mixture of (90) (50 mg, 0.2 mmol) and aqueous HC1 (2 M, 20 ml) were stirred at 
room temperature for 30 min. Evaporation and recrystallisation (MeOH) yielded (91) 
(53 mg, 91%) as a yellow-brown solid; Rf = 0.59 (MeOH); mp 192-193°C; ‘H NMR 
(D20) 6 6.98 (1 H, s, 4-H), 7.52-7.59 (3 H, m, 3',4',5'-H3), 7.59 (1 H, t, 8.1 Hz,
7-H), 7.68-7.75 (2 H, m, 2',6'-H2), 7.84 (1 H, d, 8.1 Hz, 6-H), 8.31 (1 H, d, 




A solution of (88) (470 mg, 2.3 mmol) in 2-methoxyethanol (100 ml) was saturated 
with NH3, boiled under reflux for 4 h, then evaporated until 10 ml remained. The 
concentrate was stored at 4°C for 16 h and the precipitated crystals were filtered, 
washed (H2O, then EtOH) and recrystallised (MeOH) to give (92) (320 mg, 68%) as 
bright yellow crystals; Rf = 0.33 (hexane / EtOAc 4:1); mp (decomp.) 231-232°C; IR 
\ w  (KBr) 1346 & 1523 (N 02), 1668 (C=0), 3435 (NH); !H NMR ((CD3)2SO)
160
5 2.29 (3 H, s, CH3), 6.78 (1 H, s, 4-H), 7.55 (1 H, t, 7 = 7.8 Hz, 7-H), 8.38 (1 H, dd, 
7 = 7.8, 1.2 Hz, 6-H), 8.49 (1 H, dd, 7 = 7.8, 1.2 Hz, 8-H), 11.79 (1 H, br s, NH); 
MS (FAB +ve ion) m/z 205.0617 (M + H) (12CioH9N203  requires 205.0613), 
189 (M - Me); Anal. Calcd. for C,oH8N20 3: C, 58.82; H, 3.95; N, 13.72. 




A mixture of (92) (320 mg, 1.6 mmol) and SnCl2 (900 mg, 4.7 mmol) in EtOH 
(20 ml) was heated at 70°C for 4 h, then carefully poured into ice-H20  (200 ml). The 
resulting suspension was made alkaline with aqueous NaOH and the precipitate was 
filtered. Extraction of the filtrate (EtOAc), evaporation and recrystallisation (hexane, 
EtOAc) gave (93) (160 mg, 59%) as yellow crystals; Rf = 0.27 (hexane / EtOAc 1:9); 
mp 183-184°C; IR \)max (KBr) 1655 (C=0), 3298 & 3375 (NH2), 3467 (NH); 
]H NMR ((CD3)2SO) 6 2.18 (3 H, s, CH3), 5.47 (2 H, br s, NH2), 6.44 (1 H, s, 4-H),
6.80 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 7.05 (1 H, t, J  = 7.8 Hz, 7-H), 7.32 (1 H, dd, 
7 = 7.8, 1.2 Hz, 8-H), 11.06 (1 H, br s, NH); MS (FAB +ve ion) m/z 175.0874 




A mixture of (93) (160 mg, 0.9 mmol) and aqueous HC1 (2 M, 20 ml) were stirred at 
room temperature for 30 min. Evaporation and recrystallisation (MeOH) yielded (94) 
(180 mg, 95%) as a pale brown solid; Rf = 0.24 (MeOH); mp >350°C; 'H NMR 
((CD3)2SO) 8 2.23 (3 H, s, CH3), 6.48 (1 H, s, 4-H), 7.37 (1 H, t, 7 = 7.8 Hz, 7-H), 
7.69(1 H, d, 7=  7.8 Hz, 6-H), 7.99(1 H,d, 7 = 7.8 Hz, 8-H), 11.50(1 H, br s, NH).
4-Hydroxy-4-(4-methoxyphenyl)but-3-en-2-one (95a). 
l-(4-Methoxyphenyl)butane-l,3-dione (95b).
A solution of 4-methoxyacetophenone (2.3 g, 15 mmol) in Ac20  (6.2 g, 60 mmol) 
was added to BF3(AcOH)2 (8.5 g, 45 mmol) at 0°C. The mixture was stirred for 30 
min and allowed to stand at room temperature for 24 h. The mixture was then poured 
into an aqueous solution of NaOAc (13%, 100 ml) and boiled under reflux for 1 h. 
Extraction (Et20), evaporation and chromatography (hexane / EtOAc 15:1) afforded 
(95a,b) (12:1)(1.7 g, 59%) as colourless crystals; Rf = 0.64 (hexane / EtOAc 15:1); 
mp 59-60°C (lit.208 mp 55-56°C); (95a): JH NMR (CDC13) 6 2.15 (3 H, s, COCH3),
3.85 (3 H, s, OCH3), 6.10 (1 H, s, CH), 6.92 (2 H, d, J  = 9.2 Hz, 3',5'-H2), 7.85 (2 H, 
d , J  = 9.2 Hz, 2',6'-H2), 16.30 (1 H, br s, OH); (95b): *H NMR (CDC13) 5 2.27 (3 H, 
s, COCH3), 3.86 (3 H, s, OCH3), 4.03 (1 H, s, CH2), 6.92 (2 H, d, J  = 9.2 Hz, 
3',5'-H2), 7.85 (2 H, d, J  = 9.2 Hz, 2',6'-H2); M S(EI+) m/z 192.0778 (M)
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(12Ci,H120 3 requires 192.0786), 177 (M
135 (M -  CH2COMe).
Me), 161 (M -  OMe),
l,4-Di(4-methoxyphenyl)-l,3-butadiyne (96).
3-(4-Methoxyphenyl)-5-nitroisocoumarin (97).






A solution of Cul (7.3 g, 38 mmol) in aqueous NH3 (100 ml) was slowly added to a 
solution of (117) (5.0 g, 38 mmol) in EtOH (200 ml). The mixture was stirred at 
room temperature for 15 min, then filtered. The precipitate was washed 5 times each 
with H20 , EtOH, then Et20  until the filtrate became colourless. It was then dried in a 
vacuum oven at 50°C (20 mmHg) for 2 h. This afforded
copper(I) 4-methoxyphenylacetylide (5.6 g, 76%) as a bright canary-yellow solid. A 
solution of (67) (1.7 g, 5.8 mmol) and copper(I) 4-methoxyphenylacetylide (1.2 g,
6.2 mmol) in dry pyridine (100 ml) was boiled under reflux for 6 h under N2. The 
solution was then poured into H20  (300 ml), extracted (Et20) and washed (2 M 
aqueous HC1, 5% aqueous NaHC03, then H20). Evaporation of the organic layer and 
chromatography (hexane / EtOAc 10:1) yielded (96) (20 mg, 1%) as pale yellow 
crystals; Rf = 0.71 (hexane / EtOAc 4:1); mp 144-145°C (lit.209 mp 149°C); 
IR \)max (KBr) 2145 (C=C); *H NMR (CDC13) 5 3.82 (6 H, s, 2 x OCH3), 6.85 (4 H, 
d, J=  8.9 Hz, 2 x 3',5'-H2), 7.46 (4 H, d, J  = 8.9 Hz, 2 x 2',6'-H2); 
MS (El +) m/z 262.0995 (M) (12C18Hi40 2 requires 262.0994), 247 (M -  Me).
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Further elution gave (97) (500 mg, 29%) as yellow crystals; Rf = 0.61 
(hexane/EtOAc 4:1); mp 241-242°C; IR umax (KBr) 1346 & 1511 (N02), 1620 
(C=C), 1738 (C=0); ‘H NMR (CDC13) 5 3.88 (3 H, s, OCH3), 6.99 (2 H, d, 
J = 9.0 Hz, 3',5'-H2), 7.54 (1 H, t, J = 8.2 Hz, 7-H), 7.76 (1 H, s, 4-H), 7.88 (2 H, d, 
J = 9.0 Hz, 2',6'-H2), 8.46 (1 H, dd, J  = 8.2, 1.2 Hz, 6-H), 8.59 (1 H, dd, J = 8.2,
1.2 Hz, 8-H); 13C NMR (CDC13) 555.56 (OCH3), 94.74 (C-4), 114.52 (C-3',5'), 
126.56 (C-7), 127.73 (C-2',6'), 131.71 (C-6), 135.92 (C-8); MS (El +) m/z 
297.0639 (M) (12Ci6H, ,N 05 requires 297.0637), 266 (M -  OMe).
Method B:
To a stirred solution of (95a) and (95b) (16.9 g, 88.1 mmol) and potassium 
f-butoxide (4.0 g, 36 mmol) in 2-methyl-2-propanol (50 ml) was added (85) 
(4.3 g, 17 mmol) and Cu powder (120 mg, 1.9 mmol). The mixture was boiled under 
reflux for 16 h, then poured into H20  (350 ml) and acidified with aqueous HC1 
(2M). Extraction (Et20), evaporation and chromatography (hexane / EtOAc 4:1) 
gave (97) (790 mg, 15%) as yellow crystals; data as above.
Further elution yielded (88) (200 mg, 6%) as yellow crystals; data as above.
Method C:
To a stirred solution of l,3-di(4-methoxyphenyl)-l,3-propanedione (10.0 g, 
35 mmol) and potassium f-butoxide (2.3 g, 20 mmol) in 2-methyl-2-propanol (50 ml) 
was added (85) (2.5 g, 10 mmol) and Cu powder (63 mg, 1.0 mmol). The mixture 
was boiled under reflux for 16 h, then poured into H20  (350 ml) and acidified with 
aqueous HC1 (2 M). Extraction (Et20), evaporation and chromatography 







A solution o f (97) (230 mg, 0.8 mmol) in 2-m ethoxyethanol (50 ml) was saturated 
with N H 3 , boiled under reflux for 4 h, then evaporated until 10 ml rem ained. The 
concentrate was stored at 4°C  for 16 h and the precipitated crystals were filtered, 
washed (H 2O, then EtOH) and recrystallised (M eOH) to give (98) (150 mg, 65%) as 
bright yellow crystals; Rf = 0.45 (hexane / EtOA c 9:1); mp (decom p.) 236-237°C; 
IR \)max (KBr) 1323 & 1515 (N 0 2), 1615 (C=C), 1677 (C = 0), 3468 (NH); *H NM R 
((CD 3 )2SO) 5 3.82 (3 H, s, O C H 3), 7.07 (2 H, d, J  = 9.0 Hz, 3 ',5 '-H 2), 7.18 (1 H, d, 
7 = 0.8 Hz, 4-H), 7.60 (1 H, t, J  = 8.2 Hz, 7-H), 7.73 (2 H, d, J  = 9.0 Hz, 2 ',6 '-H 2),
8.45 (1 H, dd, J = 8.2, 1.2 Hz, 6 -H), 8.55 (1 H, ddd, J = 8.2, 1.2, 0.8 Hz, 8 -H), 
12.00(1 H, br s, NH); MS (E l +) m/z 296.0802 (M ) ( 12C i6 H i2 N 2 0 4  
requires 296.0797), 250 (M  -  N 0 2); Anal. Calcd. for C 16H i2N 2O 4 0.5H 2O: C, 62.95; 






A m ixture o f (98) (80 mg, 0.3 mmol) and SnC l2 (160 mg, 0.8 m mol) in EtO H  (30 ml) 
was heated at 70°C for 4 h, then carefully poured into ice-H 20  (200 ml). The 
resulting suspension was m ade alkaline with aqueous NaOH and the precipitate was 
filtered. Extraction o f the filtrate (EtO Ac), evaporation and recrystallisation
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(hexane / EtOAc) gave (99) (60 mg, 83%) as yellow crystals; Rf = 0.60 
(hexane / EtOAc 1:4); mp 189-190°C; IR \)max(KBr) 1660 (C = 0), 3233 (N H 2), 3438 
(NH); 'H NM R (CDC13) 5 3.86 (3 H, s, O CH3), 4.11 (2 H, br s, N H 2), 6.64 (1 H, s,
4-H), 6.97 (1 H, dd, J  = 7.8, 1.2 Hz, 6-H), 6.99 (2 H, d, J  = 8.8 Hz, 3,,5/-H2), 
7.25 (1 H, t, J  = 7.8 Hz, 7-H), 7.66 (2 H, d, J  = 8.8 Hz, 2',6'-H2), 7.85 (1 H, dd, 
J  = 7.8, 1.2 Hz, 8-H), 10.45 (1 H, br s, NH); MS (FAB +ve ion) m/z 267.1132 




A m ixture o f (99) (60 mg, 0.2 mmol) and aqueous HC1 (2 M, 20 ml) were stirred at 
room  tem perature for 30 min. Evaporation and recrystallisation (M eOH) yielded 
(100) (65 mg, 95% ) as a dark brown solid; Rf = 0.83 (M eOH); mp >350°C; 
!H NM R (D 20 )  8  3.86 (3 H, s, OCH3), 6.84 (2 H, d, J  = 8.1 Hz, 3 ',5 '-H 2), 6.92 (1 H, 
s, 4-H), 7.11 (1 H, t, J  = 8.1 Hz, 7-H), 7.55 (1 H, d, J  = 8.1 Hz, 6 -H), 7.70 (1 H, d, 








A solution of 4-m ethylacetophenone (2.0 g, 14.9 mmol) in Ac20  (6.2 g, 60.8 mmol) 
was added to B F 3 (A cO H ) 2 (8.5 g, 45.2 mmol) at 0°C. The m ixture was stirred for 30
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min and allowed to stand at room  tem perature for 24 h. The m ixture was then poured
into an aqueous solution of NaOAc (13% , 100 ml) and boiled under reflux for 1 h.
Extraction (Et20), evaporation and chrom atography (hexane /  EtOAc 20:1) afforded
(101a,b) (8:1) (2.3 g, 86%) as a colourless oil; Rf = 0.40 (hexane / E tO A c 20:1);
(101a): ‘H NM R (CDC13) S 2.20 (3 H, s, CO CH j), 2.41 (3 H, s, A rC H 3), 6.16 (1 H, 
©
s, CH), 7.24 (2 H, d, J  = 8.2 Hz, 3 ',5 '-H 2), 7.78 (2 H, d, J  = 8.2 Hz, 2 ',6 '-H 2), 
16.22 (1 H, br s, OH); (101b): *H N M R (CDC13) 5 2.30 (3 H, s, CO C H 3), 2.59 (3 H, 
s, A rCH 3), 4.08 (1 H, s, CH 2), 7.24 (2 H, d, J = 8.2 Hz, 3 ',5 '-H 2), 7.78 (2 H, d, 
J  = 8.2 Hz, 2 ',6 '-H 2); MS (El +) m/z 176.0838 (M) (12C n H i20 2 requires 176.0837), 









A solution o f Cul (6.6 g, 35 mmol) in aqueous N H 3 (35%, 100 ml) was slow ly added 
to a solution of l-ethynyl-4-m ethylbenzene (4.0 g, 35 mmol) in EtOH (200 ml). The 
m ixture was stirred at room  tem perature for 15 min, then filtered. The precipitate was 
washed 5 tim es each w ith H 20 ,  EtOH, then Et20  until the filtrate becam e colourless. 
It was then dried in a vacuum  oven at 50°C (20 torr) for 2 h. This afforded 
copper(I) 4-m ethylphenylacetylide (4.4 g, 71%) as a bright canary-yellow  solid. A 
solution o f (67) (6.0 g, 20 m m ol) and copper(I) 4-m ethylphenylacetylide
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(3.7 g, 21 mmol) in dry pyridine (100 ml) was boiled under reflux for 6 h under N2. 
The solution was then poured into H2O (300 ml), extracted (Et20) and washed (2 M 
aqueous HC1, 5% aqueous NaHCC>3, then H2O). Evaporation of the organic layer and 
chromatography (hexane / EtOAc 10:1) yielded (102) (20 mg, 0.4%) as pale yellow 
crystals; Rf = 0.98 (hexane / EtOAc 4:1); mp 180-181°C (lit.210 mp 183°C (Et20)); 
IR \)max (KBr) 2130 (O C ); JH NMR (CDC13) 5 2.36 (6 H, s, 2 x CH3), 7.14 (4 H, d, 
J  = 8.1 Hz, 2 x 3',5'-H2), 7.41 (4 H, d, J = 8.1 Hz, 2 x 2',6'-H2); MS (FAB +ve ion) 
m/z 231.1141 (M + H) (12Ci8Hi5 requires 231.1174).
Further elution gave (103) (1.0 g, 18%) as yellow crystals; Rf = 0.48
(hexane / EtOAc 4:1); mp 161-162°C; IR Dmax (KBr) 1321 & 1511 (NO2),
1618 (C=C), 1737 (C=0); NM R (CDC13) 6 2.42 (3 H, s, CH3), 7.29 (2 H, d, 
J  = 8.2 Hz, 3 ',5 '-H 2), 7.56 (1 H, t, J  = 8.2 Hz, 7-H), 7.80 (1 H, s, 4-H), 7.81 (2 H, d, 
J  = 8.2 Hz, 2 ',6 '-H 2), 8.46 (1 H, dd, J  = 8.2, 1.2 Hz, 6-H), 8.60 (1 H, td, J  = 8.2,
1.2 Hz, 8-H); MS (FAB +ve ion) m/z 282.0762 (M + H) (12Ci6Hn N 04
requires 282.0766).
Method B:
To a stirred solution of (101a) and (101b) (22.7 g, 0.1 mol) and potassium f-butoxide 
(5.8 g, 52 mmol) in 2-methyl-2-propanol (50 ml) was added (85) (6.3 g, 26 mmol) 
and Cu powder (170 mg, 2.7 mmol). The mixture was boiled under reflux for 16 h, 
then poured into H2O (350 ml) and acidified with aqueous HC1 (2 M). Extraction 
(Et20), evaporation and chromatography (hexane / EtOAc 10:1) gave
(103) (1.5 g, 21%) as yellow crystals; data as above.







A solution of (103) (1.0 g, 3.6 mmol) in 2-methoxyethanol (50 ml) was saturated 
with NH3, boiled under reflux for 4 h, then evaporated until 10 ml remained. The 
concentrate was stored at 4°C for 16 h and the precipitated crystals were filtered, 
washed (H2O, then EtOH) and recrystallised (MeOH) to give (104) (860 mg, 86%) as 
bright yellow crystals; Rf = 0.23 (hexane / EtOAc 3:2); mp 175°C; IR Umax (KBr) 
1324 & 1516 (NO2), 1620 (C=C), 1673 (C=0), 3457 (NH); *H NMR ((CD3)2SO) 
6 2.37 (3 H, s, CH3), 7.20 (1 H, d, J  = 0.8 Hz, 4-H), 7.32 (2 H, d, /  = 8.2 Hz, 
3',5'-H2), 7.62 (1 H, t, J  = 8.2 Hz, 7-H), 7.66 (2 H, d, J  = 8.2 Hz, 2',6'-H2), 8.45 (1 H, 
dd, J  = 8.2, 1.2 Hz, 6-H), 8.56 (1 H, ddd, J  = 8.2, 1.2, 0.8 Hz, 8-H), 
12.03 (lH ,b rs ,N H ); MS (El +) m/z 280.0856 (M) (I2Ci6Hi2N20 3
requires 280.0848); Anal. Calcd. for Ci6Hi2N20 3: C, 68.56; H, 4.32; N, 9.99. 





A mixture of (104) (280 mg, 1.0 mmol) and SnCl2 (550 mg, 2.9 mmol) in EtOH 
(30 ml) was heated at 70°C for 4 h, then carefully poured into ice-H20  (200 ml). The 
resulting suspension was made alkaline with aqueous NaOH and the precipitate was 
filtered. Extraction of the filtrate (EtOAc), evaporation and recrystallisation (hexane,
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EtOAc) gave (105) (230 mg, 92%) as yellow crystals; Rf = 0.24 (hexane / EtOAc 
3:2); mp 213-214°C; IR \)max (KBr) 1669 (0=0), 3253 (NH2), 3476 (NH); 
‘H NMR (CDC13) 6 2.41 (3 H, s, CH3), 4.06 (2 H, br s, NH2), 6.68 (1 H, s, 4-H), 
6.99(1 H, d, J  = 7.8 Hz, 6-H), 7.28 (1 H, t, = 7.8 Hz, 7-H), 7.29 (2 H, d, 
J  = 7.8 Hz, 3',5'-H2), 7.59 (2 H, d, J  = 7.8 Hz, 2',6'-H2), 7.86 (1 H, d, 7.8 Hz, 





A mixture of (105) (25 mg, 0.1 mmol) and aqueous HC1 (2 M, 20 ml) were stirred at 
room temperature for 30 min. Evaporation and recrystallisation (MeOH) yielded 
(106) (27 mg, 94%) as a brown solid; Rf = 0.74 (MeOH); mp >350°C; *H NMR 
((CD3)2SO) 6 2.23 (3 H, s, CH3), 6.48 (1 H, s, 4-H), 7.31 (2 H, d, 7 = 7.8 Hz, 
3',5'-H2), 7.36 (1 H, t, 7 = 7.8 Hz, 7-H), 7.61 (1 H, d, 7 = 7.8 Hz, 6-H), 7.75 (1 H, d, 






A solution of 4-(trifluoromethyl)acetophenone (2.5 g, 13 mmol) in AC2O (5.5 g, 54 
mmol) was added to BF3(AcOH)2 (7.6 g, 40 mmol) at 0°C. The mixture was stirred 
for 30 min and allowed to stand at room temperature for 24 h. The mixture was then 
poured into an aqueous solution of NaOAc (13%, 100 ml) and boiled under reflux for 
1 h. Extraction (EtoO), evaporation and chromatography (hexane / EtOAc 7:3) 
afforded (108a,b) (27:1) (2.1 g, 68%) as pale orange crystals; Rf = 0.57 
(hexane / EtOAc 4 :1); mp 48-49°C; (108a): ‘H NMR (CDCI3) 6 2.23 (3 H, s, CH3), 
6.19 (1 H, s, CH), 7.68 (2 H, d, J  = 8.2 Hz, 3',5'-H2), 7.95 (2 H, d, = 8.2 Hz,
2',6'-H2), 15.98 (1 H, br s, OH); l9F NMR (CDC13) 8 -63.62 (3 F, s, CF3); 
(108b): 'HNMR (CDCI3) 8 2.32 (3 H, s, CH3), 4.13 (2 H, s, CH2), 7.71 (2 H, d, 
J = 8.2 Hz, 3',5'-H2), 8.04 (2 H, d, J  = 8.2 Hz, 2',6'-H2); l9F NMR (CDCI3) 8  -63.62 
(3 F, s, CF3); MS (El +) m/z230.0551 (M) (,2CnH9F3 0 2 requires 230.0555), 








To a stirred solution of (108a) and (108b) (3.5 g, 15 mol) and NaOEt (1.6 g, 
23 mmol) in EtOH (35 ml) was added (85) (2.5 g, 10 mmol) and Cu powder 
(220 mg, 3.5 mmol). The mixture was boiled under reflux for 16 h, then poured into 
H2O (350 ml) and acidified with aqueous HC1 (2 M). Extraction (Et2 0 ), evaporation 
and chromatography (hexane / EtOAc 4:1) gave (109) (160 mg, 5%) as yellow 
crystals; Rf = 0.50 (hexane / EtOAc 4:1); mp 163-164°C; IR \)max (KBr) 1324 & 1531 
(N 02), 1615 (C=C), 1732 (C=0); ‘H N M R (CDC13) 6 7.67 (1 H, t, 7 = 8.2 Hz, 7-H), 
7.77 (2 H, d, 7 = 8.2 Hz, 3',5'-H2), 7.96 (1 H, d, 7 = 0.8 Hz, 4-H), 8.06 (2 H, d, 
7 = 8.2 Hz, 2\6'-H2), 8.53 (1 H, dd, 7 = 8.2, 1.6 Hz, 6-H), 8.57 (1 H, ddd, 
7 = 8.2, 1.6, 0.8 Hz, 8-H); 19F NM R (CDC13) 6 -63.54 (3 F, s, CF3); 
MS (El +) m/z3 5.0404 (M) (l2C |6H8F3N0 4 requires 335.0405).
Also isolated were the following side products:
(110) (210 mg, 11%) as a colourless oil; ‘H NMR (CDClj) 5 2.56 (3 H, s, CHj), 
7.55 (2 H, d, 7 = 8.2 Hz, 3\5'-H2), 8.14 (2 H, d, 7 = 8.2 Hz, 2',6'-H2); MS (El +) 
188.0457 (M) (12C9H7F30  requires 188.0450).
(111) (130 mg, 6%) as a colourless oil; 'H NMR (CDC13) 6 1.41 (3 H, t, 7 = 7.2 Hz, 
CHjCtfj), 4.41 (2 H, q, 7 = 7.2 Hz, C//2CH3), 7.75 (2 H, d, 7 = 8.2 Hz, 3',5'-H2),
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8.16 (2 H, d, J  = 8.2 Hz, 2',6'-H2); MS (El +) 218.0553 (M) (l2Ci0H9F,O2
requires 218.0555).
Method B:
To a stirred solution of (108a) and (108b) (3.6 g, 16 mol) and potassium /-butoxide 
(700 mg, 6.3 mmol) in 2-methyl-2-propanol (50 ml) was added (85) (760 mg, 3.1 
mmol) and Cu powder (20 mg, 0.3 mmol). The mixture was boiled under reflux for 
16 h, then poured into H20  (350 ml) and acidified with aqueous HC1 (2 M). 
Extraction (Et20), evaporation and chromatography (hexane / EtOAc 9:1) gave 
(109) (160 mg, 16%) as yellow crystals; data as above.
Further elution yielded (88) (40 mg, 6%) as yellow crystals; data as above.
5-Nitro-3-[4-(trifluoromethyl)phenyl]isoquinoIin-l(2//)-one (112).
NH
A solution of (109) (560 mg, 1.7 mmol) in 2-methoxyethanol (50 ml) was saturated 
with N H 3 , boiled under reflux for 4 h, then evaporated until 10 ml remained. The 
concentrate was stored at 4°C for 16 h and the precipitated crystals were filtered, 
washed (H20 , then EtOH) and recrystallised (MeOH) to give (112) (150 mg, 27%) as 
bright yellow crystals; Rf = 0.43 (hexane / EtOAc 1:4); mp 230-231°C; IR \)max (KBr) 
1323 & 1526 (N02), 1663 (C=0), 3437 (NH); ]H NMR ((CD3)2SO) 5 7.28 (1 H, s,
4-H), 7.68 (1 H, t, J  = 7.8 Hz, 7-H), 7.88 (2 H, d, = 8.2 Hz, 3',5'-H2), 7.97 (2 H, d, 
7 = 8.2 Hz, 2',6'-H2), 8.47 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 8.58 (1 H, d, 7.8,
1.2 Hz, 8-H), 12.21 (1 H, br s, NH); l9F NMR ((CD3)2SO) 8 -61.84 (3 F, s, CF3); 






A mixture of (112) (1.0 g, 3.0 mmol) and SnCE (1.8 g, 9.5 mmol) in EtOH (50 ml) 
was heated at 70°C for 4 h, then carefully poured into ice-H20  (200 ml). The 
resulting suspension was made alkaline with aqueous NaOH and the precipitate was 
filtered. Extraction of the filtrate (EtOAc), evaporation and recrystallisation (hexane, 
EtOAc) gave (113) (360 mg, 40%) as yellow crystals; Rf = 0.35 
(hexane / EtOAc 1:4); mp 214-215°C; IR \)max (KBr) 1651 (0=0), 3218 (NH2), 3419 
(NH); 'H NMR ((CD3)2SO) 5 5.86 (2 H, br s, NH2), 6.88 (1 H, dd, 7.8, 1.2 Hz,
6-H), 7.18(1 H, t, J  =7.8 Hz, 7-H), 7.22(1 H, s, 4-H), 7.40(1 H, d, = 7.8, 1.2 Hz, 
8-H), 7.82 (2 H, d, J  = 8.2 Hz, 3\5'-H2), 8.02 (2 H, d, 8.2 Hz, 2',6'-H2),
11.45 (1H, br s, NH); 19F NMR ((CD3)2SO) 5 -61.60 (3 F, s CF3); 




A mixture of (113) (360 mg, 1.2 mmol) and aqueous HC1 (2 M, 20 ml) were stirred 
at room temperature for 30 min. Evaporation and recrystallisation (MeOH) yielded 
(114) (370 mg, 92%) as a pale brown solid; Rf = 0.81 (MeOH); mp >350°C; 
'HNMR ((CD3)2SO) 8 7.14 (1 H, dd, J  7.8, 1.2 Hz, 6-H), 7.18 (1 H, s, 4-H),
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7.31 (1 H, t, J  = 7.8 Hz, 7-H), 7.63 (1 H, dd, J  = 7.8, 1.2 Hz, 8-H), 7.85 (2 H, d, 
7 =  8.2 Hz, 3',5'-H2), 8.01 (2 H, d, J  = 8.2 Hz, 2',6'-H2), 11.60 (1 H, br s, NH); 







A solution of 4-chloroacetophenone (4.6 g, 30 mmol) in Ac20  (12.3 g, 121 mmol) 
was added to BF3(AcOH)2 (17.1 g, 91 mmol) at 0°C. The mixture was stirred for 30 
min and allowed to stand at room temperature for 24 h. The mixture was then poured 
into an aqueous solution of NaOAc (13%, 100 ml) and boiled under reflux for 1 h. 
Extraction (Et20), evaporation and chromatography (hexane / EtOAc 4:1) afforded 
(115a,b) (20:1) (4.9 g, 84%) as pale orange crystals; Rf = 0.54 (hexane / EtOAc 4:1); 
mp 58-59°C; (115a): 'H NMR (CDClj) 5 2.20 (3 H, s, CH3), 6.13 (1 H, s, CH), 
7.40 (2 H, d, J  = 8.6 Hz, 3',5'-H2), 7.79 (2 H, d, = 8.6 Hz, 2 ',6 '-H2), 16.09 (1 H, 
brs, OH); (115b): 'H  NMR (CDCI3) 5 2.30 (3 H, s, CH3), 4.07 (2 H, s, C H 2), 
7.43 (2 H, d, J  = 8.6 Hz, 3',5'-H2), 7.87 (2 H, d, = 8.2 Hz, 2',6'-H2); 
MS (El +) m/z198.0261 (M) ( ,2C,oH937C102 requires 198.0262), 196.0290 (M)
(12Ci0H935C1O2 requires 196.0291), 161 (M -  Cl), 139 (M -  CH2COMe), 




To a stirred solution of (115a) and (115b) (7.1 g, 36 mmol) and potassium f-butoxide 
(1.7 g, 15 mmol) in 2-methyl-2-propanol (50 ml) was added (85) (1.8 g, 7.3 mmol) 
and Cu powder (47 mg, 0.7 mmol). The mixture was boiled under reflux for 16 h, 
then poured into H20  (350 ml) and acidified with aqueous HC1 (2 M). Extraction 
(Et20), evaporation and chromatography (hexane / EtOAc 9:1) gave 
(116) (720 mg, 33%) as yellow crystals; Rf = 0.71 (hexane / EtOAc 9:1); 
mp 204-205°C; IR umax (KBr) 1340 & 1522 (N02), 1626 (C=C), 1745 (C=0); 
'H NM R (CDCI3) 8 7.47 (2 H, d, J  = 9.0 Hz, 3',5'-H2), 7.61 (1 H, t, = 8.2 Hz, 7-H),
7.85 (1 H, d, J = 0.8 Hz, 4-H), 7.87 (2 H, d, 9.0 Hz, 2',6'-H2), 8.49 (1 H, dd, 
J = 8.2, 1.2 Hz, 6-H), 8.62 (1 H, ddd, J  = 8.2, 1.2, 0.8 Hz, 8-H); 13C NM R (CDC13) 
8 96.62(C-4), 127.23 (C-3',5'), 127.50 (C-7), 129.44 (C-2',6 '), 131.74 (0 -6 ), 135.92 
(C-8); MS (El +) m/z 303.0111 (M ) (12Ci5H837ClN0 4 requires 303.0112), 301.0137 
(M) (12Ci5H835C1N04 requires 301.0142).




To ethynylmagnesium bromide (0.5 M in THF, 44 ml, 22 mmol) were sequentially 
added 4-methoxyiodobenzene (4.0 g, 17 mmol) in dry THF (10 ml) and (PPh3)4Pd 
(1.0 g, 0.9 mmol) in dry THF (10 ml). The mixture was stirred at room temperature
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for 1 h under Ar, then quenched with aqueous NaCl solution. Extraction (Et2 0 ), 
evaporation and chromatography (hexane / EtOAc 20:1) yielded (117) (2.0 g, 90%) 
as a colourless oil; Rf = 0.65 (hexane / EtOAc 15:1); lit.203 bp 118 (20 torr); 
IR \w (K B r) 2122 (O C ), 3303 (OCH); 'H NMR (CDC13) 8 3.00 (1 H, s, O CH ),
3.80 (3 H, s, OCH3), 6.83 (2 H, d, J  = 9.0 Hz, 3,5-H2), 7.42 (2 H, d, 9.0 Hz,




To ethynylmagnesium bromide (0.5 M in THF, 44 ml, 22 mmol) were sequentially 
added 4-methyliodobenzene (3.7 g, 17 mmol) in dry THF (10 ml) and (PPh^Pd 
(1.0 g, 0.9 mmol) in dry THF (10 ml). The mixture was stirred at room temperature 
for 1 h under Ar, then quenched with aqueous NaCl solution. Extraction (Et20 ), 
evaporation and chromatography (hexane / EtOAc 15:1) yielded (118) (1.8 g, 92%) 
as a colourless oil; Rf = 0.74 (hexane / EtOAc 15:1); lit.224 bp 54 (10 torr); 
IR Umax (KBr) 2125 (O C ), 3303 (O CH ); ‘H NMR (CDCI3) 8 2.36 (3 H, s, CH3), 
3.04 (1 H, s, O C H ), 7.13 (2 H, d, J  = 8.2 Hz, 3,5-H2), 7.40 (2 H, d, 8.2 Hz,




A solution of (116) (720 mg, 2.4 mmol) in 2-methoxyethanol (50 ml) was saturated 
with N H 3 ,  boiled under reflux for 4 h, then evaporated until 10 ml remained. The
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concentrate was stored at 4°C for 16 h and the precipitated crystals were filtered, 
washed (H20 , then EtOH) and recrystallised (MeOH) to give (119) (460 mg, 64%) as 
bright yellow crystals; Rf = 0.33 (hexane / EtOAc 1:4); mp (decomp.) 271-273°C; 
IR \ w  (KBr) 1325 & 1525 (N 02), 1625 (C=C), 1674 (C=0), 3465 (NH); 'H NMR 
((CD3)2SO) 8 7.22 (1 H, d, 7 = 0.8 Hz, 4-H), 7.59 (2 H, d, 7 = 8.6 Hz, 3',5'-H2), 
7.65 (1 H, t, 7 = 8.2 Hz, 7-H), 7.79 (2 H, d, 7 = 8.6 Hz, 2',6'-H2), 8.47 (1 H, dd, 
7 = 8.2, 1.2 Hz, 6-H), 8.58 (1 H, ddd, 7 = 8.2, 1.2, 0.8 Hz, 8-H), 12.13 (1 H, br s, 
NH); MS (FAB +ve ion) m/z303.0360 (M + H) ( '2C |5Hio37C1N20 3 
requires 303.0350), 301.0377 (M + H) (12Ci5Hio35C1N20 3 requires 301.0380); 
Anal. Calcd. for Ci5H9C1N2O3 0.25H2O: C, 59.02; H, 3.11; N, 9.18. Found: C, 58.8; 




A mixture of (119) (460 mg, 1.5 mmol) and SnCl2 (870 mg, 4.6 mmol) in EtOH 
(30 ml) was heated at 70°C for 4 h, then carefully poured into ice-H20  (200 ml). The 
resulting suspension was made alkaline with aqueous NaOH and the precipitate was 
filtered. Extraction of the filtrate (EtOAc), evaporation and recrystallisation (hexane, 
EtOAc) gave (120) (170 mg, 41%) as yellow crystals; Rf = 0.72 (hexane / EtOAc 
1:4); mp 231-232°C; IR umax (KBr) 1654 (0=0), 3236 & 3338 (NH2), 3548 (NH); 
'H NMR ((CD3)2SO) 5 5.81 (2 H, br s, NH2), 6.86 (1 H, dd, = 7.8, 1.2 Hz, 6-H), 
7.11 (1 H, s, 4-H), 7.15(1 H, t , 7= 7 .8  Hz, 7-H),7.38(1 H, dd, 7=7.8 , 1.2 Hz, 8-H), 
7.53 (2 H, d, 7 = 9.0 Hz, 3',5'-H2), 7.83 (2 H, d, 7 = 9.0 Hz, 2',6'-H2), 11.34 (1 H, br 
s, NH); MS (FAB +ve ion) m/z273.0618 (M + H) (12Ci5H1237C1N20  requires 
273.0609); 271.0629 (M + H) (12C,5Hi235C1N20  requires 271.0638).
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5-Amino-3-(4-chlorophenyl)isoquinoIin-l(2//)-one hydrochloride (121).
A mixture of (120) (170 mg, 0.6 mmol) and aqueous HC1 (2 M, 20 ml) were stirred 
at room temperature for 30 min. Evaporation and recrystallisation (MeOH) yielded 
(121) (180 mg, 95%) as a brown solid; Rf = 0.74 (MeOH); mp >350°C; 'H NMR 
((CD3)2SO) 5 7.08 (1 H, s, 4-H), 7.14 (1 H, dd, 7 = 7.8, 1.2 Hz, 6-H), 7.28 (1 H, t, 
7 = 7.8 Hz, 7-H), 7.56 (2 H, d, 7 = 9.0 Hz, 3',5'-H2), 7.64 (1 H, dd, 7 = 7.8, 1.2 Hz,






A solution of 2-acetylthiophene (13.2 g, 105 mmol) in AC2O (42.8 g, 420 mmol) was 
added to BF3(AcOH)2 (59.5 g, 316 mmol) at 0°C. The mixture was stirred for 30 min 
and allowed to stand at room temperature for 24 h. The mixture was then poured into 
an aqueous solution of NaOAc (13%, 100 ml) and boiled under reflux for 1 h. 
Extraction (Et20), evaporation and chromatography (hexane / EtOAc 9:1) afforded 
(122a,b) (5:1) (1.2 g, 7%) as reddish-brown solid; Rf = 0.40 (hexane / EtOAc 9:1); 
mp 30-31°C; (122a): *H NMR (CDC13) 5 2.12 (3 H, s, CH3), 6.01 (1 H, s, CH), 
7.10 (1 H, dd, J = 4.9, 3.6 Hz, 4'-H), 7.57 (1 H, dd, J  = 4.9, 1.1 Hz, 5'-H), 7.66 (1 H, 
dd, J  = 3.6, 1.1 Hz, 3'-H), 15.64 (1 H, br s, OH); (122b): ‘H NMR (CDC13)
(122b)
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8 2.30 (3 H, s, CHj), 4.01 (2 H, s, CH2), 7.12 (1 H, dd, = 4.9, 3.6 Hz, 4'-H),
7.68 (1H, dd, J  = 4.9, 1.1 Hz, 5'-H), 7.70 (1 H, dd, = 3.6, 1.1 Hz, 3'-H);
MS (El +) m/z168.0241 (M) (12C8H80 2S requires 168.0245), 111 (M -  CH2COMe).
Method B:
To a solution of NaNH2 (50% in toluene, 31.2 ml, 0.4 mol) in dry Et20 (100 ml) was 
added, during 10 min, a solution of 2-acetylthiophene (25.2 g, 0.2 mol) in dry Et20 
(50 ml). After stirring for 30 min, dry EtOAc (35.2 g, 0.4 mol) in dry Et20 (50 ml) 
was slowly added. The mixture was boiled under reflux for 2 h, poured into FEO 
(300 ml), then neutralised with aqueous HC1 (2 M). Extraction (Et20) and 
evaporation (Et20 ) yielded a residue which was dissolved in an equal volume of 
MeOH. To this methanolic solution was added a hot, filtered solution of Cu(OAc)2 
(40.0 g) in H2O (350 ml) and the mixture was allowed to stand until it cooled to 
room temperature. The precipitated copper salt was filtered, washed with cold 
petroleum ether and shaken with a mixture of H2SO4 (10%, 300 ml) and Et20 (100 
ml) until the Et20 layer was colourless. Evaporation of the organic layer yielded 
(122a,b) (18.6 g, 55%) as reddish-brown crystals. Data identical to above.
5-Nitro-3-(2-thienyl)isocoumarin (123).
To a stirred solution of (122a) and (122b) (18.6 g, 111 mmol) and potassium 
Ebutoxide (5.1 g, 45 mmol) in 2-methyl-2-propanol (100 ml) was added (85) (5.5 g, 
22 mmol) and Cu powder (145 mg, 2.3 mmol). The mixture was boiled under reflux 
for 16 h, then poured into H2O (350 ml) and acidified with aqueous HC1 (2 M). 
Extraction (Et20), evaporation and chromatography (hexane / EtOAc 10:1) gave 
(123) (1.3 g, 21%) as yellow crystals; Rf = 0.68 (hexane / EtOAc 10:1);
mp 189-190°C; IR t)max (KBr) 1338 & 1530 (N02), 1619 (C=C), 1744 (C=0);
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'H N M R  (CDCI3 ) 5 7.15 (1 H, dd, 7 =  5.1, 3.9 Hz, 4 '-H ), 7.50 (1 H, dd, 
7 = 5.1, 1.2 Hz, 5'-H), 7.55 (1 H, t, 7 = 8.2 Hz, 7-H), 7.71 (1 H, dd, 7  = 3.9, 1.2 Hz, 
3 '-H ), 7.71 (1 H, d, 7 =  0.8 H z, 4-H ), 8 .47 (1  H, dd, 7 = 8 .2 ,  1.2 Hz, 6 -H), 8 .59 (1  H, 





A solution of (123) (810 mg, 3.0 mmol) in 2-methoxyethanol (50 ml) was saturated 
with N H 3 ,  boiled under reflux for 4 h, then evaporated until 10 ml remained. The 
concentrate was stored at 4°C for 16 h and the precipitated crystals were filtered, 
washed (H20 , then EtOH) and recrystallised (MeOH) to give (124) (510 mg, 63%) as 
orange crystals; Rf = 0.44 (hexane / EtOAc 1:4); mp (decomp.) 225°C; IR a w  (KBr) 
1319 & 1514 (N02), 1616 (C=C), 1670 (C=0), 3458 (NH); *H NMR ((CD3)2SO) 
5 7.21 (1 H, dd, J  = 5.1, 3.9 Hz, 4'-H), 7.33 (1 H, d, J = 0.8 Hz, 4-H), 7.60 (1 H, t, 
J = 8.2 Hz, 7-H), 7.77 (1 H, dd, J = 5.1, 1.2 Hz, 5'-H), 7.93 (1 H, dd, J  = 3.9, 1.2 Hz, 
3'-H), 8.47 (1 H, dd, J  = 8.2, 1.2 Hz, 6-H), 8.54 (1 H, ddd, J=  8.2, 1.2, 0.8 Hz, 8-H), 
12.13 (1 H, br s, N H ) ;  MS (El +) m/z 272.0257 (M) (12C13H8N20 3S 
requires 272.0256), 226 (M -  N 02); Anal. Calcd. for C13H8N2O3S0.25H2O: 





A mixture of (124) (510 mg, 1.9 mmol) and SnCl2 (1.1 g, 5.8 mmol) in EtOH (30 ml) 
was heated at 70°C for 4 h, then carefully poured into ice-H20  (200 ml). The 
resulting suspension was made alkaline with aqueous NaOH and the precipitate was 
filtered. Extraction of the filtrate (EtOAc), evaporation and recrystallisation (hexane, 
EtOAc) gave (125) (300 mg, 66%) as yellow crystals; Rf = 0.74 (hexane / EtOAc 
3:7); mp 229-230°C; IR i w  (KBr) 1659 (C=0), 3365 (NH2), 3470 (NH); 
'HNMR(CDC13) 6 4.03 (2 H, br s, NH2), 6.70 (1 H, s, 4-H), 6.99 (1 H, dd, 
J  = 7.8, 1.1 Hz, 6 H), 7.14 (1 H, dd, J  = 4.9, 3.8 Hz, 4'-H), 7.28 (1 H, t, J  = 7.8 Hz,
7-H), 7.37 (1 H, dd, J  = 4.9, 1.1 Hz, 5'-H), 7.49 (1 H, dd, J  = 3.8, 1.1 Hz, 3'-H), 
7.86(1 H, dd, J  = 7.8, 1.1 Hz, 8-H), 9.50 (1 H, br s, NH); MS (El +) m/z 




A mixture of (120) (24 mg, 0.1 mmol) and aqueous HC1 (2 M, 20 ml) were stirred at 
room temperature for 30 min. Evaporation and recrystallisation (MeOH) yielded 
(121) (26 mg, 94%) as a dark brown solid; Rf = 0.64 (MeOH); mp >350°C; 
'H NMR (D20) 8 6.87 ( lH ,s ,  4-H), 7.07 (1 H, dd, = 4.9, 3.8 Hz, 4'-H), 7.26 (1 H,
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d, J  = 4.9 Hz, 5'-H), 7.53 (1 H, d, J  = 3.8 Hz, 3'-H), 7.58 (1 H, t, J  = 7.8 Hz, 7-H), 




A solution of 4-nitroacetophenone (5.0 g, 30 mmol) in AC2O (12.3 g, 121 mmol) was 
added to BF3(AcOH)2 (17.1 g, 91.0 mmol) at 0°C. The mixture was stirred for 30 
min and allowed to stand at room temperature for 24 h. The mixture was then poured 
into an aqueous solution of NaOAc (13%, 100 ml) and boiled under reflux for 1 h. 
Extraction (Et2 0 ), evaporation and chromatography (hexane / EtOAc 4:1) afforded 
(127a,b) (66:1) (3.2 g, 51%) as yellow crystals; Rf = 0.63 (hexane / EtOAc 7:3); 
mp 115-116°C (lit.208 mp 112-113°C (EtOH)); (127a): *H NMR (CDC13) 5 2.26 (3 
H, s, CH3), 6.22 (1 H, s, CH), 8.00 (2 H, d, J  = 9.0 Hz, 2',6'-H2), 8.27 (2 H, d, 
J  = 9.0 Hz, 3',5'-H2), 15.89 (1 H, br s, OH); (127b): !H NMR (CDC13) 8 2.35 (3 H, s, 
CH3), 4.16 (2 H, s, CH2), 8.10 (2 H, d, J  = 9.0 Hz, 2',6'-H2), 8.31 (2 H, d, J  = 9.0 Hz, 
3',5'-H2); MS (El +) mJz 207.0536 (M) (12C,0H9NO4 requires 207.0532), 





To a solution of NaNH2 (50% in toluene, 31.2 ml, 0.4 mol) in dry Et20  (100 ml) was 
added, during 10 min, a solution of 2-acetylpyridine (24.2 g, 0.2 mol) in dry Et20  (50 
ml). After stirring for 30 min, dry EtOAc (35.2 g, 0.4 mol) in dry Et20  (50 ml) was 
slowly added. The mixture was boiled under reflux for 2 h, poured into H20  (300 
ml), then neutralised with aqueous HC1 (2 M). Extraction (Et20) and evaporation 
(Et20) yielded a residue which was dissolved in an equal volume of MeOH. To this 
methanolic solution was added a hot, filtered solution of Cu(OAc)2 (40 g) in H20  
(350 ml) and the mixture was allowed to stand until it cooled to room temperature. 
The precipitated copper salt was filtered, washed with cold petroleum ether and 
shaken with a mixture of H2S04  (10%, 300 ml) and Et20  (100 ml) until the Et20  
layer was colourless. Evaporation of the organic layer yielded (128a,b) (11:1) 
(11.9 g, 37%) as a yellow oil; Rf = 0.60 (hexane / EtOAc 9:1); lit.211 bp 118-120 
(5 torr); (128a): 'H NMR (CDCI3) 6 2.24 (3 H, s, CH3), 6.20 (1 H, s, CH), 7.68 (2 H, 
d, 7 = 5.2 Hz, 3',5'-H2), 8.73 (2 H, d, 7 = 5.2 Hz, 2',6'-H2), 15.73 (1 H, br s, OH); 
(128b): ‘H NMR (CDC13) 8 2.39 (3 H, s, CH3), 3.97 (2 H, s, CH2), 7.62 (2 H, d, 
7 = 5.2 Hz, 3\5'-H2), 8.69 (2 H, d, 7 = 5.2 Hz, 2',6'-H2); MS (El +) 












A solution of 4-hydroxyacetophenone (12.2 g, 90 mmol) in Ac20  (37.3 g, 366 mmol) 
was added to BF3(AcOH)2 (51.4 g, 273 mmol) at 0°C. The mixture was stirred for 30 
min and allowed to stand at room temperature for 24 h. The mixture was then poured 
into an aqueous solution of NaOAc (13%, 100 ml) and boiled under reflux for 1 h. 
Extraction (Et20), evaporation and chromatography (hexane / EtOAc 4:1) afforded 
(129a,b) (3:1) (1.0 g, 6%) as a cream solid; Rf = 0.20 (hexane / EtOAc 4:1); mp 
112-113°C; (129a): 'H NMR (CDCI3) 8  2.13 (3 H, s, CH3), 6.40 (1 H, s, CH), 6.85 
(2 H, d, 7 = 9.0 Hz, 3',5'-H2), 7.83 (2 H, d, 9 .0 Hz, 2',6'-H2), 10.37 (1 H. br s, 
phenolic OH), 16.05 (1 H, br s, enolic OH); (129b): 'H NMR (CDCI3) 8  2.20 (3 H, s, 
CH3), 4.14 (1 H, s, CH2), 6.84 (2 H, d, J  = 9.0 Hz, 3',5'-H2), 7.79 (2 H, d, = 9.0 Hz, 
2',6'-H2), 10.37 (1 H, br s, phenolic OH); MS (El +) 178.0625 (M) (l2Ci0H10O3
requires 178.0630), 121 (M -C H 2COMe).
Also isolated from the column was (130a,b) (10:1) (8.9 g, 45%) as a white solid; 
Rf= 0.33 (hexane / EtOAc 4:1); mp 65-66°C; (130a): *H NMR (CDC13) 6 2.19 (3 H, 
s, COCH3), 2.32 (3 H, s, OCOCH3), 6.13 (1 H, s, CH), 7.16 (2 H, d, J  = 8.8 Hz, 
2',6'-H2), 7.88 (2 H, d, /  = 8.8 Hz, 3',5'-H2), 16.10 (1 H, br s, OH);
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(130b): ‘H NMR (CDC13) 8 2.29 (3 H, s, COCHj), 2.32 (3 H, s, OCOCHj),
4.07 (2 H, s, CH2), 7.20 (2 H, d, J  = 8.8 Hz, 2',6/-H2), 7.96 (2 H, d, = 8.8 Hz,
3',5'-H2); MS (El +) m/z2 0.0736 (M) (12Ci2H120 4 requires 220.0736), 
163 (M -  CH2COMe).
3-Ethyl-5-nitroisocoumarin (131).
o
To a stirred solution of heptane-3,5-dione (6.4 g, 50 mmol) and potassium f-butoxide 
(2.3 g, 20 mmol) in 2-methyl-2-propanol (50 ml) was added (85) (2.5 g, 10.2 mmol) 
and Cu powder (65 mg, 1.0 mmol). The mixture was boiled under reflux for 16 h, 
then poured into H20  (350 ml) and acidified with aqueous HC1 (2 M). Extraction 
(Et20), evaporation and chromatography (hexane / EtOAc 9:1) gave 
(131) (520 mg, 24%) as yellow crystals; Rf = 0.52 (hexane / EtOAc 4:1); 
mp 77-78°C; IR umax (KBr) 1347 & 1524 (N02), 1645 (C=C), 1747 (C=0); 
'H NMR (CDCI3) 8 1.17 (3 H, t, J=  7.6 Hz, CH3), 2.55 (2 H, q, = 7.6 Hz, CH2),
7.01 (1 H, d, J  = 0.9 Hz, 4-H), 7.48 (1 H, t, = 8.1 Hz, 7-H), 8.32 (1 H, dd, = 8.1, 
2.6 Hz, 6-H), 8.44 (1 H. ddd, J  = 8.1, 2.6, 0.9 Hz, 8-H); 13C NMR (CDCI3) 
8 11.73 (CH3), 27.99 (CH2), 97.41 (C-4), 122.65 (C-3), 127.41 (C-7), 131.84 (C-6), 
132.38 (C-10), 136.22 (C-8), 144.43 (C-9), 161.43 (C-5), 163.92 (C=0); 





A solution of (131) (520 mg, 2.4 mmol) in 2-methoxyethanol (50 ml) was saturated 
with NH3, boiled under reflux for 4 h, then evaporated until 10 ml remained. The 
concentrate was stored at 4°C for 16 h and the precipitated crystals were filtered, 
washed (H2O, then EtOH) and recrystallised (MeOH) to give (132) (200 mg, 38%) as 
bright yellow crystals; Rf = 0.13 (hexane / EtOAc 4:1); mp (decomp.) 196-197°C; 
IR \ w  (KBr) 1372 & 1524 (N02), 1666 (C=0), 3432 (NH); ‘H NMR ((CD3)2SO) 
61.22 (3 H, t, 7 = 7.5 Hz, CH3), 2.59 (2 H, q, 7 = 7.5 Hz, CH2), 6.80 (1 H, s, 4-H), 
7.56 (1 H, t, 7 = 8.1 Hz, 7-H), 8.40 (1 H, dd, 7 = 8 .1, 1.5 Hz, 6-H), 8.51 (1 H, dd. 
7 = 8.1, 1.5 Hz, 8-H), 11.79 (1 H, br s, NH); MS (FAB +ve ion) 
219.0779 (M + H) ( l2C, iHnN20 3 requires 219.0770), 173 (M -  N 02).
5-Amino-3-ethyIisoquinolin-1 (2Z7)-one (133).
NH
A mixture of (132) (200 mg, 0.9 mmol) and SnC^ (520 mg, 2.7 mmol) in EtOH 
(20 ml) was heated at 70°C for 4 h, then carefully poured into ice-H20  (200 ml). The 
resulting suspension was made alkaline with aqueous NaOH and the precipitate was 
filtered. Extraction of the filtrate (EtOAc), evaporation and recrystallisation (hexane, 
EtOAc) gave (133) (40 mg, 24%) as yellow crystals; Rf = 0.50 (hexane / EtOAc 1:9); 
mp 162-163°C; IR a w  (KBr) 1646 (C=0), 3164 & 3395 (NH2), 3447 (NH); 
'H NM R ((CD3)2SO) 8 1.21 (3 H, t, 7 = 7.5 Hz, CH3), 2.47 (2 H, q, 7 = 7.4 Hz, CH2),
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5.51 (2 H, br s, NH2), 6.44 (1 H, d, J  = 0.8 Hz, 4-H), 6.80 (1 H, dd, J  = 7.8, 1.2 Hz,
6-H), 7.05 (1 H, t, J  = 7.8 Hz, 7-H), 7.33 (1 H, ddd, J  = 7.8, 1.2, 0.8 Hz, 8-H), 





A mixture of (133) (40 mg, 0.2 mmol) and aqueous HC1 (2 M, 20 ml) were stirred at 
room temperature for 30 min. Evaporation and recrystallisation (MeOH) yielded 
(134) (45 mg, 94%) as a brown solid; Rf = 0.74 (MeOH); mp 133-134°C; 'H NMR 
((CD3)2SO) 5 1.22 (3 H, t, 7 = 7.4 Hz, CH3), 2.53 (2 H, q, 7 = 7.4 Hz, CH2), 
6.44(1 H, s, 4-H),7.34(1 H, t ,7= 7 .8  Hz, 7-H),7.47(1 H, dd, 7 = 7.8, 1.2 Hz, 6-H), 




To a solution of NaNH2 (50% in toluene, 46.8 ml, 0.6 mol) in dry Et20  (100 ml) was 
added, during 10 min, a solution of 2-heptanone (34.2 g, 0.3 mol) in dry Et20  (50 
ml). After stirring for 30 min, ethyl hexanoate (86.4 g, 0.6 mol) in dry Et20  (50 ml) 
was slowly added. The mixture was boiled under reflux for 2 h, poured into H20
188
(300 ml), then neutralised with aqueous HC1 (2 M). Extraction (Et2 0 ) and
evaporation (Et2 0 ) yielded a residue which was dissolved in an equal volume of
MeOH. To this methanolic solution was added a hot, filtered solution of Cu(OAc)2
(40.0 g) in H2O (350 ml) and the mixture was allowed to stand until it cooled to
room temperature. The precipitated copper salt was filtered, washed with cold
©
petroleum ether and shaken with a mixture of H2SO4 (10%, 300 ml) and Et20  (100 
ml) until the Et20  layer was colourless. Evaporation of the organic layer yielded 
(135a,b) (4:1) (32.0 g, 50%) as a colourless oil; Rf = 0.44 (hexane / EtOAc 20:1); 
(135a): ‘H NMR (CDCI3) 8 0.82-0.87 (6 H, m, 1,13-H6), 1.19-1.33 (8 H, m, 
2,3,11,12-Hs), 1.49-1.60 (4 H, m, 4,10-ft,), 2.22 (4 H, t, = 7.6 Hz, 5,9-R,), 
5.43 (1H, s, 7-H), 15.49 (1 H, br s, OH); (135b): 'H NMR (CDCI3)
80.82-0.87 (6 H, m, 1,13-H6), 1.19-1.33 (8 H, m, 2,3,11,12-Hs), 1.49-1.60 (4 H, m, 
4, IO-H4), 2.45 (4 H, t, J  = 7.6 Hz, 5,9-H4), 3.50 (2 H, s, 7-H); MS (El +) 
212.1775 (M) (l2Ci3H2402 requires 212.1776), 141 (M -  (CH2)4CH3),




To a stirred solution of nonane-2,4-dione (5.0 g, 32 mmol) and potassium r-butoxide 
(1.5 g, 13 mmol) in 2-methyl-2-propanol (50 ml) was added (85) (1.6 g, 6.5 mmol) 
and Cu powder (42 mg, 0.7 mmol). The mixture was boiled under reflux for 16 h, 
then poured into H2O (350 ml) and acidified with aqueous HC1 (2 M). Extraction 
(Et2 0 ), evaporation and chromatography (hexane / EtOAc 10:1) gave 
(136) (70 mg, 4%) as a yellow oil; Rf = 0.65 (hexane / EtOAc 15:1); IR Dmax (film) 
1344 & 1530 (N02), 1646 (C=C), 1736 (C=0); *H NMR (CDC13) 8 0.90-0.94 (3 H, 
m, 5'-H3), 1.35-1.40 (4 H, m, 3 ',4 '-^ ), 1.70-1.78 (2 H, m, 2'-H2), 2.59 (2 H, t,
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J  = 7.8 Hz, l'-H2), 7.12 (1 H, d, J  = 0.8 Hz, 4-H), 7.55 (1 H, t, J  = 7.8 Hz, 7-H), 
8.41 (1 H, dd, J  = 7.8, 1.6 Hz, 6-H), 8.56 (1 H, ddd, J  = 7.8, 1.6, 0.8 Hz, 8-H); 
13CNMR (CDC13) 613.96 (C-5'), 22.37 (C-4'), 26.61 (C-3'), 31.18 (C-2'), 
34.20 (C-l'), 97.69 (C-4), 122.08 (C-3), 126.83 (C-7), 131.34 (C-6 ), 131.85 (C-10), 
135.71 (C-8), 143.82 (C-9), 160.99 (C-5), 162.36 (C=0); MS (El +) m/z
261.1002 (M) (12C,4H15N04  requires 261.1001).
Further elution yielded (88) (120 mg, 9%) as yellow crystals; data as above.
Method B:
To a stirred solution of (135a) and (135b) (31.8 g, 150 mmol) and potassium 
r-butoxide (6.8 g, 61 mmol) in 2 -methyl-2-propanol (100 ml) was added 
(85) (7.4 g, 30 mmol) and Cu powder (190 mg, 3.0 mmol). The mixture was boiled 
under reflux for 16 h, then poured into H20  (350 ml) and acidified with aqueous HC1 
(2 M). Extraction (Et20), evaporation and chromatography (hexane / EtOAc 4:1) 




A solution of (136) (70 mg, 0.3 mmol) in 2-methoxyethanol (50 ml) was saturated 
with NH3, boiled under reflux for 4 h, then evaporated until 10 ml remained. The 
concentrate was stored at 4°C for 16 h and the precipitated crystals were filtered, 
washed (H20 , then EtOH) and recrystallised (MeOH) to give (137) (20 mg, 29%) as 
bright yellow crystals; Rf = 0.13 (hexane / EtOAc 4:1); mp (decomp.) 158-159°C; 
IR \)„,ax (KBr) 1375 & 1524 (N02), 1666 (C=0), 3467 (NH); 'H NMR ((CD3)2SO) 
60.86-0.89 (3 H, m, 5'-H3), 1.28-1.34 (4 H, m, 3',4'-H4), 1.60-1.67 (2 H, m, 2'-H2), 
2.55 (2 H, t, J  = 7.6 Hz, l'-H2), 6.79 (1 H, s, 4-H), 7.56 (1 H, t, = 7.8 Hz, 7-H),
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8.39 (1 H, dd, J  = 7.8, 1.2 Hz, 6-H), 8.50 (1 H, dd, = 7.8, 1.2 Hz, 8-H), 11.77 (1 H, 
br s, NH); MS (El +) m/z 260.1162 (M) (12C l4Hi6N20 3 requires 260.1161).
5-Amino-3-pentylisoquinolin-l(2/T)-one (138).
o
A mixture of (137) (240 mg, 0.9 mmol) and SnCl2 (550 mg, 2.9 mmol) in EtOH 
(20 ml) was heated at 70°C for 4 h, then carefully poured into ice-H20  (200 ml). The 
resulting suspension was made alkaline with aqueous NaOH and the precipitate was 
filtered. Extraction of the filtrate (EtOAc), evaporation and recrystallisation (hexane, 
EtOAc) gave (138) (140 mg, 67%) as yellow crystals; R f = 0.30 (hexane / EtOAc 
1:4); mp 75-76°C; IR \)max (KBr) 1651 (C=0), 3166 & 3395 (NH2), 3448 (NH); 
‘HNMR (CDC13) 5 0.76-0.88 (3 H, m, 5'-H3), 1.21-1.34 (4 H, m, 3',4'-H4), 
1.66-1.78 (2 H, m, 2'-H2), 2.57 (2 H, t, J  = 7.6 Hz, l'-H2), 3.94 (2 H, br s, NH2), 
6.21 (1 H, s, 4-H), 6.92(1 H, dd, 7=7.7, 1.2 Hz, 6-H), 7.20(1 H, t,7 = 7 .7  Hz, 7-H),
7.84 (1 H, dd, J  = 7.7, 1.2 Hz, 8-H), 11.75 (1 H, br s, NH); MS (El +) mJz 
230.1418 (M) (12Ci4H18N20  requires 230.1419).
5-Amino-3-pentylisoquinolin-l(2Z7)-one hydrochloride (139).
A mixture of (138) (130 mg, 0.6 mmol) and aqueous HC1 (2 M, 20 ml) were stirred 
at room temperature for 30 min. Evaporation and recrystallisation (MeOH) yielded 




1HNM R(D 20) 5 0.74-0.82 (3 H, m, 5'-H3), 1.19-1.29 (4 H, m, 3',4'-H4),
1.55-1.66(2 H, m, 2'-H2), 2.55 (2 H, t, J  = 7.6 Hz, l'-H2), 6.53 (1 H, s, 4-H),






To a solution of NaNH2 (50% in toluene, 31.2 ml, 0.4 mol) in dry Et20  (100 ml) was 
added, during 10 min, a solution of 4-methyl-2-pentanone (20.0 g, 0.2 mol) in dry 
Et20  (50 ml). After stirring for 30 min, ethyl 2-methylbutanoate (52.0 g, 0.4 mol) in 
dry Et20  (50 ml) was slowly added. The mixture was boiled under reflux for 2 h, 
poured into H20  (300 ml), then neutralised with aqueous HC1 (2 M). Extraction 
(Et20) and evaporation (Et20) yielded a residue which was dissolved in an equal 
volume of MeOH. To this methanolic solution was added a hot, filtered solution of 
C u ( O A c ) 2 (40.0 g) in H20  (350 ml) and the mixture was allowed to stand until it 
cooled to room temperature. The precipitated copper salt was filtered, washed with 
cold petroleum ether and shaken with a mixture of H2S04 (10%, 300 ml) and Et20  
(100 ml) until the Et20  layer was colourless. Evaporation of the organic layer yielded 
(140a,b) (10:1) (27.5 g, 75%) as a colourless oil; Rf = 0.53 (hexane / EtOAc 25:1); 
(140a): *H NMR (CDC13) 8 0.92 (12 H, d, J  = 6.6 Hz, 1,9-H6, 2 x CH3), 
2.01-2.08 (2 H, m, 2,8-H2), 2.12 (4 H, d, J  = 6.6 Hz, 3,7-Rf), 5.41 (1 H, s, 5-H), 
15.58 (1 H, br s, OH); (140b): !H NMR (CDC13) 5 0.90 (12 H, d, J  = 6.6 Hz, 1,9-H6, 
2 x CH3), 2.01-2.08 (2 H, m, 2,8-H2), 2.36 (4 H, d, J  = 6.6 Hz, 3 ,7 -^), 3.49 (2 H, s,
5-H); MS (El +) m/z 184.1459 (M) (12Ci,H20O2 requires 184.1463), 




To a stirred solution of (140a) and (140b) (17.4 g, 94.6 mmol) and potassium 
r-butoxide (4.4 g, 39 mmol) in 2-methyl-2-propanol (100 ml) was added 
(85) (4.7 g, 19 mmol) and Cu powder (123 mg, 1.9 mmol). The mixture was boiled 
under reflux for 16 h, then poured into H2O (350 ml) and acidified with aqueous HC1 
(2 M). Extraction (Et20 ), evaporation and chromatography (hexane / EtOAc 4:1) 
gave (141) (1.2 g, 26%) as yellow crystals; Rf = 0.61 (hexane / EtOAc 1:4);
mp 71-72°C; IR \)max (KBr) 1346 & 1531 (N02), 1645 (C=C), 1737 (C=0); 
‘H NMR (CDCI3 ) 6 0.99 (6 H, d, J  = 6.6 Hz, 2 x CH3), 2.12-2.19 (1 H, m, CH2Ctf), 
2.45 (2 H, d, J  = 7.4 Hz, CH2CH), 7.09 (1 H, s, 4-H), 7.55 (1 H, t, J  = 8.2 Hz, 7-H). 
8.40 (1 H, dd, J  = 8.2, 1.2 Hz, 6-H), 8.54 (1 H, dd, J  = 8.2, 1.2 Hz, 8-H); 
MS (El +) m/z 247.0848 (M) (12C13H13N 04 requires 247.0845).
5-Nitro-3-(2-methyIpropyI)isoquinolin-l(2//)-one (142).
NH
A solution of (141) (620 mg, 2.5 mmol) in 2-methoxyethanol (50 ml) was saturated 
with NH3, boiled under reflux for 4 h, then evaporated until 10 ml remained. The 
concentrate was stored at 4°C for 16 h and the precipitated crystals were filtered, 
washed (H20 , then EtOH) and recrystallised (MeOH) to give (142) (550 mg, 89%) as 
bright yellow crystals; Rf = 0.74 (hexane / EtOAc 1:4); mp 184-185°C; IR \)max (KBr) 
1376 & 1523 (N02), 1655 (C=0), 3436 (NH); 'H NMR ((CD3)2SO) 6 0.91 (6 H, d,
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7 = 6.6 Hz, 2 x CH3), 1.97-2.04 (1 H, m, CH2CH), 2.43 (2 H, d, 7 = 7.0 Hz, CH2CH), 
6.77(1 H, s, 4-H), 7.56(1 H, t, 7 = 7.8 Hz, 7-H), 8.40(1 H, dd,7=7.8, 1.2 Hz, 6-H), 
8.50 (1 H, dd, 7 = 7.8, 1.2 Hz, 8-H), 11.76 (1 H, br s, NH); MS (El +) m/z




A mixture of (142) (370 mg, 1.5 mmol) and SnCl2 (900 mg, 4.7 mmol) in EtOH 
(20 ml) was heated at 70°C for 4 h, then carefully poured into ice-H20  (200 ml). The 
resulting suspension was made alkaline with aqueous NaOH and the precipitate was 
filtered. Extraction of the filtrate (EtOAc), evaporation and recrystallisation (hexane, 
EtOAc) gave (143) (270 mg, 83%) as yellow crystals; Rf = 0.58 (hexane / EtOAc 
1:4); mp 113-114°C; IR umax (KBr) 1645 (C=0), 3165 & 3396 (NH2), 3468 (NH); 
‘H NMR (CDC13) 6 0.82 (6 H, d, 7 = 6.4 Hz, 2 x CH3), 1.90-2.02 (1 H, m, CH2CT/), 
2.32 (2 H, d, 7 = 7.4 Hz, CH2CH), 3.99 (2 H, br s, NH2), 6.14 (1 H, s, 4-H),
6.84 (1 H, dd, 7 = 7.9, 1.2 Hz, 6-H), 7.10 (1 H, t, 7 = 7.9 Hz, 7-H), 7.71 (1 H, dd, 
7 = 7.9, 1.2 Hz, 8-H), 11.52 (1 H, br s, NH); MS (El +) m/z 216.1263 (M) 




A mixture of (143) (220 mg, 1.0 mmol) and aqueous HC1 (2 M, 20 ml) were stirred 
at room temperature for 30 min. Evaporation and recrystallisation (MeOH) yielded 
(144) (250 mg, 97%) as a brown solid; Rf = 0.76 (MeOH); mp 151-152°C; 
*H NMR (D20) 5 0.88 (6 H, d, J  = 6.6 Hz, 2 x CH3), 1.89-1.93 (1 H, m, CH2C//), 
2.47 (2 H, d, J  = 1A  Hz, CH2CH), 6.52 (1 H, s, 4-H), 7.50 (1 H, t, J  = 7.9 Hz, 7-H), 








To a solution of NaNH2 (50% in toluene, 31.2 ml, 0.4 mol) in dry Et20  (100 ml) was 
added, during 10 min, a solution of 3-phenyl-2-propanone (26.8 g, 0.2 mol) in dry 
Et20  (50 ml). After stirring for 30 min, ethyl phenylacetate (65.6 g, 0.4 mol) in dry 
Et20  (50 ml) was slowly added. The mixture was boiled under reflux for 2 h, poured 
into H20  (300 ml), then neutralised with aqueous HC1 (2 M). Extraction (Et20) and
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evaporation (Et2 0 ) yielded a residue which was dissolved in an equal volume of 
MeOH. To this methanolic solution was added a hot, filtered solution of Cu(OAc)2 
(40.0 g) in H2O (350 ml) and the mixture was allowed to stand until it cooled to 
room temperature. The precipitated copper salt was filtered, washed with cold 
petroleum ether and shaken with a mixture of H2SO4 (10%, 300 ml) and Et20  (100 
ml) until the Et20  layer was colourless. Evaporation and recrystallisation (hexane, 
EtOAc) yielded (145a,b) (50:1) (12.9 g, 26%) as orange crystals; Rf = 0.50 
(hexane/CH2CI2 1:1); mp 68-69°C (lit.212 mp 65.2-66.5°C); (145a): ‘H NMR 
(CDCI3) § 3.56 (4 H, s, 1,5-Ht), 5.43 (1 H, s, 3-H), 7.18-7.32 (10 H, m, 2 x Ph-H5), 
15.27 (1 H, br s, OH); (145b): 'H NMR (CDCI3) 8 3.55 (2 H, s, 3-H2), 3.68 (4 H, s,
1,5-tt,), 7.11-7.27 (10 H, m, 2 x Ph-H5); MS (El +) 252.1144 (M) (i2Ci7H1602
requires 252.1150), 161 (M -  CH2Ph), 133 (M -  COCH2Ph).
Also isolated was the Claisen condensation product (146) (23.4 g, 41%) as colourless 
crystals; Rf = 0.43 (hexane / CH2C12 1:1); mp 76-78°C (lit.213 mp 75°C); 
IR \)max(KBr) 1715 (ketone C=0), 1734 (ester C=0); *H NMR (CDCI3 ) 6 1.22 (3 H, 
t, J  = 7.1 Hz, CH2CH3), 3.74 (2 H, s, 4-H2), 4.17 (2 H, q, J = 7.1 Hz, CH2CH3), 
4.81 (1 H, s, 2-H), 7.05-7.39 (10 H, m, 2 x Ph-H5); MS (El +) m/z 282.1255 (M) 
(,2Ci8H1803  requires 282.1256).
3-Benzyl-5-nitroisocoumarin (147).
To a stirred solution of (145a) and (145b) (7.5 g, 33 mmol) and potassium f-butoxide 
(1.3 g, 12 mmol) in 2-methyl-2-propanol (100 ml) was added (85) (1.5 g, 6.1 mmol) 
and Cu powder (40 mg, 0.6 mmol). The mixture was boiled under reflux for 16 h, 
then poured into H20  (350 ml) and acidified with aqueous HC1 (2 M). Extraction 
(Et2Q), evaporation and chromatography (hexane / EtOAc 9:1) gave
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(147) (540 mg, 32%) as yellow crystals; Rt = 0.44 (hexane / EtOAc 4:1); 
mp 137-138°C; IR t w  (KBr) 1346 & 1564 (N02), 1647 (C=C), 1740 (C=0); 
'H NMR (CDCI3) 8 3.88 (2 H, s CH2), 7.13 (1 H, d, = 0.5 Hz, 4-H), 7.24-7.36 (5 H, 
m, 2',3',4',5',6'-H5), 7.54 (1 H, t, J  = 8.0 Hz, 7-H), 8.39 (1 H, dd, = 8.0, 1.4 Hz,
6-H), 8.53 (1 H, ddd, J  = 8.0, 1.4, 0.5 Hz, 8-H); MS (El +) 281.0690 (M)_




A solution of (147) (340 mg, 1.2 mmol) in 2-methoxyethanol (50 ml) was saturated 
with N H 3 , boiled under reflux for 4 h, then evaporated until 10 ml remained. The 
concentrate was stored at 4°C for 16 h and the precipitated crystals were filtered, 
washed (H20 , then EtOH) and recrystallised (MeOH) to give (148) (280 mg, 83%) as 
bright yellow crystals; Rf = 0.73 (hexane / EtOAc 1:4); mp (decomp.) 203-204°C; 
IR r w  (KBr) 1323 & 1524 (N 02), 1645 (C=C), 1688 (C=0), 3186 (NH ); 'H NMR 
((CD3)2SO) 8 3.92 (2 H, s CH2), 6.80 (1 H, s, 4-H), 7.24-7.34 (5 H, m, 
2',3,,4',5',6,-H5), 7.57 (1 H, t, J  = 7.8 Hz, 7-H), 8.39 (1 H, d, 7.8 Hz, 6-H),
8.49 (1 H, d, J  = 7.8 Hz, 8-H), 11.93 (1 H, br s, NH); MS (El +) 280.0848 (M)





A mixture of (148) (280 mg, 1.0 mmol) and SnCl2 (530 mg, 2.8 mmol) in EtOH 
(20 ml) was heated at 70°C for 4 h, then carefully poured into ice-H20  (200 ml). The 
resulting suspension was made alkaline with aqueous NaOH and the precipitate was 
filtered. Extraction of the filtrate (EtOAc), evaporation and recrystallisation (hexane, 
EtOAc) gave (149) (160 mg, 64%) as yellow crystals; Rf = 0.53 (hexane / EtOAc 
1:4); mp 85-86°C; IR umax (KBr) 1661 (C=0), 3162 & 3394 (NH2), 3469 (NH); 
'HNMR (CDC13) 8 3.91 (2 H, s CH2), 4.00 (2 H, br s, NH2), 6.72 (1 H, d, 
7=  8.1 Hz, 6-H), 6.86 (1 H, s, 4-H), 6.91 (1 H, t, 8.1 Hz, 7-H), 7.17-7.43 (5 H, 
m, 2,,3',4/,5,,6,-H5), 7.83 (1 H, d, J  = 8.1 Hz, 8-H), 10.94 (1 H, br s, NH); 
MS (El +) m/z 250.1100 (M) (12C16Hi4N20  requires 250.1106).
Amino-3-benzylisoquinolin-l(2i/)-one hydrochloride (150).
NH
A mixture of (149) (150 mg, 0.6 mmol) and aqueous HC1 (2 M, 20 ml) were stirred 
at room temperature for 30 min. Evaporation and recrystallisation (MeOH) yielded 
(150) (160 mg, 93%) as a dark brown solid; Rf = 0.60 (MeOH); mp >350°C; 
’HNMR (D20) 6 3.94 (2 H, s CH2), 6.49 (1 H, s, 4-H), 7.25-7.37 (5 H, m, 
2,,3',4',5',6'-H5), 7.51 (1 H, t, J  = 7.8 Hz, 7-H), 7.73 (1 H, d, J  = 7.8 Hz, 6-H), 






A solution of 2-methyl-3-nitrobenzoic acid (10.0 g, 55.2 mmol) in MeOH (200 ml) 
and concentrated H2SO4 (1 ml) was boiled under reflux for 48 h, then poured into 
ice-H20 (300 ml). The precipitated ester was filtered, washed (H2O) and 
recrystallised (MeOH) to give (154) (9.7 g, 90%) as yellow crystals; Rf = 0.55 
(hexane / EtOAc 4:1); mp 65-66°C (lit.215 mp 64.2-65.5°C); IR t)max (KBr) 1352 & 
1548 (N02), 1724 (C=0); ‘H NMR (CDC13) 5 2.53 (3 H, s, ArCH3), 3.87 (3 H, s, 
C 0 2CH3), 7.30 (1 H, t, J  = 8.2 Hz, 5-H), 7.74 (1 H, dd, = 8.2, 1.2 Hz, 4-H), 
7.89(1 H, dd, J = 8.2, 1.2 Hz, 6-H); MS (El +) 195.0535 (M) ( l2C9H9N 0 4
requires 195.0532).
5-Nitroisocoumarin (155).
The ester (154) (5.0 g, 25.6 mmol) was heated with dimethylformamide dimethyl 
acetal (2.5 g, 21 mmol) in DMF (30 ml) at 150°C for 16 h. Evaporation, 
chromatography (hexane / EtOAc 10:1) and recrystallisation (EtOH) gave 
(155) (2.6 g, 53%) as yellow crystals; Rf = 0.34 (hexane / EtOAc 10:1); 
mp 171-172°C; *H NMR (CDC13) 5 7.39 (1 H, dd, J  = 6.0, 0.5 Hz, 4-H), 7.44 (1 H, 
dd, J  = 6.0 Hz, 3-H), 7.68 (1 H, t, J  = 8.0 Hz, 7-H), 8.50 (1 H, dd, J  = 8.0, 1.3 Hz,
6-H), 8.64 (1 H, ddd, J  = 8.0, 1.3, 0.5 Hz, 8-H); MS (El +) m/z 191.1220 (M) 




A solution of Br2 (11.8 g, 73.7 mmol) in CCI4 (30 ml) was added over 30 min to a 
boiling solution of (154) (11.5 g, 59.0 mmol) and dibenzoyl peroxide (1.1 g, 4.5 
mmol) in CCI4 (100 ml) under irradiation using a 150 W tungsten lamp. After 20 h, 
additional Bn (0.9 ml, 17 mmol) and dibenzoyl peroxide (240 mg, 1.0 mmol) in CCI4 
(10 ml) was added. Heating and irradiation were continued for another 29 h. 
Evaporation and recrystallisation (MeOH) gave (156) (15.9 g, 98%) as pale brown 
crystals; Rf = 0.40 (hexane / EtOAc 4:1); mp 68-69°C (lit.216 mp 68-69°C); 
IR vmax (KBr) 1271 & 1530 (N 02), 1722 (C=0); 'H NMR (CDCI3) 6 3.98 (3 H, s, 
CH3), 5.14 (2 H, s, CH2), 7.52 (1 H, t, J  = 7.9 Hz, 5-H), 7.94 (1 H, d, = 7.9 Hz,
4-H), 8.09 (1 H, d, J  = 7.9 Hz, 6-H); MS (El +) m/z 274.9612 (M) (,2C9H881BrN04 





To a solution of (156) (7.0 g, 25 mmol) in acetonitrile (100 ml) was added 
tetraethylammonium cyanide (4.8 g, 31 mmol) and the mixture was stirred at room 
temperature for 4 h. Evaporation and chromatography (Et20  / heptane 1:1) yielded 
(157) (3.8 g, 68%) as pale yellow crystals; Rf = 0.17 (Et20  / heptane 1:1); 
mp 93-94°C (lit.217 mp 95.5-96°C); IR umax (KBr) 1353 & 1538 (N 02), 1728 (C=0), 
2265 (CN); 'H NMR (CDCI3) 8 4.01 (3 H, s, C 0 2CH3), 4.35 (2 H, s, CH2),
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7.62 (1 H, t, J  = 8.2 Hz, 5-H), 8.12 (1 H. dd, 8.2, 1.2 Hz, 4-H), 8.27 (1 H, dd, 
J  = 8.2, 1.2 Hz, 6-H); MS (El +) m/z2 0.0489 (M) (l2Cl0H8N2O4 requires 220.0484).
2-(Dimethylaminomethyl)-3-nitro-A7,A-dimethylbenzamicle (158).
o
A solution of (156) (2.7 g, 9.9 mmol) and dimethylformamide dimethyl acetal (4.2 g, 
35 mmol) in DMF (20 ml) was heated at 150°C for 16 h. Evaporation and 
chromatography (hexane / EtOAc 9:1) gave (158) (940 mg, 38%) as orange oil; 
Rf= 0.40 (hexane / EtOAc 9:1); IR \ ) max (film) 1364 & 1537 (N02), 1629 (C=0); 
‘H NMR (CDC13) 8 2.15 (6 H, s, CH2N(C//3)2), 2.82 (3 H, s, NCH3), 3.11 (3 H, s, 
NCH3), 3.40 (1 H, d, J  = 13.4 Hz) and 3.80 (1 H, d, = 13.4 Hz) (CH2), 7.34 (1 H, 
dd, J = 7.7, 1.5 Hz, 6-H), 7.39 (1 H, t, = 7.7 Hz, 5-H), 7.62 (1 H, dd, 






Compound (157) (550 mg, 2.5 mmol) was heated with dimethylformamide dimethyl 
acetal (1.1 g, 9.2 mmol) in DMF (10 ml) at 150°C for 16 h. Evaporation and 
chromatography (hexane / EtOAc 2:3) gave (159) (160 mg, 23%) as orange crystals; 
Rf = 0.47 (hexane / EtOAc 2:3); mp 87-88°C; IR \)max (KBr) 1362 & 1537 (N02), 
1631 (C=C), 1728 (C=0), 2195 (CN); 'H NMR (CDC13) 8 3.17 (6 H, s, 2 x NCH3),
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3.95 (3 H, s, CO2CH3), 6.34 (1 H, s, CH), 7.45 (1 H, t, J  = 7.8 Hz, 5-H), 7.76 (1 H, 
dd, J  = 7.8, 1.6 Hz, 4-H), 7.91 (1 H, dd, J  = 7.8, 1.6 Hz, 6-H); MS (El +) m/z 




A solution of (155) (1.5 g, 7.9 mmol) in 2-methoxyethanol (100 ml) was saturated 
with NH3 and boiled under reflux for 4 h, then evaporated until 10 ml remained. The 
concentrate was stored at 4°C for 16 h and the precipitated crystals were filtered, 
washed (H20, then EtOH) and recrystallised (MeOH) to give (160) (1.1 g, 73%) as 
yellow crystals; Rf = 0.49 (hexane / EtOAc 2:3); mp (decomp.) 247-249°C; *H NMR 
((CD3)2SO) 5 6.97 (1 H, dd, J  = 7.7, 0.7 Hz, 4-H), 7.45 (1 H, dd, /  = 7.7, 1.8 Hz,
3-H), 7.66 (1 H, t, J  = 7.7 Hz, 7-H), 8.46 (1 H, dd, J  = 7.7, 1.5 Hz, 6-H), 8.58 (1 H, 
ddd, J  = 7.7, 1.5, 0.7 Hz, 8-H), 11.80 (1 H, br s, NH); MS (El +) m/z 190.0383 (M) 
(12C9H6N203 requires 190.0378).
Method B:
DIBAL-H (1.0 M in hexane, 7.5 ml, 7.5 mmol) was added dropwise to a solution of 
(157) (1.1 g, 5.0 mmol) in dry CH2C12 (50 ml) at -78°C and the solution was stirred 
for 1 h. Aqueous HC1 (2 M, 35 ml) was then added the solution was extracted with 
CH2C12. Evaporation and chromatography (hexane / EtOAc 2:3) afforded 





A mixture of (68) (2.5 g, 8.1 mmol) and benzyl zinc bromide (0.5 M in THF, 24.5 
ml, 12.2 mmol) in dry THF (30 ml) was added to (PPh3)2PdCl2 (330 mg, 500 |imol) 
and DEBAL-H (1.0 M in hexane, 1.0 ml, 1.0 mmol) in dry THF (15 ml) under Ar and 
the mixture was stirred at 45°C for 72 h. Extraction (CHCI3), evaporation and 
chromatography (hexane / EtOAc 9:1) afforded (161) (700 mg, 32%) as a yellow oil; 
Rf = 0.53 (hexane / EtOAc 9:1); ER umax (film) 1362 & 1532 (N02), 1731 (C=0); 
'HNMR (CDCI3) 8 3.77 (3 H, s, CH3), 4.52 (2 H, s, CH2), 7.01-7.04 (2 H, m, 
2/,6/-H2), 7.12-7.23 (3 H, m, 3',4\5'-H3), 7.42 (1 H, t, J  = 7.8 Hz, 5-H), 7.81 (1 H, 
dd, J  = 7.8, 1.6 Hz, 4-H), 7.95 (1 H, dd, J  = 7.8, 1.6 Hz, 6-H); MS (FAB +ve ion) m/z 
272.0921 (M + H) (12Ci5Hi4N 04 requires 272.0923), 240 (M -  OMe), 195 (M -  Ph).
(2H)-one (23d).
A mixture of (160) (190 mg, 1.0 mmol) and SnCl2 (600 mg, 3.2 mmol) in EtOH 
(30 ml) was heated at 70°C for 4 h, then carefully poured into ice-H20  (200 ml). The 
resulting suspension was made alkaline with aqueous NaOH and the precipitate was 
filtered. Extraction of the filtrate (EtOAc), evaporation and recrystallisation (hexane, 
EtOAc) gave (23d) (98 mg, 61%) as yellow crystals; Rf = 0.79 (hexane / EtOAc 1:4); 
mp 249-250°C; 'H NMR ((CD3)2SO) 8 5.59 (2 H, br s, NH2), 6.65 (1 H, d,
5-AminoisoquinoIin-l
203
J  = 7.0 Hz, 4-H), 6.83 (1 H, d, J  = 7.8 Hz, 6-H), 7.00 (1 H, d, J  = 7.0 Hz, 3-H), 7.12 
(1 H, t, J  = 7.8 Hz, 7-H), 7.36 (1 H, d, J  = 7.8 Hz, 8-H), 11.04 (1 H, br s, NH); 







A solution of (23d) (900 mg, 5.6 mmol) in dry DMF (15 ml) was stirred with 
dimethylformamide dimethyl acetal (3.7 g, 31 mmol) under N2 at 45°C for 3 h. 
Evaporation and chromatography (CH2C12 / MeOH / NMe3 95:5:0.5) gave (163) (1.0 
g, 83%) as yellow crystals; Rf = 0.47 (hexane / EtOAc 4:1); mp 195-196°C; 
IR Umax (KBr) 1634 (C=0), 3410 (NH); *H NMR (CDC13) 8 3.05 (3 H, s, NCH3),
3.08 (3 H, s, NCH3), 7.05 (1 H, dd, J  = 7.8, 0.8 Hz, 6-H), 7.14 (2 H, s, 3-H, 4-H), 
7.35 (1 H, t, J  = 7.8 Hz, 7-H), 7.52 (1 H, s, N=CH), 8.05 (1 H, dd, J  = 7.8, 0.8 Hz,
8-H), 12.00 (1 H, br s, NH); 13C NMR (CDC13) 8 34.95 (NCH3), 40.63 (NCH3), 
103.74 (C-4), 120.76 (C-6), 121.00 (C-8), 126.50 (C-3), 126.81 (C-10), 127.24 (C-7), 
133.79 (C-9), 148.18 (C-5), 153.23 (C=N), 164.88 (C=0); MS (El +) m/z 






A mixture of (163) (1.0 g, 4.7 mmol) and aqueous HC1 (2 M, 15 ml) was stirred at 
room temperature for 5 min. Evaporation and recrystallisation (MeOH) yielded 
(164) (1.1 g, 94%) as orange crystals; Rf = 0.50 (hexane / EtOAc 1:4); 
mp 154-155°C; *H NMR (D20) 8 3.27 (3 H, s, NCH3), 3.36 (3 H, s, NCH3),
6.62 (1 H, d, 7 = 7.4 Hz, 4-H), 7.06 (1 H, d, J  = 7.4 Hz, 3-H), 7.30 (1 H, t, J  = 7.8 Hz,
7-H), 7.49 (1 H, dd, J  = 7.8, 1.2 Hz, 6-H), 7.79 (1 H, dd, J = 7.8, 1.2 Hz, 8-H), 
8.14 (1H, s, N=CH).
l-Phenyl-l-(trimethylsilyloxy)ethylene (165).
Acetophenone (5.0 ml, 43 mmol) was added dropwise to a mixture of DIPA (6.5 ml, 
46 mmol) and n-butyllithium (18.5 ml, 46 mmol, 2.5 M in hexane) in THF (80 ml) at 
-78°C and the mixture was allowed to stir at that temperature for 2 h. 
Chlorotrimethylsilane (6 ml, 47 mmol) was then added and the mixture was allowed 
to stir at room temperature for 6 h. Evaporation and chromatography 
(hexane / EtOAc 10:1) gave (165) (7.6 g, 92%) as a colourless oil; Rf = 0.90 
(hexane / EtOAc 4:1); lit.225 bp 53-54 (0.3 torr); *H NM R (CDC13) 8 0.38 (9 H, s, 
Si(CH3)3), 4.54 (1 H, d, J  = 1.7 Hz, 2-H), 5.02 (1 H, d, J  = 1.7 Hz, 2-H), 7.35-7.45
205
(3 H, m, 3',4',5'-H3), 7.67-7.74 (2 H, m, 2',6'-H2); MS (El +) m/z 192.0963 (M) 
(12CnHi6OSi requires 192.0970), 103 (M -  OSiMe3).
l - m e t h o x y - 3 - ( / V , / V - d i m e t h y l a m i n o ) - 5 - n i t r o n a p h t h a l e n e  ( 1 6 7 ) .
OMe
NMe'
Ester ( 1 5 4 )  (1.01 g, 5.2 mmol) was heated at 150°C with MeC(OMe)2NMe2 
(2.5 g, 19 mmol) in MeCONMe2 (6 ml) for 16 h. Evaporation and chromatography 
(hexane / EtOAc 10:1) gave ( 1 6 7 )  (990 mg, 77%) as dark red needles; Rf = 0.50 
(hexane / EtOAc 1:4); mp 123-124°C; IR umax (KBr) 1343 and 1522 (N02); 
‘HNMRtCDCE) 6 3.13 (6 H, s, NMe2), 4.00 (3 H, s, OMe), 6.48 (1 H, d, 
J  = 2.3 Hz, 2-H), 7.11 (1 H, dd, J  = 8.2, 7.8 Hz, 7-H), 7.37 (1 H, d, J  = 2.3 Hz, 4-H), 
8.24 (1 H, dd, J  = 7.8, 1.2 Hz, 8-H), 8.37 (1 H, dd, J  = 8.2, 1.2 Hz, 6-H); 
MS (El +) m/z 246.1006 (M) (12Ci3Hi4N20 3 requires 246.1004);
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Appendix
X-ray crystallography of 3-(4-methylphenyl)-5-nitroisocoumarin (103).
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Reflections observed (>2 a)
Data Completeness
Max. and min. transmission
Refinement method
Data /  restraints /  parameters
Goodness-of-fit on F2
Final R indices [I>2 a  (I)]
R indices (all data)
Largest diff. peak and hole
Compound (103)






a = 5.8870(2)A a  = 90° 
b = 12.0270(3)A |3 = 96.8020(10)° 








-7<=h<=7; -13<=k<= 15; -23<=1<=23 
13240
2964 [R(int) = 0.0686]
1523
0.996
0.9922 and 0.9593 
Full-matrix least-squares on F2 
2 9 6 4 /0 /1 9 2  
0.950
R i=  0.0548 wR2 = 0.1228 
R i=  0.1295 wR2 = 0.1617 
0.300 and -0.279 eA'3
Table 22. Crystal data and structure refinement fo r  (103).
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Atom X y z U (eq)
0 (1) 3993(2) 3632(1) 860(1) 60(1)
0 (2) 2944(3) 1897(1) 668(1) 73(1)
0(3) 11238(3) 4273(1) 2604(1) 96(1)
0(4) 13723(3) 2966(1) 2636(1) 82(1)
N(l) 11802(3) 3325(2) 2456(1) 63(1)
C(l) 4402(3) 2506(2) 942(1) 55(1)
0 (2) 6543(3) 2182(2) 1368(1) 52(1)
0(3) 6962(4) 1055(2) 1481(1) 61(1)
0(4) 8922(4) 690(2) 1880(1) 66(1)
0(5) 10498(4) 1458(2) 2177(1) 61(1)
0 (6) 10079(3) 2574(2) 2083(1) 52(1)
0(7) 8094(3) 2998(2) 1673(1) 50(1)
0 (8) 7528(3) 4137(2) 1522(1) 52(1)
0(9) 5543(3) 4426(2) 1129(1) 51(1)
0 (10) 4726(3) 5554(2) 952(1) 51(1)
0 (11) 6099(3) 6479(2) 1123(1) 59(1)
0 (12) 5291(3) 7536(2) 961(1) 63(1)
0(13) 3096(4) 7722(2) 620(1) 59(1)
0(14) 1755(4) 6803(2) 440(1) 63(1)
0(15) 2541(4) 5742(2) 603(1) 61(1)
0(16) 2208(4) 8881(2) 452(1) 76(1)
Table 23. Atomic coordinates (A2 x  1(f)  and equivalent isotropic displacement 
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Atom U ll U22 U33 U23 U13 U12
0(1) 58(1) 50(1) 70(1) KD -4(1) -4(1)
0(2) 70(1) 57(1) 89(1) -2(1) -9(1) -15(1)
0(3) 90(1) 57(1) 130(2) -16(1) -35(1) 4(1)
0(4) 56(1) 88(1) 98(1) -9(1) -4(1) 6(1)
N(l) 58(1) 63(1) 66(1) 1(1) -2(1) -1(1)
C(l) 61(1) 45(1) 59(1) KD 6(1) -3(1)
C(2) 61(1) 46(1) 49(1) 1(1) 9(1) 0(1)
0(3) 73(1) 44(1) 64(1) -2(1) 6(1) -7(1)
0(4) 85(2) 46(1) 68(1) 5(1) 8(1) 7(1)
0(5) 67(1) 54(2) 62(1) 3(1) 4(1) 7(1)
0(6) 56(1) 49(1) 52(1) -1(1) 7(1) 0(1)
0(7) 55(1) 47(1) 47(1) -KD 11(1) -KD
0(8) 56(1) 44(1) 56(1) -3(1) 3(1) -2(1)
0(9) 54(1) 47(1) 52(1) -KD 7(1) -2(1)
0(10) 56(1) 49(1) 48(1) 1(1) 7(1) 1(1)
0(11) 55(1) 52(1) 67(1) 5(1) -1(1) 2(1)
0(12) 66(1) 52(2) 69(1) 0(1) 1(1) -5(1)
0(13) 71(1) 55(2) 53(1) -KD 8(1) 5(1)
0(14) 59(1) 56(2) 73(1) 0(1) -4(1) 6(1)
0(15) 59(1) 52(1) 70(1) -2(1) -3(1) -3(1)
0(16) 93(2) 53(2) 80(2) -3(1) -2(1) 12(1)
Table 25. Anisotropic displacement parameters (A2 x 1(f)  fo r  (103).
Atom X y z U(eq)
H(3) 5887 540 1282 73
H(4) 9188 -67 1949 79
H(5) 11852 1220 2442 73
H(8) 8551 4689 1699 63
H(11) 7582 6383 1350 71
H(12) 6243 8141 1085 75
H(14) 284 6899 203 76
H(15) 1586 5139 477 74
H(16A) 819 8841 124 114
H(16B) 3329 9299 231 114
H(16C) 1910 9239 895 114
Table 26. Hydrogen coordinates ( x 1(f) and isotropic displacement 
parameters (A2 x l ( f  ) fo r  (103).
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Poly (ADP-ribose) polymerases as  Novel Therapeutic Targets -  PARP 2003
fcfc l Systemic administration of the PARP-1 
inhibitor GPI15427 increases the 
anti-tumor activity of temozoiomide 
against metastatic melanoma
Tentori L1, Leonetti C2, Scarsella M2, d'AmatiG3, Xu W4, 
Kalish V4, Zhang J4, Graziani 6i
1 D epartm en t of N euroscience, University of Rome T or Vergata', Italy
2 Experimental Preclinical Laboratory, Regina Elena Institute for Cancer 
R esearch , Italy
3 D epartm en t of Experimental M edicine and Pathology, University of Rome 
‘La Sapienza '; Rome, Italy
4 Guilford P harm aceuticals Inc., Baltimore, MD, USA
keyw ords: PARP-1 inhibitor • an ticancer therapy •  tem ozoiom ide • 
m elanom a
We previously demonstrated that the antitumor activity of te­
mozoiomide (TMZ) can be enhanced at the CNS site by intra- 
cerebral injection of a PARP-1 inhibitor that does not permeate 
the blood-brain barrier [1], TMZ is an anticancer agent with 
promising activity against metastatic melanoma [2,3]. Here we 
tested whether systemic administration of GPI 15427, a novel 
PARP inhibitor capable o f crossing the blood-brain barrier, 
could enhance the anti-tumor efficacy o f TMZ against melano­
ma involving the CNS site. The efficacy of drug treatment was 
also tested against lung metastases.
Murine B16 melanoma cells were injected intracranially in syn­
geneic mice. Animals were treated for three days with TMZ 
(100 mg/kg, i.p.) ± GPI 15427 (1 mg/mouse, i.v.) when neo­
plastic infiltration of the brain tissue was evident in histological 
sections. Administration of GPI 15427 shortly before TMZ sig­
nificantly increased life-span o f tumor-bearing mice with re­
spect to untreated controls, or to groups treated with either 
GPI 15427 or TMZ only (PcO.OOOl). The increase in survival 
detected in the group treated with the drug combination was 
accompanied by a marked reduction of tumor infiltration in 
the brain, as evidenced by histological studies.
GPI 15427 also enhanced the anti-metastatic activity o f TMZ. 
In fact, the number of pulmonary metastases obtained after iv 
injection of B 16 cells was significantly lower in mice treated 
with GPI 15427+TMZ than in those receiving TMZ only 
(P=0.004).
In conclusion, these data indicate that systemic administration 
of GPI 15427 induces significant enhancement of TMZ anti-tu­
mor activity against melanoma, even at the CNS site. 
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PARP and myocardial 
ischaemia-reperfusion injury
Thiemermann C
William Harvey R esearch Institute, London, UK, 
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key words: heart •  infarction •  5-AIQ • reperfusion injury • cardiac 
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There is now good evidence that inhibitors of PARP activity re­
duce the tissue injury caused by regional myocardial ischemia 
and reperfusion. For instance, various, chemically distinct inhi­
bitors o f PARP activity [including 3-aminobenzamide (3-AB) 
and 1, 5-dihydroxyisoquinoline (ISO)] reduce the infarct size 
caused by ischaemia-reperfusion injury of the rabbit heart in vi­
vo. In addidon, 3-AB and ISO also reduce the infarct size cau­
sed by regional myocardial ischaemia and reperfusion in the 
heart of the rat in vivo  and in vitro. Moreover, ISO reduces the 
contractile dysfunction, the fall in high-energy phosphates cau­
sed by global myocardial ischemia and reperfusion in the rat 
heart. Exposure of human cardiac myoblasts in vitro results in 
an increase in PARP activity, and secondary cell death. Inhibi­
tion of this increase in PARP activity reduces the impairment in 
mitochondrial respiradon as well as the associated cell death 
caused by these reactive oxygen species. The tissue injury cau­
sed by coronary artery occlusion and reperfusion in PARP-1 
knock out mice is substantially reduced (when compared to 
their wild-type litter mates). Potent, water-soluble inhibitors of 
PARP activity (including 5-aminoisoquinolinone, PJ-34 and ot­
hers) cause a substantial reduction in myocardial infarct size in 
the rat in vivo. Taken together, these findings support the view 
that (1) the excessive activation of PARP contributes to myocar­
dial reperfusion injury, and (2) potent, water-soluble inhibitors 
of PARP activity may be useful in conditions associated with 
acute myocardial ischemia and reperfiision. These conditions 
may include acute myocardial infarction, coronary angioplasty, 
cardiac transplantation and bypass heart surgery.
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5-Aminoisoquinolin-l-one and other 
water-soluble PARP inhibitors
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• prodrug • solubility • reperfusion
Inhibitors of the activity of PARP have applications in the treat­
ment of many disease states. Most o f  the known inhibitors of 
PARP mimic the nicotinamide of the substrate NAD+. The con­
sensus pharmacophore for PARP inhibitors is a primary or se­
condary benzamide with N-H conformationally constrained 
anti to the carbonyl-arene bond. However, this can also be con­
sidered as a ‘pharmacophore’ for insolubility in water. In this 
presentation, the results of our work on extending this phar­
macophore into heterocyclyl carboxamides, into more water- 
soluble inhibitors and into potential prodrugs will be outlined. 
For example, 5-substituted isoquinolin-l-ones and 2, 8 -substi- 
tuted quinazolin-4-ones are known [1,2] to be potent inhibitors 
of PARP; we have shown [3] that the analogous thieno [3,4- 
c]pyridin-4(5H)-ones and thieno [3,4-d]pyrimidin-4(3H)-ones 
are also strongly active. New synthetic routes to 5-aminoisoqui- 
nolin-l-one (5-AIQ) have been developed [4], making this inhi­





inst PARP activity in a broken nuclear preparation; its corres­
ponding IC5 0 against a mono-ADP-ribosyl transferase (diphthe­
ria toxin) is 80 /xM, making 5-AIQ highly selective for PARP. 
This compound is highly water-soluble as its hydrochloride, 
making it suitable for rapid i.v. administration. 5-AIQ protects 
against organ damage in a rat model of haemorrhagic shock at 
the remarkably low dose of 30 /xg-Kg-1. It is similarly active in  
v ivo  in models o f myocardial infarction and acute lung inflam­
mation. Potential bioreductively activated prodrugs of this and 
other isoquinolin-l-ones have been synthesised [5,6] and are 
shown to release drug rapidly in experimental systems; these 
include 2-(2-nitroimidazol-5-ylmethyl)isoquinolin-l-ones and 
1, 2-dimethyl-3-(isoquinolin-l-yloxymethyl)-5-methoxyindole- 
4, 7-diones. Further developments from these leads are under 
active research.
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Niacin deficiency enhances spontaneous 
and nitrosourea-induced micronuctei in 
rat bone marrow
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Niacin deficiency in rats decreases bone marrow NAD+, impai­
ring PARP function. Using the micronucleus (MN) assay, this 
study examined altered dietary niacin status on genomic stabi­
lity in rats. Weanling male Long-Evans rats were fed niacin de­
ficient (ND), or pair-fed niacin replete (PF) diet for 3 weeks. 
Bone marrow MN frequency in polychromatic erythrocytes 
(MN-PCEs) was increased significandy (4.4-fold) by deficiency 
alone. As the decrease in marrow NAD+ levels was dramatic 
(80%), the model was extended to include adolescent rats, 
using 2 diets which cause moderate and mild deficiencies. ND 
rats with a moderate decrease in marrow NAD+ (55%), showed 
a significant increase in MN-PCE (1.9-fold). However, ND rats 
with a mild decrease in NAD+ (25%) did not have a significant­
ly enhanced MN-PCE frequency (1.2-fold). These experiments 
have identified the range of marrow NAD+ levels that lead to 
this type of genomic instability. To further characterize the in­
teraction between niacin status and MN formation, ethylnitro­
sourea (ENU) treatment (30 mg/kg) was used to induce DNA 
damage. ND, in the weanling model, caused a dramatic increa­
se (3.6-fold) in ENU-induced MN-PCEs (likely clastogenic in 
nature). This study emphasizes the importance of niacin in the 
maintenance of genomic stability in rats. We are working on 
identification of aneugenic versus clastogenic MN to help defi­
ne the mechanisms by which ND increases genomic instability. 
Other data from our laboratory using comet analysis suggests 
that clastogenicity will not account for the large increase in ge­
nomic instability due to ND alone.
Supported by the National Cancer Institute o f Canada.
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During the last decade of neurobiological research, it has beco­
me evident that inflammatory pathways in the CNS, involving 
a network of non-neuronal and neuronal cells, are important 
contributors to the onset and progress of several major neuro- 
degenerative diseases [1]. One major component of inflamma­
tory neuronal damage is the transformation of microglia cells 
into activated immunoeffector cells and their migration to­
wards the sites of injury, where they produce large amounts of 
toxic cytokines and oxygen radicals [2]. During this transfor­
mation, PARP-1 is highly activated and enables microglia cells 
to cope with oxidative challenges, in particular by upregulating 
the proteasomal degradation of damaged nuclear proteins [3]. 
Besides the initiation of intracellular defense pathways, PARP- 
1 -dependent signalling is also involved in regulating specific 
functions of activated microglia: It regulates the expression of 
the integrin C D lla  through interaction with the translocated 
NF-kB and therefore strongly controls migration into the re­
gions o f neuronal injury [4]. Furthermore, it enhances the pro­
duction of the proinflammatory cytokine TNF-alpha and o f  the 
antiinflammatory endocannabinoid 2-AG, which in turn down- 
regulates the release of nitric oxide. We are therefore conside­
ring PARP-1 to be a multiple player in the concert of neuroin­
flammation, in which therapeutic interventions directed aga­
inst PARP-1 would affect both neuronal and non-neuronal 
components. Downregulation of PARP-1 specifically in micro­
glia almost completely abrogates microglial migration and pre­
vents neurons from secondary damage. This renders PARP-1 a 
target for therapeutic strategies in neurodegenerative diseases, 
in which pathological microglia activation and migration play a 
major role.
Supported by the DFG, SFB 507/C6 and the Friedrich-Althoff-Prog­
ram
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Competition and co-operation of PARP-1 
and DNA-PK in the repair of DNA strand 
breaks______________________________
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Cells deficient in poly(ADP-ribose) polymerase (PARP-1) or 
DNA-dependent protein kinase (DNA-PK) are highly radiosen­
sitive. Potent, specific inhibitors of PARP-1 (AG14361) and 
DNA-PK (NU7026) developed in collaboration with KuDOS 
Pharmaceuticals (UK) and Agouron/Pfizer GRD (CA), respecti­
vely, are radiosensitizers when used alone and in combination 
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A new synthesis of ‘push-pull’ naphthalenes by condensation of 
nitro-2-methylbenzoate esters with dimethylacetamide
dimethyl acetal
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Abstract— Whereas condensation o f  2-methyl-3-nitrobenzoate esters with dimethylformamide dimethyl acetal gives 5-nitroisocou- 
marin, analogous condensation with dimethylacetamide dimethyl acetal proceeds via a different route, affording l-methoxy-3- 
dimethylamino-5-nitronaphthalene in good yield. Extension o f  the reaction to other naphthalenes with this novel ‘push-pull’ 
substitution m otif has been explored. A  deuterium labelling study revealed that equilibration o f the alkoxy groups in the reaction 
mixture took place before the final carbocyclisation. © 2002 Elsevier Science Ltd. All rights reserved.
Most syntheses o f polysubstituted naphthalenes involve 
modification and substitution of a preformed bicyclic 
naphthalene core, with a few employing construction of 
the rings with the substituents already attached to the 
acyclic or monocyclic precursors. Examples of the latter 
ring-closure routes include Diels-Alder cyclisations of 
dienes with benzoquinones, 1 ,2  acid-catalysed cyclisa­
tions o f phenylethylidenemalononitriles to 2 -cyanon- 
aphthyl-1 -amines3 and base-catalysed cyclisation of 
2-allyl-A,jV-dialkylbenzamides to naphth-l-ols . 4  How­
ever, these routes are not generally amenable to synthe­
sis o f  substituted alkoxy- and amino-naphthalenes. We 
report here a new synthesis of novel polysubstituted 
naphthalenes, which bear the ‘push-pull’ motif o f elec­
tron-withdrawing substituents on one ring and electron- 
donating substituents on the other.
We5 ,6  and others7 have previously reported that con­
densation of methyl 2-methyl-3-nitrobenzoate la  with 
dimethylformamide dimethyl acetal (dimethoxymethyl 
dimethylamine, DM FDM A) gives the enamine 2 
(Scheme 1). Treatment of this crude enamine with silica 
gel provides sufficient acid catalysis to hydrolyse the 
enamine and cyclise the intermediate enol to the isocou- 
marin 3. In an initial attempt to explore the scope and 
mechanism o f this reaction, the isopropyl ester lb 8 was 
treated similarly with DMFDMA; the condensation
* Corresponding author. Tel.: +44-1225-826840; fax: +44-1225- 
826114; e-mail: m.d.threadgill@bath.ac.uk
0040-4039/02/$ - see front matter © 2002 Elsevier Science Ltd. All rights reserved. 
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followed a similar path but the cyclisation with silica 
gel was much slower and gave lower yields o f 3 
(Scheme 1). This observation is consistent with steric 




1a: R = Me
1b: R = FV
NO;
L«
4a: R = Me
4b: R = Pr1
5a: R = Me
5b: R = Pr
Scheme 1. Reactions o f  2-methyl-3-nitrobenzoate esters with 
orthoamides. Reagents and conditions', (i) HC(OM e)2N M e2, 
DM F, 150°C, 16 h, 53%; (ii) S i0 2, EtOAc; (iii) 
MeC(OMe)2N M e2, M eCONM e2, 150°C, 16 h, 77%.
Pergamon
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In contrast, when the ester la was treated with 
dimethylacetamide dimethyl acetal ( 1 , 1 -dimethoxyethyl 
dimethylamine, DM ADM A ) , 9  none of the expected 
3-methyl-5-nitroisocoumarin was formed. The sole 
isolable product was a deep red solid, formed in high 
yield. The strong colour suggested that it was not an 
isocoumarin (most 5-nitroisocoumarins are pale yel­
low); this was borne out by the lack of a carbonyl 
absorption in the IR spectrum . 9 The 'H NMR  
spectrum9  showed five aromatic protons, togetheT with 
signals for NM e2 and OMe. One o f the aromatic pro­
ton signals was shifted markedly upfield at S 6.48, 
corresponding to a location between the electron- 
donating NMe2  and OMe groups. These data, together 
with the mass spectrum, allowed the assignment of the 
naphthalene structure 6  to the condensation product. 
The locations o f the NM e2  and OMe substituents were 
confirmed by a NOESY spectrum, which showed NOE 
connectivity between OMe and the 2-H (S  6.48, d, 
7 = 2 .3  Hz) and between NMe2  and the 2-H and 4-H («5 
7.37, d, 7 = 2 .3  Hz). The deep red colour is a conse­
quence o f the ‘push-pull’ substitution pattern o f the 
naphthalene chromophore. Compounds with a nitro 
group at one end of a conjugated system and an amine 
at the other are often deeply coloured, ranging from 
simple 2 -nitroethenamines10 to laser dyes and dark red
l-nitro-7-aminonaphthalenes . 1 , - 1 4  For this unprece­
dented synthesis o f the naphthalene ring system, we 
propose the course of reaction shown in Scheme 1. 
Initial condensation with the DM ADM A gives the 
enamine 4, by analogy with the identified intermediate 
enamine 2 for the sequence employing DM FDM A. 
Whereas the C-H  enamine 2 has no opportunity for 
further reaction under the conditions, the C-M e enam­
ine 4 can tautomerise to the alternative enamine 5, 
presumably via an iminium species. This second enam­
ine 5 then provides a nucleophilic carbon correctly 
located to attack the ester carbonyl. It is noteworthy 
that water is the sole leaving group in the condensation 
of the enamine with the ester (giving 6 ); no 3-dimethyl- 
amino-5-nitronaphth-l-ol was obtained (through loss of 
methanol).
A short study revealed aspects o f the mechanism, gen­
erality and limitations o f this new synthesis of substi­
tuted naphthalenes. Firstly, condensation of the 
isopropyl ester lb 8 with DM ADM A gave the methoxy- 
naphthalene 6  as the sole naphthalene product (Scheme 
1 ); no isopropoxynaphthalene was evident in the crude 
product mixture. This observation suggests either that 
the mechanism o f the reaction is complex and involves 
intramolecular transfer of a methoxy group in an inter­
mediate or that there is an equilibrium exchange of 
alkoxy groups (Pr'0<->Me0) between the ester and the 
orthoamide before the final ring-closure. The complete 
absence of isopropoxynaphthalenes is consistent with 
the latter, since it is likely that ring-closure with the 
isopropyl ester 5b will be much slower than that with 
the methyl ester 5a, owing to the greater steric bulk of 
the Pr'O; this steric retardation of ring-closure is 
analogous to that observed in the formation of the 
isocoumarin 3 from lb . Secondly, to select between 
these two alternative mechanisms (intramolecular MeO
transfer and ester exchange), an isotopic competition 
experiment was performed (Scheme 2). 2-Methyl-3- 
nitrobenzoic acid 7 was converted to its 
trideuteromethyl (CD,) ester 8 15 in 88% yield. This 
isotopomer was then treated with DM ADM A in which 
the methoxy groups were all OCH,, under the standard 
reaction conditions. Mass spectroscopic and NMR  
analysis of the product 9 showed that the ratio of 
OCD, to OCH, corresponded to the ratio of OCD, (in 
8 ) to OCH, (in DM ADM A) in the reaction mixture. 
Thus, as there is virtually no difference between the 
steric requirements of C D , and CH„ the mechanism 
must involve full equilibration of the alkoxy groups 
between the ester and the orthoamide before final ring- 
closure. Hence, introduction of alternative alkoxy 
groups at position - 1 of the naphthalene in this new 
condensation will require other appropriate 
orthoamides.
Scheme 3 shows three further studies on the generality 
of the reaction. Treatment of methyl 2-methyl-5- 
nitrobenzoate 10 16 with DM ADM A under the standard 
reaction conditions gave the corresponding 1 -methoxy- 
3-dimethylamino-7-nitronaphthalene l l . 17 In contrast, 
similar treatment o f the 3,5-dinitro analogue 12,18 in 
which the arylmethyl group is further activated, gave 
only degradation products. To explore an alternative 
approach to activating the arylmethyl further and, 
simultaneously, to introduce a 4-substituent into the 
naphthalene, methyl 2-benzyl-3-nitrobenzoate 16 was 
synthesised. 3-Nitrophthalic acid 14 was decarboxyl- 
ated/mercurated with Hg(OAc) 2  and the intermediate 
aryl-Hg compound was treated with iodine to give
2-iodo-3-nitrobenzoic acid, by the method of Seno et 
al. ; 1 9  this was converted to its methyl ester 15. Negishi 
coupling with benzyl zinc bromide/DIBAL-H/ 
Pd(PPh3)2 Cl2 then afforded the novel 2-benzylbenzoate 
ester 16 in moderate yield . 2 0  However, this failed to 
afford the target 4-phenylnaphthalene 17 on treatment 
with DM ADMA.
In this letter, we report a novel method for the synthe­
sis o f substituted naphthalenes by treatment of nitro-2 - 
methylbenzoate esters with dimethylacetamide dimethyl 







Scheme 2. Studies on the source of the naphthalene 1-sub­
stituent. R eagents an d  conditions: (i) CD,OD, H2S04, reflux, 
72 h; (iii) MeC(OCH,)2 NMe2  (3 equiv.), MeCONMe2, 150°C, 
16 h.
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Scheme 3. Synthesis o f  l-methoxy-3-dimethylamino-7-nitronaphthalene 11 and preliminary exploration o f  the limitations o f  the 
naphthalene-forming condensation reaction. Reagents and conditions: (i) MeC(OMe)2N M e2, M eCONM e2, 150°C, 16 h, 5.3%; (ii) 
Hg(OAc)2, aq. NaOH (10%), reflux, 3 days; (iii) I2, aq. NaOH (3.4%), reflux, 16 h; (iv) MeOH, H->S04, 62% from 14; (v) 
PhCH2ZnBr, Bu'2A1H, Pd(PPh3)2Cl2, THF, 45°C, 72 h, 32%.
mechanism and generality. This condensation has con­
siderable potential for construction of ‘push-pull’-sub- 
stituted polycyclic arenes. The results of a more 
comprehensive study on this reaction will be published 
later.
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